[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 557
1. Yaqub A: Familial Hurthle cell carcinoma of the thyroid: case reports and review of the literature. W V Med J; 2009 Jul-Aug;105(4):23-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Familial Hurthle cell carcinoma of the thyroid: case reports and review of the literature.
  • OBJECTIVE: To describe case reports of a brother and sister pair with Hurthle cell carcinoma of thyroid.
  • Family history was pertinent for benign nodular thyroid disease in multiple family members.
  • CONCLUSION: HCC is a rare malignancy of thyroid.
  • Our case describes a rare familial occurrence of this malignancy and highlights the importance of obtaining a careful family history in management and surveillance of thyroid cancer.
  • [MeSH-major] Adenoma, Oxyphilic / genetics. Thyroid Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19585901.001).
  • [ISSN] 0043-3284
  • [Journal-full-title] The West Virginia medical journal
  • [ISO-abbreviation] W V Med J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 28
  •  go-up   go-down


2. Henderson A, Douglas F, Perros P, Morgan C, Maher ER: SDHB-associated renal oncocytoma suggests a broadening of the renal phenotype in hereditary paragangliomatosis. Fam Cancer; 2009;8(3):257-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] SDHB-associated renal oncocytoma suggests a broadening of the renal phenotype in hereditary paragangliomatosis.
  • Renal tumours are also increasingly being reported as component tumours in hereditary paragangliomatosis associated with mutations in SDHB.
  • We present the first reported case of a family in whom an individual shown to carry a mutation in SDHB developed a renal oncocytoma.
  • We review other reports of renal tumours associated with SDHB-associated hereditary paragangliomatosis and suggest that various histological subtypes of renal tumours are part of this condition.
  • This observation indicates that SDHB-associated hereditary paragangliomatosis is unlike most tumour predisposition syndromes associated with the development of renal tumours which are usually associated with specific histological sub-types.
  • The increasing recognition of the involvement of renal tumours in SDHB mutation carriers suggests that renal screening is likely to be valuable for these patients.
  • SDHB mutations should also be considered in the context of genetic testing when renal tumours, regardless of histopathology, present in families with other tumours consistent hereditary paraganglioma syndrome.
  • [MeSH-major] Adrenal Gland Neoplasms / genetics. Chromosomes, Human, Pair 1. Germ-Line Mutation. Iron-Sulfur Proteins / genetics. Pheochromocytoma / genetics
  • [MeSH-minor] Aged. Case-Control Studies. DNA Mutational Analysis. Female. Genetic Predisposition to Disease. Genotype. Head and Neck Neoplasms / genetics. Humans. Kidney Neoplasms / genetics. Male. Pedigree. Phenotype. Retroperitoneal Neoplasms / genetics. Thyroid Neoplasms / genetics

  • Genetic Alliance. consumer health - Oncocytoma renal.
  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • MedlinePlus Health Information. consumer health - Pheochromocytoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nature. 1999 May 20;399(6733):271-5 [10353251.001]
  • [Cites] Clin Endocrinol (Oxf). 2008 Oct;69(4):587-96 [18419787.001]
  • [Cites] Am J Hum Genet. 2004 Jan;74(1):153-9 [14685938.001]
  • [Cites] J Natl Cancer Inst. 2008 Sep 3;100(17):1260-2 [18728283.001]
  • [Cites] J Pathol. 1997 Oct;183(2):131-3 [9390023.001]
  • [Cites] J Clin Endocrinol Metab. 2007 Mar;92(3):779-86 [17200167.001]
  • [Cites] J Clin Endocrinol Metab. 2006 Nov;91(11):4593-8 [16954163.001]
  • [Cites] Cancer Cell. 2002 Jun;1(5):459-68 [12124175.001]
  • [Cites] Nat Rev Cancer. 2004 May;4(5):381-93 [15122209.001]
  • [Cites] JAMA. 2004 Aug 25;292(8):943-51 [15328326.001]
  • [Cites] Am J Hum Genet. 2005 Jun;76(6):1023-33 [15852235.001]
  • [Cites] Diagn Mol Pathol. 2008 Jun;17(2):94-100 [18382370.001]
  • [Cites] Medicine (Baltimore). 1997 Nov;76(6):381-91 [9413424.001]
  • [Cites] Nat Clin Pract Endocrinol Metab. 2006 Dec;2(12 ):702-6; quiz following 706 [17143317.001]
  • (PMID = 19184535.001).
  • [ISSN] 1573-7292
  • [Journal-full-title] Familial cancer
  • [ISO-abbreviation] Fam. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Iron-Sulfur Proteins
  •  go-up   go-down


3. Lee SS, Baek KH, Lee YS, Lee JM, Kang MI, Cha BY, Lee KW, Son HY, Kang SK: Subclinical Cushing's syndrome associated with an adrenocortical oncocytoma. J Endocrinol Invest; 2008 Jul;31(7):675-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Subclinical Cushing's syndrome associated with an adrenocortical oncocytoma.
  • Oncocytoma is a neoplasm that can arise in several organs, and it has been more commonly described in the kidney, salivary gland and thyroid.
  • Oncocytoma arising in the adrenal gland is a rare finding.
  • Moreover, functioning adrenocortical oncocytoma is exceptionally rare.
  • Right adrenalectomy was performed, and this revealed a well-circumscribed dark-brown tumor that measured 2.4x2.2 cm.
  • The tumor consisted almost exclusively of large eosinophilic and epitheloid cells whose cytoplasm was packed with eosinophilic granulations, which corresponded to the numerous mitochondria confirmed on electron microscopy.
  • This is a rare case of subclinical Cushing's syndrome that was caused by adrenocortical oncocytoma.
  • [MeSH-major] Adenoma, Oxyphilic / pathology. Adrenal Cortex Neoplasms / pathology. Cushing Syndrome / pathology

  • Genetic Alliance. consumer health - Cushing's Syndrome.
  • MedlinePlus Health Information. consumer health - Cushing's Syndrome.
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Appl Immunohistochem Mol Morphol. 2001 Sep;9(3):222-8 [11556749.001]
  • [Cites] Virchows Arch. 1998 Jul;433(1):5-12 [9692819.001]
  • [Cites] Am J Clin Pathol. 1995 Oct;104(4):382-90 [7572786.001]
  • [Cites] N Engl J Med. 1985 May 23;312(21):1371-5 [3990735.001]
  • [Cites] Ann Diagn Pathol. 2005 Oct;9(5):295-7 [16198960.001]
  • [Cites] Am J Surg Pathol. 2002 Dec;26(12):1612-9 [12459628.001]
  • [Cites] Clin Imaging. 2003 Nov-Dec;27(6):426-30 [14585574.001]
  • [Cites] Ultrastruct Pathol. 1991 Jul-Oct;15(4-5):539-47 [1721751.001]
  • [Cites] Am J Surg Pathol. 1991 Oct;15(10 ):949-56 [1928551.001]
  • [Cites] Tumori. 1998 May-Jun;84(3):403-7 [9678626.001]
  • [Cites] Eur J Endocrinol. 2003 Apr;148(4):457-61 [12656667.001]
  • [Cites] J Clin Pathol. 1999 Feb;52(2):151-3 [10396247.001]
  • [Cites] Am J Surg Pathol. 1989 Mar;13(3):202-6 [2919718.001]
  • [Cites] Urology. 1997 Apr;49(4):624-8 [9111640.001]
  • [Cites] Medicine (Baltimore). 1965 Jan;44:37-79 [14264352.001]
  • [Cites] J Clin Endocrinol Metab. 2000 Feb;85(2):637-44 [10690869.001]
  • [Cites] J Comput Assist Tomogr. 1996 May-Jun;20(3):407-9 [8626901.001]
  • [Cites] Ultrastruct Pathol. 1991 Jul-Oct;15(4-5):549-56 [1755111.001]
  • [Cites] Am J Med. 1981 Nov;71(5):855-75 [6272575.001]
  • [Cites] Am J Surg Pathol. 1998 May;22(5):603-14 [9591731.001]
  • [Cites] Pediatr Blood Cancer. 2008 Mar;50(3):718-21 [17091483.001]
  • [Cites] Pathol Int. 2004 Aug;54(8):603-10 [15260851.001]
  • [Cites] Cancer. 1992 Dec 1;70(11):2681-4 [1423199.001]
  • [Cites] Clin Endocrinol (Oxf). 1998 Jan;48(1):89-97 [9509073.001]
  • [Cites] Obstet Gynecol. 2001 Nov;98(5 Pt 2):916-8 [11704201.001]
  • [Cites] Pathol Annu. 1992;27 Pt 1:263-304 [1736246.001]
  • [Cites] Hinyokika Kiyo. 1986 May;32(5):757-63 [3751804.001]
  • [Cites] J Clin Endocrinol Metab. 1996 Sep;81(9):3173-6 [8784064.001]
  • [Cites] Virchows Arch A Pathol Anat Histopathol. 1992;421(6):533-7 [1281594.001]
  • [Cites] J Clin Endocrinol Metab. 2002 May;87(5):2367-75 [11994389.001]
  • [Cites] Int J Surg Pathol. 2004 Jul;12(3):231-43 [15306935.001]
  • [Cites] Arch Esp Urol. 1999 Jun;52(5):525-8 [10427894.001]
  • [Cites] Nat Clin Pract Urol. 2006 Nov;3(11):618-21 [17088930.001]
  • (PMID = 18787391.001).
  • [ISSN] 1720-8386
  • [Journal-full-title] Journal of endocrinological investigation
  • [ISO-abbreviation] J. Endocrinol. Invest.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Glucocorticoids; 0 / Synaptophysin; 0 / inhibin A; 57285-09-3 / Inhibins; 68238-35-7 / Keratins; 7S5I7G3JQL / Dexamethasone
  •  go-up   go-down


Advertisement
4. Arias LF, Hernández S, Bocardo G, González L, Vélez M, Arteta A, Blanco J: [Ancillary studies in the differential diagnosis of epithelial renal cell tumors with granular cells]. Actas Urol Esp; 2008 Feb;32(2):194-201
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Ancillary studies in the differential diagnosis of epithelial renal cell tumors with granular cells].
  • [Transliterated title] Estudios auxiliares en el diagnóstico diferencial de tumores epiteliales renales con células granulares.
  • INTRODUCTION AND OBJECTIVES: Differential diagnosis of renal neoplasms with granular cells may pose difficulties and implications on ontogeny and prognosis.
  • METHODS: We studied with colloidal iron staining (Mowry's modified method) and 22 commonly used immunomarkers 22 conventional carcinomas (CC), 37 chromophobe carcinomas (CPC), 8 oncocytomas (OC), and 7 collecting duct carcinomas (CDC) with granular cells.
  • RESULTS: Colloidal iron staining was diffuse, strong, reticular, and cytoplasmic in 32 CPC cases, the diffuse and strong pattern was not observed in other tumors.
  • CONCLUSIONS: Morphologic features, colloidal iron staining (modified Mowry's method), and immunostaining with CK7/CD10/vim permit the final diagnosis with high specificity.
  • [MeSH-major] Kidney Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18409469.001).
  • [ISSN] 0210-4806
  • [Journal-full-title] Actas urologicas españolas
  • [ISO-abbreviation] Actas Urol Esp
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


5. Mertz KD, Tchinda J, Küfer R, Möller P, Rubin MA, Moch H, Perner S: [Cytogenetic alterations in renal tumors. Applications for comparative genomic hybridization and fluorescence in situ hybridization]. Urologe A; 2006 Mar;45(3):316-8, 320-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Cytogenetic alterations in renal tumors. Applications for comparative genomic hybridization and fluorescence in situ hybridization].
  • The WHO classification of renal cell carcinomas (RCC) takes into account chromosomal alterations.
  • Clear cell (classic) RCC frequently show the loss of 3p.
  • Oncocytomas can be divided into cases with rearrangements in the 11q13 region and those with loss of chromosome 1 and the sex chromosomes.
  • Translocations involving chromosome 3, such as t(3;8)(p14;q24.13) and t(2;3)(q35;q21) have been described in familial clear cell RCC.
  • The most recent class of RCC, seen only in men, is referred to as translocation tumors.
  • These tumors demonstrate a tubulopapillary growth pattern and have a t(X;1)(p11.2;q21.2) translocation.
  • [MeSH-major] Carcinoma, Renal Cell / genetics. Chromosome Banding. Genetic Markers / genetics. Hybridization, Genetic. In Situ Hybridization, Fluorescence. Kidney Neoplasms / genetics
  • [MeSH-minor] DNA Mutational Analysis. DNA, Neoplasm / genetics. Female. Humans. Male. Prognosis. Translocation, Genetic / genetics

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Pathol. 1999 Jul;155(1):267-74 [10393858.001]
  • [Cites] Int J Cancer. 1999 Jan 5;80(1):22-4 [9935224.001]
  • [Cites] Diagn Mol Pathol. 1996 Mar;5(1):53-64 [8919546.001]
  • [Cites] Hum Mol Genet. 2002 Mar 15;11(6):641-9 [11912179.001]
  • [Cites] Clin Lab Med. 2005 Jun;25(2):363-78 [15848741.001]
  • [Cites] Cancer Genet Cytogenet. 1998 Nov;107(1):1-6 [9809026.001]
  • [Cites] Genes Chromosomes Cancer. 1996 Dec;17(4):199-204 [8946201.001]
  • [Cites] Am J Pathol. 1998 Nov;153(5):1467-73 [9811338.001]
  • [Cites] Am J Pathol. 1994 Aug;145(2):356-64 [7519827.001]
  • [Cites] Nature. 2005 Jul 7;436(7047):117-22 [16001072.001]
  • [Cites] Cancer Res. 2000 Nov 15;60(22):6503-9 [11103820.001]
  • [Cites] Exp Cell Res. 1980 Aug;128(2):485-90 [6157553.001]
  • [Cites] Rev Clin Exp Hematol. 2002 Jun;6(2):91-113; discussion 200-2 [12196211.001]
  • [Cites] Oncogene. 1998 Aug 13;17(6):733-9 [9715275.001]
  • [Cites] Mol Pathol. 1999 Oct;52(5):243-51 [10748872.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Aug 4;95(16):9572-7 [9689122.001]
  • [Cites] Mod Pathol. 2003 Oct;16(10):1053-9 [14559990.001]
  • [Cites] Cancer Genet Cytogenet. 2005 Apr 15;158(2):110-8 [15796957.001]
  • [Cites] J Natl Cancer Inst. 1999 Jul 7;91(13):1159-60 [10393725.001]
  • [Cites] Hum Mol Genet. 1996 Sep;5(9):1333-8 [8872474.001]
  • [Cites] Hum Mol Genet. 2002 Oct 1;11(20):2489-98 [12351585.001]
  • [Cites] Am J Pathol. 1998 May;152(5):1107-23 [9588877.001]
  • [Cites] Environ Mol Mutagen. 1996;27(4):245-54 [8665869.001]
  • [Cites] J Cell Sci. 2003 Jul 15;116(Pt 14):2833-8 [12808017.001]
  • [Cites] Science. 1992 Oct 30;258(5083):818-21 [1359641.001]
  • [Cites] Cancer Res. 1996 Jan 1;56(1):27-30 [8548768.001]
  • [Cites] Cytogenet Cell Genet. 2001;93(3-4):221-7 [11528115.001]
  • [Cites] J Urol. 2005 Aug;174(2):731-5 [16006966.001]
  • (PMID = 16465524.001).
  • [ISSN] 0340-2592
  • [Journal-full-title] Der Urologe. Ausg. A
  • [ISO-abbreviation] Urologe A
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / DNA, Neoplasm; 0 / Genetic Markers
  • [Number-of-references] 27
  •  go-up   go-down


6. Henske EP: Tuberous sclerosis and the kidney: from mesenchyme to epithelium, and beyond. Pediatr Nephrol; 2005 Jul;20(7):854-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The renal manifestations of tuberous sclerosis complex (TSC) are remarkably diverse, including polycystic kidney disease, oncocytomas, renal cell carcinomas, and both benign and malignant angiomyolipomas.
  • What is particularly unusual about TSC, setting it apart from virtually all other inherited forms of renal disease, is the abnormalities of both mesenchymal cells (angiomyolipomas) and epithelial cells (cysts, oncocytomas, and carcinomas).
  • This places TSC1/TSC2 at center stage in signaling pathways that regulate cell growth.
  • Here, we will address the genetic, cellular and biochemical mechanisms that may contribute to the unusually broad spectrum of renal disease in cells with TSC1 or TSC2 mutations, and consider how the TSC signaling pathways may be linked to other renal diseases such as polycystic kidney disease and renal cell carcinoma.
  • [MeSH-major] Angiomyolipoma / etiology. Carcinoma / etiology. Kidney Neoplasms / etiology. Tuberous Sclerosis / complications
  • [MeSH-minor] Humans. Mutation. Repressor Proteins / genetics. Repressor Proteins / metabolism. Signal Transduction. Tumor Suppressor Proteins / genetics. Tumor Suppressor Proteins / metabolism

  • Genetic Alliance. consumer health - Tuberous sclerosis.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • MedlinePlus Health Information. consumer health - Tuberous Sclerosis.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nat Cell Biol. 2000 May;2(5):281-7 [10806479.001]
  • [Cites] Am J Hum Genet. 2001 Jan;68(1):64-80 [11112665.001]
  • [Cites] Cancer Cell. 2003 Aug;4(2):147-58 [12957289.001]
  • [Cites] Cell. 1993 Dec 31;75(7):1305-15 [8269512.001]
  • [Cites] Am J Pathol. 2003 Feb;162(2):457-68 [12547704.001]
  • [Cites] Am J Hum Genet. 1999 May;64(5):1305-15 [10205261.001]
  • [Cites] Oncogene. 2002 Sep 12;21(41):6356-65 [12214276.001]
  • [Cites] Am J Physiol Lung Cell Mol Physiol. 2004 Apr;286(4):L694-700 [12922981.001]
  • [Cites] Am J Hum Genet. 2001 Sep;69(3):493-503 [11468687.001]
  • [Cites] Oncogene. 2004 Apr 19;23(18):3151-71 [15094765.001]
  • [Cites] Oncogene. 2002 Dec 5;21(55):8470-6 [12466966.001]
  • [Cites] Hum Mol Genet. 1998 Jun;7(6):1053-7 [9580671.001]
  • [Cites] J Urol. 1998 Jul;160(1):141-5 [9628635.001]
  • [Cites] Pediatr Radiol. 2002 Sep;32(9):677-80 [12195309.001]
  • [Cites] Lancet. 2003 Apr 19;361(9366):1348-9 [12711473.001]
  • [Cites] Am J Surg Pathol. 1998 Feb;22(2):180-7 [9500218.001]
  • [Cites] Cell. 2003 Nov 26;115(5):577-90 [14651849.001]
  • [Cites] Am J Pathol. 2003 Feb;162(2):491-500 [12547707.001]
  • [Cites] Cancer. 1998 Nov 15;83(10):2208-16 [9827727.001]
  • [Cites] Cancer Res. 1998 Nov 1;58(21):4766-70 [9809973.001]
  • [Cites] Am J Surg Pathol. 1998 Jun;22(6):663-72 [9630173.001]
  • [Cites] Mod Pathol. 2002 Mar;15(3):205-10 [11904337.001]
  • [Cites] J Urol. 2003 Dec;170(6 Pt 1):2163-72 [14634372.001]
  • [Cites] J Biol Chem. 2004 Jul 16;279(29):29930-7 [15150271.001]
  • [Cites] Cancer Res. 2003 May 15;63(10):2675-80 [12750296.001]
  • [Cites] Mayo Clin Proc. 1991 Aug;66(8):792-6 [1861550.001]
  • [Cites] J Biol Chem. 2003 Dec 19;278(51):51372-9 [14551205.001]
  • [Cites] Am J Pathol. 1996 Oct;149(4):1201-8 [8863669.001]
  • [Cites] Mol Cell. 2001 Apr;7(4):823-32 [11336705.001]
  • [Cites] J Clin Invest. 1997 Jan 15;99(2):194-9 [9005987.001]
  • [Cites] Am J Hum Genet. 1996 Aug;59(2):400-6 [8755927.001]
  • [Cites] Urology. 1991 Apr;37(4):340-3 [2014599.001]
  • [Cites] Eur J Radiol. 1998 May;27(2):131-8 [9639138.001]
  • [Cites] Nat Genet. 1994 Dec;8(4):328-32 [7894481.001]
  • [Cites] Nat Genet. 1994 Feb;6(2):193-6 [8162074.001]
  • [Cites] Hum Mol Genet. 1994 Oct;3(10):1829-32 [7849708.001]
  • [Cites] Kidney Int. 2004 Sep;66(3):924-34 [15327383.001]
  • [Cites] J Pediatr Surg. 1996 May;31(5):729-30 [8861495.001]
  • [Cites] Am J Surg Pathol. 2000 Jun;24(6):889-94 [10843294.001]
  • [Cites] Hum Mol Genet. 1994 Oct;3(10):1833-4 [7849709.001]
  • [Cites] Science. 1997 Aug 8;277(5327):805-8 [9242607.001]
  • (PMID = 15856327.001).
  • [ISSN] 0931-041X
  • [Journal-full-title] Pediatric nephrology (Berlin, Germany)
  • [ISO-abbreviation] Pediatr. Nephrol.
  • [Language] eng
  • [Grant] United States / NIDDK NIH HHS / DK / DK 51052
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Repressor Proteins; 0 / Tumor Suppressor Proteins; 0 / tuberous sclerosis complex 1 protein; 4JG2LF96VF / tuberous sclerosis complex 2 protein
  • [Number-of-references] 43
  •  go-up   go-down


7. Klomp JA, Petillo D, Niemi NM, Dykema KJ, Chen J, Yang XJ, Sääf A, Zickert P, Aly M, Bergerheim U, Nordenskjöld M, Gad S, Giraud S, Denoux Y, Yonneau L, Méjean A, Vasiliu V, Richard S, MacKeigan JP, Teh BT, Furge KA: Birt-Hogg-Dubé renal tumors are genetically distinct from other renal neoplasias and are associated with up-regulation of mitochondrial gene expression. BMC Med Genomics; 2010;3:59
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Birt-Hogg-Dubé renal tumors are genetically distinct from other renal neoplasias and are associated with up-regulation of mitochondrial gene expression.
  • The majority of renal tumors that arise in BHDS-affected individuals are histologically similar to sporadic chromophobe renal cell carcinoma (RCC) and sporadic renal oncocytoma.
  • However, most sporadic tumors lack FLCN mutations and the extent to which the BHDS-derived renal tumors share genetic defects associated with the sporadic tumors has not been well studied.
  • Comparative gene expression profiling analyses were carried out on renal tumors isolated from individuals afflicted with BHDS and a panel of sporadic renal tumors of different subtypes using discriminate and clustering approaches. qRT-PCR was used to confirm selected results of the gene expression analyses.
  • RESULTS: Renal tumors isolated from individuals with BHDS showed distinct gene expression and cytogenetic characteristics from sporadic renal oncocytoma and chromophobe RCC.
  • The most prominent molecular feature of BHDS-derived kidney tumors was high expression of mitochondria-and oxidative phosphorylation (OXPHOS)-associated genes.
  • Loss of FLCN expression across various tumor types is also associated with increased nuclear mitochondrial gene expression.
  • CONCLUSIONS: Our results support a genetic distinction between BHDS-associated tumors and other renal neoplasias.
  • In addition, deregulation of the PGC-1α-TFAM signaling axis is most pronounced in renal tumors that harbor FLCN mutations and in tumors from other organs that have relatively low expression of FLCN.
  • [MeSH-major] Birt-Hogg-Dube Syndrome / genetics. Genes, Mitochondrial. Kidney Neoplasms / genetics. Up-Regulation
  • [MeSH-minor] Adenoma, Oxyphilic / genetics. Carcinoma, Renal Cell / genetics. DNA-Binding Proteins / metabolism. Estrone / genetics. Heat-Shock Proteins / genetics. Heat-Shock Proteins / metabolism. Humans. Mitochondrial Proteins / metabolism. Oxidative Phosphorylation. Signal Transduction. Transcription Factors / genetics. Transcription Factors / metabolism

  • Genetic Alliance. consumer health - Birt-Hogg-Dube Syndrome.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ESTRONE .
  • SciCrunch. ArrayExpress: Data: Microarray .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] BJU Int. 2005 Dec;96(9):1275-9 [16287444.001]
  • [Cites] PLoS One. 2008;3(10):e3581 [18974783.001]
  • [Cites] Am J Surg Pathol. 2008 Dec;32(12):1822-34 [18813125.001]
  • [Cites] Oncogene. 2009 Apr 2;28(13):1594-604 [19234517.001]
  • [Cites] Cancer Res. 2009 Jun 1;69(11):4674-81 [19470766.001]
  • [Cites] Annu Rev Physiol. 2009;71:177-203 [19575678.001]
  • [Cites] Cancer Res. 2009 Nov 1;69(21):8256-64 [19843858.001]
  • [Cites] Proc Natl Acad Sci U S A. 2009 Nov 3;106(44):18722-7 [19850877.001]
  • [Cites] Lancet Oncol. 2009 Dec;10(12):1199-206 [19959076.001]
  • [Cites] Int J Biol Sci. 2010;6(3):213-24 [20440404.001]
  • [Cites] Int J Urol. 2010 Jul;17(7):592-600 [20590942.001]
  • [Cites] Int J Urol. 2010 Jul;17(7):602-12 [20590944.001]
  • [Cites] Oncogene. 2006 May 11;25(20):2885-9 [16369488.001]
  • [Cites] Bioinformatics. 2006 Jun 15;22(12):1540-2 [16595560.001]
  • [Cites] Cancer Res. 2006 Jun 15;66(12):6087-96 [16778181.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Oct 17;103(42):15552-7 [17028174.001]
  • [Cites] Genes Chromosomes Cancer. 2007 Jan;46(1):75-86 [17044051.001]
  • [Cites] Clin Cancer Res. 2006 Dec 1;12(23):6937-45 [17145811.001]
  • [Cites] Arch Pathol Lab Med. 2006 Dec;130(12):1865-70 [17149965.001]
  • [Cites] Mol Cell. 2006 Dec 8;24(5):797-803 [17157261.001]
  • [Cites] Arch Pathol Lab Med. 2007 Jan;131(1):81-5 [17227127.001]
  • [Cites] Br J Cancer. 2007 Jan 29;96(2):336-40 [17133269.001]
  • [Cites] Clin Cancer Res. 2007 Jan 15;13(2 Pt 2):671s-679s [17255292.001]
  • [Cites] Clin Cancer Res. 2007 Jan 15;13(2 Pt 2):680s-684s [17255293.001]
  • [Cites] Oncogene. 2007 Feb 26;26(9):1346-50 [17322920.001]
  • [Cites] J Pathol. 2007 Apr;211(5):524-31 [17323425.001]
  • [Cites] Cancer Res. 2007 Apr 1;67(7):3171-6 [17409424.001]
  • [Cites] Hum Mol Genet. 2007 Apr 15;16(8):993-1005 [17341490.001]
  • [Cites] Nature. 2007 Nov 29;450(7170):736-40 [18046414.001]
  • [Cites] J Natl Cancer Inst. 2008 Jan 16;100(2):140-54 [18182616.001]
  • [Cites] Cancer Genet Cytogenet. 2008 Jan 15;180(2):100-9 [18206534.001]
  • [Cites] Hum Mol Genet. 2008 Apr 1;17(7):986-95 [18156159.001]
  • [Cites] Physiol Rev. 2008 Apr;88(2):611-38 [18391175.001]
  • [Cites] Clin Cancer Res. 2008 Apr 15;14(8):2270-5 [18413815.001]
  • [Cites] Gene. 2008 May 31;415(1-2):60-7 [18403135.001]
  • [Cites] Cancer Res. 2008 Jun 1;68(11):4034-8 [18519660.001]
  • [Cites] J Med Genet. 2008 Jun;45(6):321-31 [18234728.001]
  • [Cites] Cardiovasc Res. 2008 Jul 15;79(2):208-17 [18430751.001]
  • [Cites] Clin Cancer Res. 2008 Aug 1;14(15):4726-34 [18676741.001]
  • [Cites] PLoS Genet. 2008;4(9):e1000176 [18773095.001]
  • [Cites] Oncogene. 2008 Sep 11;27(40):5339-47 [18663353.001]
  • [Cites] Mod Pathol. 2001 Aug;14(8):760-7 [11504835.001]
  • [Cites] Eur Urol. 2001 Sep;40(3):330-6 [11684851.001]
  • [Cites] Cancer Cell. 2002 Aug;2(2):157-64 [12204536.001]
  • [Cites] Am J Surg Pathol. 2002 Dec;26(12):1542-52 [12459621.001]
  • [Cites] J Med Genet. 2002 Dec;39(12):906-12 [12471204.001]
  • [Cites] Am J Pathol. 2003 Mar;162(3):925-32 [12598325.001]
  • [Cites] Nat Genet. 2003 Jul;34(3):267-73 [12808457.001]
  • [Cites] Cancer Res. 2003 Aug 1;63(15):4583-7 [12907635.001]
  • [Cites] Biochem Biophys Res Commun. 2003 Oct 24;310(3):779-84 [14550271.001]
  • [Cites] Oncogene. 2003 Oct 2;22(43):6810-8 [14555994.001]
  • [Cites] Genome Biol. 2004;5(10):R80 [15461798.001]
  • [Cites] Bioinformatics. 2004 Oct 12;20(15):2471-2 [15073005.001]
  • [Cites] Genes Chromosomes Cancer. 1989 Sep;1(1):79-82 [2487148.001]
  • [Cites] J Pathol. 1992 Jul;167(3):273-7 [1381433.001]
  • [Cites] Histopathology. 1993 Jan;22(1):1-8 [8436337.001]
  • [Cites] J Biol Chem. 1993 Jun 5;268(16):12156-63 [8505336.001]
  • [Cites] Cancer Genet Cytogenet. 1997 Jul 15;96(2):95-101 [9216713.001]
  • [Cites] J Mol Diagn. 2005 May;7(2):206-18 [15858144.001]
  • [Cites] BMC Genomics. 2005;6:67 [15882461.001]
  • [Cites] J Natl Cancer Inst. 2005 Jun 15;97(12):931-5 [15956655.001]
  • [Cites] Cancer Res. 2005 Jul 1;65(13):5628-37 [15994935.001]
  • [Cites] Science. 2005 Oct 28;310(5748):644-8 [16254181.001]
  • [Cites] J Cell Physiol. 2006 Jan;206(1):103-11 [15920738.001]
  • [Cites] Nucleic Acids Res. 2005;33(20):e175 [16284200.001]
  • (PMID = 21162720.001).
  • [ISSN] 1755-8794
  • [Journal-full-title] BMC medical genomics
  • [ISO-abbreviation] BMC Med Genomics
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA-Binding Proteins; 0 / Heat-Shock Proteins; 0 / Mitochondrial Proteins; 0 / PPARGC1A protein, human; 0 / TFAM protein, human; 0 / Transcription Factors; 2DI9HA706A / Estrone; Oncocytoma, renal
  • [Other-IDs] NLM/ PMC3012009
  •  go-up   go-down


8. Sanz-Ortega J, Olivier C, Pérez Segura P, Galante Romo I, San José Mansó L, Saez M: [Hereditary renal cancer]. Actas Urol Esp; 2009 Feb;33(2):127-33
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Cáncer de riñón hereditario.
  • People with Von Hippel-Lindau syndrome have about a 40% risk of developing multiple bilateral clear cell kidney cancers.
  • They can also develop retinal and brain hemangioblastoma, kidneys or pancreas cysts, pheochromocytoma and endolymphatic sac tumor.
  • Hereditary papillary renal cell carcinoma syndrome has type 1 papillary renal cell carcinomas associated with protooncogene c-MET germline mutations.
  • Birt-Hogg-Dubé syndrome has FLCN gene mutations associated with fibrofolliculomas, lung cysts with a high risk for spontaneous pneumothorax, and a 15% to 30% risk of kidney cancer (most classified as chromophobe carcinoma, oncocytoma or oncocytic hybrid, but clear cell and papillary kidney cancers have also been reported).
  • Histopathological findings such as oncocytosis and oncocytic hybrids are very unusual outside the syndrome.
  • Hereditary leiomyomatosis and renal cell cancer syndrome shows mutations of Fumarate hydratase gene and cutaneous leiomyomata in 76% of affected individuals, uterine leiomyomata in 100% of females, and unilateral, solitary, and aggressive papillary renal cancer in 10 to 16% of patients.
  • Tuberous sclerosis complex is one of the most prevalent (1/5.800) hereditary syndromes where renal disease is the second leading cause of death, associated with angiomyolipomas (70%), renal cysts, oncocytomas or clear cell cancer.
  • [MeSH-major] Kidney Neoplasms / genetics
  • [MeSH-minor] Cysts / genetics. Hair Follicle. Humans. Lung Diseases / genetics. Skin Neoplasms / genetics. Syndrome. von Hippel-Lindau Disease / diagnosis. von Hippel-Lindau Disease / genetics


9. Pobes Martínez De Salinas A, Suárez Laurés AM, Quiñones Ortiz L, Menéndez Fernández CL: [Renal oncocytoma and papillary microcarcinoma coexisting with cystic disease acquired before dialysis]. Nefrologia; 2008;28(3):356-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Renal oncocytoma and papillary microcarcinoma coexisting with cystic disease acquired before dialysis].
  • [MeSH-major] Adenoma, Oxyphilic / complications. Carcinoma, Papillary / complications. Kidney Diseases, Cystic / complications. Kidney Neoplasms / complications. Neoplasms, Multiple Primary / complications

  • Genetic Alliance. consumer health - Oncocytoma renal.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • MedlinePlus Health Information. consumer health - Kidney Cysts.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18590511.001).
  • [ISSN] 0211-6995
  • [Journal-full-title] Nefrología : publicación oficial de la Sociedad Española Nefrologia
  • [ISO-abbreviation] Nefrologia
  • [Language] spa
  • [Publication-type] Case Reports; Letter
  • [Publication-country] Spain
  •  go-up   go-down


10. Kostiukov SI, Medvedev VL, Kogan MI: [Diagnosis and laparoscopic treatment of renal cysts of Bosniak type III and IV]. Urologiia; 2008 May-Jun;(3):21-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Cystic carcinoma was detected histologically in 8 Bosniak III cases.
  • Renal cell carcinoma was detected in 3 of 4 Bosniak IV cases, oncocytoma--in 1 case.
  • During the mean follow-up of 40 months no events of local recurrence, progression or tumor growth in places of trocar installation were detected.
  • [MeSH-major] Kidney Diseases, Cystic. Kidney Neoplasms. Laparoscopy. Nephrectomy / methods

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • MedlinePlus Health Information. consumer health - Kidney Cysts.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18669342.001).
  • [ISSN] 1728-2985
  • [Journal-full-title] Urologii︠a︡ (Moscow, Russia : 1999)
  • [ISO-abbreviation] Urologiia
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  •  go-up   go-down


11. Al-Ahmadie HA, Olgac S, Gregor PD, Tickoo SK, Fine SW, Kondagunta GV, Scher HI, Morris MJ, Russo P, Motzer RJ, Reuter VE: Expression of prostate-specific membrane antigen in renal cortical tumors. Mod Pathol; 2008 Jun;21(6):727-32
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of prostate-specific membrane antigen in renal cortical tumors.
  • Prostate-specific membrane antigen is a type II membrane glycoprotein that is expressed in benign and neoplastic prostatic tissue and has been recently shown to be also expressed in the neovasculature of various solid malignant tumors including renal cell carcinoma.
  • Renal cell carcinoma is a heterogeneous group of tumors with distinct morphologic and genetic characteristics and clinical behaviors.
  • The study included 30 clear cell renal cell carcinomas, and 15 of each of papillary and chromophobe renal cell carcinoma and oncocytoma.
  • In all cases, immunoreactivity was detected only in the tumor-associated neovasculature and not in tumor cells.
  • Clear cell renal cell carcinoma showed the most diffuse staining pattern, where 24/30 cases or 80% had >50% reactive vessels, followed by chromophobe renal cell carcinoma (9/15; 60%) and oncocytoma (5/15, 33%).
  • No diffuse staining was detected in any of the papillary renal cell carcinomas and only focal staining was detected in 11 cases (11/15; 73%).
  • Staining intensity was the strongest in clear cell renal cell carcinoma (25/30; 83%) followed by chromophobe renal cell carcinoma (9/15; 60%), oncocytoma (8/15, 53%) and papillary renal cell carcinoma (5/15; 33%).
  • In summary, prostate-specific membrane antigen is expressed in tumor-associated neovasculature of the majority of renal cortical tumors and is most diffusely and intensely expressed in clear cell renal cell carcinoma and least in papillary renal cell carcinoma.
  • The differences in the expression of prostate-specific membrane antigen in renal cell carcinoma subtypes provide further evidence of the biological diversity of these tumors, and diagnostic and therapeutic applications of such expression can be expanded to include subtypes of renal cell carcinoma.
  • [MeSH-major] Antigens, Surface / biosynthesis. Biomarkers, Tumor / analysis. Carcinoma, Renal Cell / metabolism. Carcinoma, Renal Cell / pathology. Glutamate Carboxypeptidase II / biosynthesis. Kidney Neoplasms / metabolism. Kidney Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18344976.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Surface; 0 / Biomarkers, Tumor; EC 3.4.17.21 / Glutamate Carboxypeptidase II; EC 3.4.17.21 / glutamate carboxypeptidase II, human
  •  go-up   go-down


12. Roncaroli F, Scheithauer BW: Papillary tumor of the pineal region and spindle cell oncocytoma of the pituitary: new tumor entities in the 2007 WHO Classification. Brain Pathol; 2007 Jul;17(3):314-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Papillary tumor of the pineal region and spindle cell oncocytoma of the pituitary: new tumor entities in the 2007 WHO Classification.
  • We have reviewed the features of two recently described intracranial tumors, which have been formally recognized as distinct entities by the 2007 WHO Classification of Brain Tumours: Papillary tumor of the pineal region and spindle cell oncocytoma of the pituitary gland.
  • [MeSH-major] Adenoma, Oxyphilic / classification. Papilloma / classification. Pinealoma / classification. Pituitary Neoplasms / classification. Sarcoma / classification. World Health Organization

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17598824.001).
  • [ISSN] 1015-6305
  • [Journal-full-title] Brain pathology (Zurich, Switzerland)
  • [ISO-abbreviation] Brain Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


13. Tamaskar I, Choueiri TK, Sercia L, Rini B, Bukowski R, Zhou M: Differential expression of caveolin-1 in renal neoplasms. Cancer; 2007 Aug 15;110(4):776-82
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differential expression of caveolin-1 in renal neoplasms.
  • BACKGROUND: Caveolin-1 is a major component of membrane caveolae, which are specialized lipid raft microdomains on cell membrane that are implicated in molecular transport, cell adhesion, and signal transduction.
  • The overexpression of caveolin-1 recently was associated with a poor outcome in patients with clear-cell renal cell carcinoma (CCRCC) and was proposed as a useful diagnostic marker.
  • In the current study, the authors used immunohistochemistry to investigate the membranous and cytoplasmic expression of caveolin-1 and its correlation with other pathologic parameters in different subtypes of renal neoplasms.
  • METHODS: A tissue microarray (TMA) was constructed from 60 normal kidneys, 22 CCRCCs, 20 papillary renal cell carcinomas (PRCCs), 16 chromophobe renal cell carcinomas (ChRCCs), and 19 oncocytomas (ONCs).
  • Both membranous and cytoplasmic caveolin-1 expression levels were measured and were correlated with tumor size, Fuhrman nuclear grade, and pathologic stage.
  • Membranous caveolin-1 expression was detected in 19 of 22 CCRCCs (86.4%), which was significantly higher than the membranous caveolin-1 expression detected in PRCCs (1 of 20 tumors; 5%), ChRCCs (0 of 16 tumors; 0%), and ONCs (1 of 19 tumors; 5.3%).
  • The percentage of tumors that expressed cytoplasmic caveolin-1 did not differ significantly among the different types of renal tumors (P = .1).
  • Only membranous caveolin-1 expression was correlated with tumor size (Pearson correlation = 0.266; P = .043).
  • There was no correlation between membranous or cytoplasmic caveolin-1 expression and other pathologic parameters, including Fuhrman nuclear grade and staging according to the American Joint Committee on Cancer tumor, lymph node, metastasis classification system.
  • CONCLUSIONS: Caveolin-1 expression has 2 distinctive patterns in renal neoplasms: membranous and cytoplasmic.
  • In the current study, membranous caveolin-1 expression was detected predominantly in CCRCCs and only rarely in other subtypes of renal neoplasms.
  • Thus, the current results indicated that caveolin-1 expression may have potential both as a diagnostic marker in the differential diagnosis of renal tumors and as a therapeutic target, especially for CCRCC.
  • [MeSH-major] Caveolin 1 / biosynthesis. Kidney Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma, Clear Cell / metabolism. Adenocarcinoma, Clear Cell / pathology. Adenoma, Oxyphilic / metabolism. Adenoma, Oxyphilic / pathology. Adult. Aged. Aged, 80 and over. Carcinoma, Papillary / metabolism. Carcinoma, Papillary / pathology. Carcinoma, Renal Cell / metabolism. Carcinoma, Renal Cell / pathology. Cohort Studies. Diagnosis, Differential. Female. Humans. Immunohistochemistry. Kidney / chemistry. Kidney / pathology. Male. Middle Aged. Tissue Array Analysis

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17594718.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Caveolin 1
  •  go-up   go-down


14. Sun G, Yang X, Tang E, Wen J, Lu M, Hu Q: The treatment of sublingual gland tumours. Int J Oral Maxillofac Surg; 2010 Sep;39(9):863-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The treatment of sublingual gland tumours.
  • This study assessed the clinical and histological features and therapeutic efficacy of 25 cases of sublingual gland tumours from 1998 to 2008.
  • 4 cases were benign tumours (16%).
  • 21 cases were malignant sublingual gland tumours (84%) and of these, 18 were adenoid cystic carcinoma (86%).
  • Adenoid cystic carcinoma was mainly of the histological type, and the other histological classifications included mucoepidermoid carcinoma, pleomorphic adenoma, myoepithelioma, oncocytoma and polymorphous low-grade adenocarcinoma.
  • Sublingual gland tumours are rare and most are malignant.
  • For malignant sublingual gland tumours, early diagnosis and aggressive surgical treatment, especially for tumours with nerve involvement, is the key to improving prognosis.
  • For benign sublingual gland tumours, the resection of tumour and sublingual gland is the preferred treatment.
  • [MeSH-major] Carcinoma / therapy. Salivary Gland Diseases / pathology. Sublingual Gland / pathology. Sublingual Gland Neoplasms / therapy
  • [MeSH-minor] Adenocarcinoma / pathology. Adenocarcinoma / therapy. Adenoma, Oxyphilic / pathology. Adenoma, Oxyphilic / therapy. Adenoma, Pleomorphic / pathology. Adenoma, Pleomorphic / therapy. Adult. Aged. Carcinoma, Adenoid Cystic / pathology. Carcinoma, Adenoid Cystic / therapy. Carcinoma, Mucoepidermoid / pathology. Carcinoma, Mucoepidermoid / therapy. Female. Humans. Male. Middle Aged. Myoepithelioma / pathology. Myoepithelioma / therapy. Reconstructive Surgical Procedures / methods

  • MedlinePlus Health Information. consumer health - Salivary Gland Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 International Association of Oral and Maxillofacial Surgeons. Published by Elsevier Ltd. All rights reserved.
  • (PMID = 20605409.001).
  • [ISSN] 1399-0020
  • [Journal-full-title] International journal of oral and maxillofacial surgery
  • [ISO-abbreviation] Int J Oral Maxillofac Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Denmark
  •  go-up   go-down


15. DeVoe WB, Kercher KW, Hope WW, Lincourt AE, Norton HJ, Teigland CM: Hand-assisted laparoscopic partial nephrectomy after 60 cases: comparison with open partial nephrectomy. Surg Endosc; 2009 May;23(5):1075-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Partial nephrectomy is the surgical standard of care for favorably located, small renal tumors.
  • As the incidence of renal cell carcinoma (RCC) and detection of small kidney masses have increased over the past 20 years, minimally invasive management of these lesions has become more common.
  • RESULTS: Average tumor size (2.6 cm HALPN versus 2.6 cm OPN, p = 0.97) was similar.
  • Although four HALPN renal tumors required intraoperative margin re-excision (based on immediate gross evaluation by a pathologist), the final positive margin rate was 0%.
  • Tumor pathology was as follows: 80.7% and 80% RCC, 12.3% and 8% oncocytoma, and 7% and 12% angiomyolipoma, for HALPN and OPN, respectively in each case.
  • In our institution, HALPN is the standard approach for patients with small, surgically accessible renal tumors.
  • [MeSH-major] Carcinoma, Renal Cell / surgery. Kidney Neoplasms / surgery. Nephrectomy / methods

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Surg Endosc. 2003 Dec;17(12):1889-95 [14569452.001]
  • [Cites] J Urol. 2007 Jul;178(1):47-50; discussion 50 [17574057.001]
  • [Cites] J Urol. 2005 May;173(5):1690-4 [15821559.001]
  • [Cites] J Endourol. 2008 Feb;22(2):313-6 [18294039.001]
  • [Cites] J Urol. 2003 Jul;170(1):64-8 [12796646.001]
  • [Cites] Urology. 2006 Oct;68(4):723-7 [17070341.001]
  • [Cites] J Endourol. 2005 May;19(4):456-9; discussion 459-60 [15910255.001]
  • [Cites] J Endourol. 2001 Mar;15(2):161-4 [11325086.001]
  • [Cites] Crit Pathw Cardiol. 2004 Sep;3(3):138-43 [18340155.001]
  • [Cites] Urol Clin North Am. 2003 Nov;30(4):843-52 [14680319.001]
  • [Cites] J Urol. 2002 Oct;168(4 Pt 1):1356-9; discussion 1359-60 [12352392.001]
  • [Cites] J Urol. 2007 Jul;178(1):41-6 [17574056.001]
  • [Cites] Urology. 2004 Sep;64(3):458-61 [15351570.001]
  • [Cites] J Urol. 1995 May;153(5):1409-14 [7714953.001]
  • [Cites] BJU Int. 2005 Oct;96(6):811-4 [16153207.001]
  • [Cites] Clin Cancer Res. 2004 Sep 15;10(18 Pt 2):6322S-7S [15448025.001]
  • [Cites] Eur Urol. 2008 Apr;53(4):732-42; discussion 742-3 [18222599.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] J Urol. 1993 Sep;150(3):940-3 [8345614.001]
  • [Cites] J Urol. 2006 Nov;176(5):1984-8; discussion 1988-9 [17070227.001]
  • [Cites] J Urol. 2000 Jun;163(6):1659-64 [10799155.001]
  • (PMID = 18830753.001).
  • [ISSN] 1432-2218
  • [Journal-full-title] Surgical endoscopy
  • [ISO-abbreviation] Surg Endosc
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


16. Foschini MP, Gaiba A, Cocchi R, Pennesi MG, Pession A: p63 expression in salivary gland tumors: role of DeltaNp73L in neoplastic transformation. Int J Surg Pathol; 2005 Oct;13(4):329-35
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] p63 expression in salivary gland tumors: role of DeltaNp73L in neoplastic transformation.
  • To illustrate the role of p63 and its truncated variants in salivary gland tumors, 23 consecutive tumors and 6 normal salivary glands were studied immunohistochemically with anti-p63 antibody and by reverse transcriptase (RT) and nested polymerase chain reaction (PCR) to detect p63 isoform expression.
  • Tumors: p63 antibody was positive in the following: Warthin tumor (WT) (3/3), oncocytoma (OC) (1/1), pleomorphic adenoma (PA) (7/7), polymorphous-low-grade adenocarcinoma (PLGA) (3/3), adenoid-cystic carcinoma (ADCC)(3/4), epithelial-myoepithelial-cell carcinoma (EMC) (1/1), and myoepithelial-cell carcinoma (MCC) (1/1).
  • By RT and nested PCR all tumors expressed p63 irrespective of their morphologic differentiation.
  • The DeltaNp73L isoform was present in tumoral tissue but absent in normal salivary gland.
  • [MeSH-major] Cell Transformation, Neoplastic. Phosphoproteins / genetics. Phosphoproteins / metabolism. Salivary Gland Neoplasms / metabolism. Salivary Gland Neoplasms / pathology. Trans-Activators / genetics. Trans-Activators / metabolism
  • [MeSH-minor] Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Adenolymphoma / metabolism. Adenolymphoma / pathology. Adenoma, Oxyphilic / metabolism. Adenoma, Oxyphilic / pathology. Adenoma, Pleomorphic / metabolism. Adenoma, Pleomorphic / pathology. Adult. Aged. Carcinoma, Adenoid Cystic / metabolism. Carcinoma, Adenoid Cystic / pathology. Cell Proliferation. DNA-Binding Proteins. Exons. Female. Gene Expression Regulation, Neoplastic. Genes, Tumor Suppressor. Humans. Immunohistochemistry. Male. Middle Aged. Myoepithelioma / metabolism. Myoepithelioma / pathology. Polymerase Chain Reaction. Protein Isoforms. Reverse Transcriptase Polymerase Chain Reaction. Salivary Glands / cytology. Salivary Glands / metabolism. Salivary Glands / pathology. Transcription Factors. Tumor Suppressor Proteins

  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16273188.001).
  • [ISSN] 1066-8969
  • [Journal-full-title] International journal of surgical pathology
  • [ISO-abbreviation] Int. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA-Binding Proteins; 0 / Phosphoproteins; 0 / Protein Isoforms; 0 / TP63 protein, human; 0 / Trans-Activators; 0 / Transcription Factors; 0 / Tumor Suppressor Proteins
  •  go-up   go-down


17. Wang KL, Weinrach DM, Luan C, Han M, Lin F, Teh BT, Yang XJ: Renal papillary adenoma--a putative precursor of papillary renal cell carcinoma. Hum Pathol; 2007 Feb;38(2):239-46
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Renal papillary adenoma--a putative precursor of papillary renal cell carcinoma.
  • The precursor lesions of renal cell carcinoma (RCC) are unknown.
  • The purpose of this study is to determine the incidence, histomorphological features, and immunohistochemical features of papillary adenoma and elucidate its potential relationship to RCC.
  • Immunohistochemistry was carried out with antibodies specific for alpha-methyl-coenzyme A racemase (AMACR) and glutathione S-transferase alpha (clear-cell RCC marker).
  • Thirty-eight (7%) nephrectomy specimens showed histologic evidence of papillary adenoma.
  • Seven papillary adenomas (18%) occurred in the setting of acquired polycystic kidney disease (APKD), 6 in clear-cell RCCs, 3 in chromophobe RCCs, 2 in end-stage kidney disease, 1 in oncocytoma, 1 in angiomyolipoma, and 1 in renal schwannoma.
  • Furthermore, papillary adenomas were more commonly found in kidneys removed for PRCC (25%, 18/71) than in kidneys harboring clear-cell RCC (1.9%, 6/318).
  • Histomorphologically, papillary adenomas were characterized by varying proportions of papillae and tubules formed by cuboidal cells with scant basophilic cytoplasm similar to those in type 1 PRCC.
  • Adenomas associated with PRCC tend to be multiple in number (61% [11/18] of cases had >2 adenomas; mean, 5).
  • In contrast, 100% of papillary adenomas arising in other conditions had less than 2 adenomas.
  • Most of the adenomas (82%, 31/38) stained strongly for AMACR in a fashion similar to that of PRCC.
  • In this study of surgical specimens, the high coincidence, multifocality, and histologic and immunohistochemical similarities between papillary adenoma and PRCC suggest that the 2 are strongly associated and may represent a continuum of 1 biologic process.
  • In contrast, adenomas associated with APKD exhibit distinct morphological and immunohistochemical features and, therefore, may have an entirely different pathogenesis.
  • [MeSH-major] Carcinoma, Papillary / pathology. Carcinoma, Renal Cell / pathology. Kidney Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma, Clear Cell / enzymology. Adenocarcinoma, Clear Cell / pathology. Adenoma. Adenoma, Oxyphilic / enzymology. Adenoma, Oxyphilic / pathology. Adult. Aged. Aged, 80 and over. Angiomyolipoma / enzymology. Angiomyolipoma / pathology. Disease Progression. Female. Glutathione Transferase / analysis. Humans. Immunohistochemistry. Isoenzymes / analysis. Kidney / enzymology. Kidney / pathology. Kidney Failure, Chronic / enzymology. Kidney Failure, Chronic / pathology. Male. Middle Aged. Models, Biological. Polycystic Kidney Diseases / enzymology. Polycystic Kidney Diseases / pathology. Racemases and Epimerases / analysis

  • Genetic Alliance. consumer health - Papillary renal cell carcinoma.
  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17056094.001).
  • [ISSN] 0046-8177
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Isoenzymes; EC 2.5.1.18 / Glutathione Transferase; EC 2.5.1.18 / glutathione S-transferase alpha; EC 5.1.- / Racemases and Epimerases; EC 5.1.99.4 / alpha-methylacyl-CoA racemase
  •  go-up   go-down


18. Vieira J, Henrique R, Ribeiro FR, Barros-Silva JD, Peixoto A, Santos C, Pinheiro M, Costa VL, Soares MJ, Oliveira J, Jerónimo C, Teixeira MR: Feasibility of differential diagnosis of kidney tumors by comparative genomic hybridization of fine needle aspiration biopsies. Genes Chromosomes Cancer; 2010 Oct;49(10):935-47
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Feasibility of differential diagnosis of kidney tumors by comparative genomic hybridization of fine needle aspiration biopsies.
  • The association of a genetic analysis that could improve the diagnostic accuracy of renal cell tumors in biopsy samples would allow better-informed therapeutic decisions.
  • We performed comparative genomic hybridization (CGH) on an ex vivo fine-needle aspiration (FNA) biopsy and a tumor fragment obtained from 75 patients consecutively diagnosed with renal tumors and subjected to radical nephrectomy.
  • The pattern of genomic changes by CGH was used blindly to classify the renal tumors and the genetic findings were subsequently compared with the histopathologic diagnosis.
  • In particular cases, including in two carcinomas with morphologically distinct tumor areas, we performed FISH with several locus-specific probes, and looked for VHL point mutations, exonic rearrangements, or promoter methylation.
  • CGH was successful in 82.7% FNA biopsies and in 96% tumor fragments, with the former allowing genetic diagnosis in 75% of renal cell tumors.
  • The genetic pattern correctly diagnosed 93.5% of clear cell renal cell carcinomas (RCC), 61.5% of chromophobe RCC, 100% of papillary RCC, and 14.3% of oncocytomas, with the negative predictive value being 93.9, 90.7, 100, and 90.2%, respectively.
  • We demonstrate that genetic diagnosis by CGH on FNA biopsies can improve differential diagnosis in patients with kidney tumors.
  • [MeSH-major] Adenoma, Oxyphilic / diagnosis. Carcinoma, Renal Cell / diagnosis. Chromosomes, Human / genetics. Comparative Genomic Hybridization. Kidney Neoplasms / diagnosis
  • [MeSH-minor] Biopsy, Fine-Needle. DNA Methylation. Diagnosis, Differential. Exons / genetics. Feasibility Studies. Humans. In Situ Hybridization, Fluorescence. Neoplasm Staging. Nephrectomy. Oligonucleotide Array Sequence Analysis. Point Mutation / genetics. Prognosis. Promoter Regions, Genetic. Survival Rate. Von Hippel-Lindau Tumor Suppressor Protein / genetics

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20629095.001).
  • [ISSN] 1098-2264
  • [Journal-full-title] Genes, chromosomes & cancer
  • [ISO-abbreviation] Genes Chromosomes Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] EC 6.3.2.19 / VHL protein, human; EC 6.3.2.19 / Von Hippel-Lindau Tumor Suppressor Protein
  •  go-up   go-down


19. Fridman E, Dotan Z, Barshack I, David MB, Dov A, Tabak S, Zion O, Benjamin S, Benjamin H, Kuker H, Avivi C, Rosenblatt K, Polak-Charcon S, Ramon J, Rosenfeld N, Spector Y: Accurate molecular classification of renal tumors using microRNA expression. J Mol Diagn; 2010 Sep;12(5):687-96
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Accurate molecular classification of renal tumors using microRNA expression.
  • Subtypes of renal tumors have different genetic backgrounds, prognoses, and responses to surgical and medical treatment, and their differential diagnosis is a frequent challenge for pathologists.
  • We extracted RNA from 71 formalin-fixed paraffin-embedded (FFPE) renal tumor samples and measured expression of more than 900 microRNAs using custom microarrays.
  • Clustering revealed similarity in microRNA expression between oncocytoma and chromophobe subtypes as well as between conventional (clear-cell) and papillary tumors.
  • We defined a two-step decision-tree classifier that uses expression levels of six microRNAs: the first step uses expression levels of hsa-miR-210 and hsa-miR-221 to distinguish between the two pairs of subtypes; the second step uses either hsa-miR-200c with hsa-miR-139-5p to identify oncocytoma from chromophobe, or hsa-miR-31 with hsa-miR-126 to identify conventional from papillary tumors.
  • The classifier was tested on an independent set of FFPE tumor samples from 54 additional patients, and identified correctly 93% of the cases.
  • MicroRNA expression profiling is a very effective molecular bioassay for classification of renal tumors and can offer a quantitative standardized complement to current methods of tumor classification.
  • [MeSH-major] Kidney Neoplasms / classification. MicroRNAs / genetics

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg Pathol. 2000 Sep;24(9):1247-56 [10976699.001]
  • [Cites] Int J Biochem Cell Biol. 2010 Aug;42(8):1355-62 [20619223.001]
  • [Cites] Hum Pathol. 2001 Jun;32(6):590-5 [11431713.001]
  • [Cites] J Urol. 2001 Jul;166(1):63-7 [11435824.001]
  • [Cites] Am J Surg Pathol. 2002 Mar;26(3):281-91 [11859199.001]
  • [Cites] J Clin Oncol. 2002 May 1;20(9):2376-81 [11981011.001]
  • [Cites] J Urol. 2002 Sep;168(3):950-5 [12187197.001]
  • [Cites] Am J Surg Pathol. 2003 May;27(5):612-24 [12717246.001]
  • [Cites] J Urol. 2003 Dec;170(6 Pt 1):2163-72 [14634372.001]
  • [Cites] Cell. 2004 Jan 23;116(2):281-97 [14744438.001]
  • [Cites] Pathol Int. 2004 Jun;54(6):377-86 [15144395.001]
  • [Cites] Am J Clin Pathol. 2004 Jun;121(6):878-83 [15198361.001]
  • [Cites] Am Rev Respir Dis. 1970 May;101(5):671-84 [4910640.001]
  • [Cites] J Natl Cancer Inst. 1989 Apr 5;81(7):527-30 [2921777.001]
  • [Cites] JAMA. 1999 May 5;281(17):1628-31 [10235157.001]
  • [Cites] Eur J Surg Oncol. 2005 Apr;31(3):299-303 [15780567.001]
  • [Cites] Hum Pathol. 2005 Mar;36(3):262-8 [15791570.001]
  • [Cites] Oncology. 2005;68(2-3):269-75 [16015044.001]
  • [Cites] Urology. 2005 Nov;66(5 Suppl):1-9 [16194700.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Dec 13;102(50):18081-6 [16330772.001]
  • [Cites] Nucleic Acids Res. 2006 Jan 1;34(Database issue):D140-4 [16381832.001]
  • [Cites] CA Cancer J Clin. 2006 Mar-Apr;56(2):106-30 [16514137.001]
  • [Cites] Pathol Oncol Res. 2006;12(1):5-11 [16554910.001]
  • [Cites] Eur Urol. 2006 Oct;50(4):786-93; discussion 793-4 [16697521.001]
  • [Cites] J Natl Cancer Inst. 2006 Sep 20;98(18):1331-4 [16985252.001]
  • [Cites] Nat Rev Cancer. 2006 Nov;6(11):857-66 [17060945.001]
  • [Cites] N Engl J Med. 2007 Jan 11;356(2):115-24 [17215529.001]
  • [Cites] J Natl Cancer Inst. 2007 Apr 4;99(7):569-70; author reply 570-1 [17406001.001]
  • [Cites] Arch Pathol Lab Med. 2007 Aug;131(8):1290-7 [17683191.001]
  • [Cites] BJU Int. 2007 Oct;100(4):802-8 [17822461.001]
  • [Cites] Urol Oncol. 2007 Sep-Oct;25(5):387-92 [17826655.001]
  • [Cites] Histopathology. 2008 Jan;52(2):158-66 [18036175.001]
  • [Cites] J Urol. 2008 Feb;179(2):439-43; discussion 443-4 [18076932.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] Genes Dev. 2008 Apr 1;22(7):894-907 [18381893.001]
  • [Cites] Nat Biotechnol. 2008 Apr;26(4):462-9 [18362881.001]
  • [Cites] Urol Oncol. 2008 May-Jun;26(3):225-38 [18452811.001]
  • [Cites] Nat Cell Biol. 2008 May;10(5):593-601 [18376396.001]
  • [Cites] J Biol Chem. 2008 May 30;283(22):14910-4 [18411277.001]
  • [Cites] Cancer. 2008 Jul 1;113(1):84-96 [18470927.001]
  • [Cites] Eur J Cancer. 2008 Aug;44(12):1701-9 [18502115.001]
  • [Cites] PLoS One. 2008;3(9):e3148 [18773077.001]
  • [Cites] J Urol. 2008 Oct;180(4):1257-61; discussion 1261 [18707712.001]
  • [Cites] Urol Clin North Am. 2008 Nov;35(4):551-61; v [18992609.001]
  • [Cites] J Pathol. 2008 Dec;216(4):418-27 [18925646.001]
  • [Cites] Semin Diagn Pathol. 2008 Nov;25(4):232-44 [19013890.001]
  • [Cites] PLoS One. 2008;3(11):e3726 [19015728.001]
  • [Cites] J Clin Oncol. 2009 Apr 20;27(12):2030-7 [19273703.001]
  • [Cites] Int J Oncol. 2009 Jul;35(1):109-14 [19513557.001]
  • [Cites] Brain Pathol. 2009 Jul;19(3):375-83 [18624795.001]
  • [Cites] Clin Cancer Res. 2010 Jan 15;16(2):610-9 [20068099.001]
  • [Cites] Mod Pathol. 2010 Jun;23(6):814-23 [20348879.001]
  • [Cites] Am J Pathol. 2001 May;158(5):1639-51 [11337362.001]
  • (PMID = 20595629.001).
  • [ISSN] 1943-7811
  • [Journal-full-title] The Journal of molecular diagnostics : JMD
  • [ISO-abbreviation] J Mol Diagn
  • [Language] eng
  • [Publication-type] Journal Article; Validation Studies
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / MicroRNAs
  • [Other-IDs] NLM/ PMC2928434
  •  go-up   go-down


20. Ameri C, Contreras P, Villasante N, Ríos Pita H, Richards N, Mazza O: [Solid renal mass up to 4 cm. Analysis of the diagnostic procedures, TNM staging and surgical treatment]. Actas Urol Esp; 2006 Sep;30(8):772-83
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Masa ocupante renal sólida de hasta 4 cm: análisis de la metodología diagnóstica, estadificación TNM y tratamiento quirúrgico.
  • OBJECTIVES: We perform a retrospective review of renal tumors operated with a maximum size of 4 cm to determine if the diagnostic methodology was adequate, the TMN staging prognostic accuracy (UICC 2002) and the goal surgical treatment.
  • MATERIAL AND METHOD: Between 1984 to 2005, 78 renal units form 74 patients (4 bilateral synchronous) operated at the Service of Urology of the Hospital Alemán de Buenos Aires.
  • Age distribution, sex, presentation form (incidental and symptomatic), diagnostic methodology, laboratory variables, surgical treatment (partial or radical surgery), histopathology, Fuhrman grade, tumor size, bilaterality, multicentricity, TNM staging, evolution and survival (Kaplan Meier) were analyzed.
  • Arteriography was used in 11 cases, 3 showed tumor and 8 were normal.
  • Biopsy was performing in 5 cases, all positive for clear cells carcinoma.
  • Globular sedimentation was the only one laboratory abnormality in 12 cases.
  • Pathology clear cells carcinoma (CCC) 79.48%, papillary carcinoma 1.28%, angiomyolipoma (AML) 8.97%, oncocytoma 7.69% and adenoma 2.56%.
  • Bilateral tumor were found in 4 cases 2 CCC, 1 CCC and AML and 1 CCC and adenoma.
  • Tumor median size was 2.93 cm.
  • At median follow-up of 52.25 months, 50 cases were disease free, 3 died by progression at 18, 33 and 82 months and all of them were symptomatic tumors, 1 died by a non related cause.
  • 2) Conservative surgery was the goal treatment in selected tumors up to 4 cm. and we believe that TNM staging should contemplate the presentation form to improve the prognostic value.
  • [MeSH-major] Kidney Neoplasms / pathology. Kidney Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Female. Humans. Male. Middle Aged. Neoplasm Staging

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17078574.001).
  • [ISSN] 0210-4806
  • [Journal-full-title] Actas urologicas españolas
  • [ISO-abbreviation] Actas Urol Esp
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


21. Hyde J, Takashima M, Dodson B, Said S: Bilateral multinodular oncocytomas of the parotid arising in a background of bilateral oncocytic nodular hyperplasia. Ear Nose Throat J; 2008 Jan;87(1):51-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bilateral multinodular oncocytomas of the parotid arising in a background of bilateral oncocytic nodular hyperplasia.
  • Oncocytic tumors of the major salivary glands are rare, accounting for less than 1% of all salivary gland tumors.
  • When they do occur, these neoplasms typically present as solitary nodules that affect only one major salivary gland, usually the parotid.
  • Multiple bilateral multinodular tumors are rare.
  • We report the case of a 53-year-old woman with a case of synchronous multiple bilateral multinodular oncocytomas that arose in a background of bilateral oncocytic nodular hyperplasia in the parotid glands.
  • [MeSH-major] Adenoma, Oxyphilic / pathology. Parotid Gland / pathology. Parotid Neoplasms / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18357950.001).
  • [ISSN] 0145-5613
  • [Journal-full-title] Ear, nose, & throat journal
  • [ISO-abbreviation] Ear Nose Throat J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


22. Benbassat CA, Mechlis-Frish S, Hirsch D: Clinicopathological characteristics and long-term outcome in patients with distant metastases from differentiated thyroid cancer. World J Surg; 2006 Jun;30(6):1088-95
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinicopathological characteristics and long-term outcome in patients with distant metastases from differentiated thyroid cancer.
  • BACKGROUND: Distant metastases are seen in a minority of patients with differentiated thyroid carcinoma (DTC) but account for most of its disease-specific mortality.
  • MATERIALS AND METHODS: We retrospectively reviewed the medical records of 660 patients with differentiated thyroid carcinoma followed at our institution from 1994 to 2004.
  • Forty-four patients (6.7%) had distant metastases, with a prevalence of 4.8% for papillary thyroid cancer, 21% for follicular thyroid cancer, and 10% for Hurthle cell cancer.
  • RESULTS: The distant metastasis occurred synchronously with the primary tumor in 45.5% and after a median follow-up of 9 years in the others.
  • CONCLUSIONS: We conclude that complete resection of the thyroid gland at diagnosis and high-dose adjuvant radioactive iodine are associated with improved survival in patients with metastatic DTC.
  • [MeSH-major] Adenoma, Oxyphilic / pathology. Carcinoma / secondary. Thyroid Neoplasms / pathology
  • [MeSH-minor] Bone Neoplasms / secondary. Brain Neoplasms / secondary. Disease-Free Survival. Female. Follow-Up Studies. Humans. Lung Neoplasms / secondary. Male. Middle Aged. Radiotherapy, Adjuvant. Survival Rate. Thyroidectomy

  • Genetic Alliance. consumer health - Thyroid Cancer.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] World J Surg. 2007 Jan;31(1):246-7; author reply 247-8 [17180558.001]
  • [Cites] Tumori. 1991 Oct 31;77(5):432-6 [1781039.001]
  • [Cites] J Clin Endocrinol Metab. 1986 Oct;63(4):960-7 [3745409.001]
  • [Cites] Hum Pathol. 1990 Mar;21(3):283-90 [2312106.001]
  • [Cites] World J Surg. 1994 Jul-Aug;18(4):600-4 [7725751.001]
  • [Cites] J Clin Endocrinol Metab. 1988 Sep;67(3):501-8 [3410936.001]
  • [Cites] Endocrinol Metab Clin North Am. 1990 Sep;19(3):685-718 [2261912.001]
  • [Cites] World J Surg. 2002 Feb;26(2):153-7 [11865341.001]
  • [Cites] Clin Endocrinol (Oxf). 2005 Jul;63(1):87-93 [15963067.001]
  • [Cites] Arch Surg. 1989 Dec;124(12):1374-7 [2589960.001]
  • [Cites] N Engl J Med. 1998 Jan 29;338(5):297-306 [9445411.001]
  • [Cites] J Clin Endocrinol Metab. 2004 Nov;89(11):5303-7 [15531474.001]
  • [Cites] J Clin Endocrinol Metab. 2001 Apr;86(4):1447-63 [11297567.001]
  • [Cites] Clin Endocrinol (Oxf). 1997 Dec;47(6):713-20 [9497879.001]
  • [Cites] Thyroid. 1999 Dec;9(12):1227-35 [10646663.001]
  • [Cites] Surgery. 1999 Dec;126(6):1173-81; discussion 1181-2 [10598204.001]
  • [Cites] Surgery. 1993 Dec;114(6):1050-7; discussion 1057-8 [8256208.001]
  • [Cites] J Clin Endocrinol Metab. 1999 Nov;84(11):4043-9 [10566647.001]
  • [Cites] J Am Coll Surg. 2003 Aug;197(2):191-7 [12892796.001]
  • [Cites] Surgery. 1989 Dec;106(6):960-6 [2588123.001]
  • [Cites] J Nucl Med. 1996 Apr;37(4):598-605 [8691248.001]
  • [Cites] J Clin Endocrinol Metab. 1995 Jul;80(7):2041-5 [7608252.001]
  • [Cites] Eur J Cancer. 2002 Sep;38(13):1762-8 [12175693.001]
  • (PMID = 16736341.001).
  • [ISSN] 0364-2313
  • [Journal-full-title] World journal of surgery
  • [ISO-abbreviation] World J Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


23. Xiao GQ, Pertsemlidis DS, Unger PD: Functioning adrenocortical oncocytoma: a case report and review of the literature. Ann Diagn Pathol; 2005 Oct;9(5):295-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Functioning adrenocortical oncocytoma: a case report and review of the literature.
  • Adrenocortical oncocytoma is exceptionally rare.
  • Most of these tumors are benign and nonfunctioning.
  • We report a case of functioning adrenocortical oncocytoma located in the right adrenal gland in a 53-year-old woman who presented with Cushing's syndrome.
  • The tumor was small, with exclusively oncocytic histologic features.
  • [MeSH-major] Adenoma, Oxyphilic / pathology. Adrenal Cortex Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16198960.001).
  • [ISSN] 1092-9134
  • [Journal-full-title] Annals of diagnostic pathology
  • [ISO-abbreviation] Ann Diagn Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


24. Barresi V, Ieni A, Bolignano D, Magno C, Buemi M, Barresi G: Neutrophil gelatinase-associated lipocalin immunoexpression in renal tumors: correlation with histotype and histological grade. Oncol Rep; 2010 Aug;24(2):305-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neutrophil gelatinase-associated lipocalin immunoexpression in renal tumors: correlation with histotype and histological grade.
  • Although the renal proximal tubule represents a major source of NGAL synthesis under various injurious stimuli to the kidney, NGAL expression has been rarely evaluated in renal tumors up to now.
  • In view of this, in the present study we analyzed the expression of this protein in renal tumors of different histotype and grade so as to evaluate whether a role for NGAL might be also proposed in the carcinogenesis of these neoplasms.
  • NGAL immunoexpression was analyzed in 30 surgically resected renal tumors [18 clear cell, 5 papillary and 3 chromophobe renal cell carcinomas (RCCs), 2 urothelial carcinomas and 2 oncocytomas] and in the peritoneal metastasis of a clear cell RCC.
  • High NGAL expression was significantly associated with the papillary and chromphobe histotypes (P=0.016) and with a higher histological grade of clear cell and papillary RCC (P=0.004).
  • Moreover, NGAL expression was retained in the peritoneal metastasis of clear cell RCC.
  • Our findings demonstrate that NGAL is expressed in several histotypes of renal tumors.
  • [MeSH-major] Acute-Phase Proteins / metabolism. Carcinoma, Renal Cell / metabolism. Carcinoma, Renal Cell / pathology. Kidney Neoplasms / metabolism. Kidney Neoplasms / pathology. Lipocalins / metabolism. Proto-Oncogene Proteins / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / metabolism. Female. Humans. Immunohistochemistry. Male. Middle Aged. Neoplasm Staging / methods. Peritoneal Neoplasms / metabolism. Peritoneal Neoplasms / secondary. Phenotype

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20596614.001).
  • [ISSN] 1791-2431
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Acute-Phase Proteins; 0 / Biomarkers, Tumor; 0 / LCN2 protein, human; 0 / Lipocalins; 0 / Proto-Oncogene Proteins
  •  go-up   go-down


25. Milas M, Barbosa GF, Mitchell J, Berber E, Siperstein A, Gupta M: Effectiveness of peripheral thyrotropin receptor mRNA in follow-up of differentiated thyroid cancer. Ann Surg Oncol; 2009 Feb;16(2):473-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effectiveness of peripheral thyrotropin receptor mRNA in follow-up of differentiated thyroid cancer.
  • Thyroid cells in peripheral circulation have been linked to thyroid cancer (TC).
  • Thirty-four patients underwent 20 +/- 14 months median follow-up for papillary (n = 31, 91%), follicular (n = 2) or Hurthle cell (n = 1) TC.
  • [MeSH-major] RNA, Messenger / blood. Receptors, Thyrotropin / genetics. Thyroid Neoplasms / blood
  • [MeSH-minor] Adenocarcinoma, Follicular / blood. Adenocarcinoma, Follicular / secondary. Adenocarcinoma, Follicular / surgery. Adenoma, Oxyphilic / blood. Adenoma, Oxyphilic / secondary. Adenoma, Oxyphilic / surgery. Adult. Aged. Autoantibodies / blood. Biomarkers, Tumor / blood. Carcinoma, Papillary / blood. Carcinoma, Papillary / secondary. Carcinoma, Papillary / surgery. Cell Differentiation. Female. Follow-Up Studies. Humans. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Recurrence, Local / blood. Neoplasm Recurrence, Local / diagnosis. Neoplasm Recurrence, Local / surgery. Positron-Emission Tomography. Prospective Studies. Reverse Transcriptase Polymerase Chain Reaction. Thyroglobulin / blood. Thyroglobulin / genetics. Thyroglobulin / immunology. Thyroidectomy. Thyrotropin / pharmacology. Young Adult

  • Genetic Alliance. consumer health - Thyroid Cancer.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • Hazardous Substances Data Bank. THYROGLOBULIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19015922.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Autoantibodies; 0 / Biomarkers, Tumor; 0 / RNA, Messenger; 0 / Receptors, Thyrotropin; 9002-71-5 / Thyrotropin; 9010-34-8 / Thyroglobulin
  •  go-up   go-down


26. Porcelli AM, Angelin A, Ghelli A, Mariani E, Martinuzzi A, Carelli V, Petronilli V, Bernardi P, Rugolo M: Respiratory complex I dysfunction due to mitochondrial DNA mutations shifts the voltage threshold for opening of the permeability transition pore toward resting levels. J Biol Chem; 2009 Jan 23;284(4):2045-52
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We have studied mitochondrial bioenergetics in HL180 cells (a cybrid line harboring the T14484C/ND6 and G14279A/ND6 mtDNA mutations of Leber hereditary optic neuropathy, leading to an approximately 50% decrease of ATP synthesis) and XTC.UC1 cells (derived from a thyroid oncocytoma bearing a disruptive frameshift mutation in MT-ND1, which impairs complex I assembly).
  • Both cell lines also displayed an anomalous response to oligomycin, with rapid onset of depolarization that was prevented by cyclosporin A and by overexpression of Bcl-2.
  • A shift of the threshold voltage for PTP opening close to the resting potential may therefore be the underlying cause facilitating cell death in diseases affecting complex I activity.
  • [MeSH-minor] Adenosine Triphosphate / biosynthesis. Biological Transport. Cell Line. Culture Media, Conditioned. Galactose / metabolism. Glucose / metabolism. Mitochondria / drug effects. Mitochondria / genetics. Mitochondria / metabolism. Mitochondrial Membranes. Mutation / genetics. Oligomycins / pharmacology. Oxygen Consumption. Permeability. Porosity. Proto-Oncogene Proteins c-bcl-2 / metabolism

  • COS Scholar Universe. author profiles.
  • Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).
  • Hazardous Substances Data Bank. GLUCOSE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19047048.001).
  • [ISSN] 0021-9258
  • [Journal-full-title] The Journal of biological chemistry
  • [ISO-abbreviation] J. Biol. Chem.
  • [Language] eng
  • [Grant] Italy / Telethon / / GGP06233
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Culture Media, Conditioned; 0 / DNA, Mitochondrial; 0 / Oligomycins; 0 / Proto-Oncogene Proteins c-bcl-2; 8L70Q75FXE / Adenosine Triphosphate; EC 1.6.5.3 / Electron Transport Complex I; IY9XDZ35W2 / Glucose; X2RN3Q8DNE / Galactose
  •  go-up   go-down


27. Seveso M, Taverna G, Giusti G, Benetti A, Piccinelli A, Graziotti P: Nephron sparing surgery of parenchymal kidney tumours in solitary kidney. Arch Ital Urol Androl; 2007 Mar;79(1):12-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nephron sparing surgery of parenchymal kidney tumours in solitary kidney.
  • Final histology showed 17 patients with clear cell renal carcinoma, six papillary cell carcinomas, one chromophobe carcinoma, one oncocytoma and two angiomyolipomas.
  • Two patients present secondary tumours (lung and liver), whereas one patient is being treated with chemotherapy for colon cancer Twenty-two patients are disease-free.

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17484397.001).
  • [ISSN] 1124-3562
  • [Journal-full-title] Archivio italiano di urologia, andrologia : organo ufficiale [di] Societa italiana di ecografia urologica e nefrologica
  • [ISO-abbreviation] Arch Ital Urol Androl
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


28. Cameron JR, Barras CW: Oncocytoma of the eyelid. Acta Ophthalmol Scand; 2005 Feb;83(1):125
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Oncocytoma of the eyelid.
  • [MeSH-major] Adenoma, Oxyphilic / pathology. Eyelid Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15715577.001).
  • [ISSN] 1395-3907
  • [Journal-full-title] Acta ophthalmologica Scandinavica
  • [ISO-abbreviation] Acta Ophthalmol Scand
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] Denmark
  •  go-up   go-down


29. Adhikari P, Pradhananga RB, Sinha BK, Pradhan B, Thapa N: Oncocytoma of maxillary sinus--a rare presentation. Nepal Med Coll J; 2006 Dec;8(4):292-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Oncocytoma of maxillary sinus--a rare presentation.
  • A case of Oncocytoma of maxillary sinus in a 73 years old female is reported along with a brief review of literature.
  • To the best of our knowledge this extremely rare tumor is the first of its kind reported in Nepal.
  • [MeSH-major] Adenoma, Oxyphilic / pathology. Maxillary Sinus Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17357654.001).
  • [Journal-full-title] Nepal Medical College journal : NMCJ
  • [ISO-abbreviation] Nepal Med Coll J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Nepal
  •  go-up   go-down


30. Sokolova IA, Hes O, Michal M, Matsko DE: [Small-cell variant of renal oncocytoma]. Arkh Patol; 2007 Sep-Oct;69(5):34-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Small-cell variant of renal oncocytoma].
  • Renal oncocytoma is a distinct benign tumor accounting for approximately 3-5% of all renal tumors.
  • This neoplasm is easily recognizable in its classic form: there are polygonal cells with abundant granular eosinophilic cytoplasm filled with mitochondria.
  • The tumor cells are arranged in nests and tubular pattern.
  • Here, 1 case of renal oncocytoma with a domination of small cells is reported (the so-called "oncoblasts") arising in elderly woman.
  • The term "small-cell variant of renal oncocytoma" was proposed for these cases.
  • The unusual extensive small-cell component of the tumor may represent a potential diagnostic pitfall for primary or metastatic malignant small cell tumors.
  • [MeSH-major] Adenoma, Oxyphilic / pathology. Carcinoma, Small Cell / pathology. Cytoplasm / pathology. Kidney Neoplasms / pathology. Mitochondria / pathology
  • [MeSH-minor] Aged. Female. Humans. Neoplasm Metastasis

  • Genetic Alliance. consumer health - Oncocytoma renal.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18074818.001).
  • [ISSN] 0004-1955
  • [Journal-full-title] Arkhiv patologii
  • [ISO-abbreviation] Arkh. Patol.
  • [Language] rus
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  •  go-up   go-down


31. Yousef GM, Ejeckam GC, Best LM, Diamandis EP: Collecting duct carcinoma associated with oncocytoma. Int Braz J Urol; 2005 Sep-Oct;31(5):465-7; discussion 467-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Collecting duct carcinoma associated with oncocytoma.
  • Collecting duct carcinoma (CDC) is a rare, highly aggressive malignant neoplasm that arises from the collecting duct epithelium of the kidney.
  • CDC was reported to coexist with renal cell and transitional cell carcinomas.
  • We report a rare case of CDC associated with oncocytoma, confirmed by the characteristic histological appearance and immunohistochemistry.
  • [MeSH-major] Adenoma, Oxyphilic / diagnosis. Carcinoma, Renal Cell / diagnosis. Kidney Neoplasms / diagnosis. Kidney Tubules, Collecting

  • Genetic Alliance. consumer health - Collecting Duct Carcinoma.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16255793.001).
  • [ISSN] 1677-5538
  • [Journal-full-title] International braz j urol : official journal of the Brazilian Society of Urology
  • [ISO-abbreviation] Int Braz J Urol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Brazil
  •  go-up   go-down


32. Fan L, Lianfang D, Jinfang X, Yijin S, Ying W: Diagnostic efficacy of contrast-enhanced ultrasonography in solid renal parenchymal lesions with maximum diameters of 5 cm. J Ultrasound Med; 2008 Jun;27(6):875-85
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The final diagnoses were 44 renal cell carcinomas (RCCs; confirmed by pathologic examination), 24 renal angiomyolipomas (4 by pathologic examination and 20 by computed tomography, magnetic resonance imaging, and follow-up studies), 1 oncocytoma (by pathologic examination), 2 hypertrophied columns of Bertin, and 1 renal abscess (both by computed tomography, magnetic resonance imaging, and follow-up studies).
  • [MeSH-major] Carcinoma, Renal Cell / ultrasonography. Kidney Neoplasms / ultrasonography. Phospholipids. Sulfur Hexafluoride

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • Hazardous Substances Data Bank. SULFUR HEXAFLUORIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18499847.001).
  • [ISSN] 0278-4297
  • [Journal-full-title] Journal of ultrasound in medicine : official journal of the American Institute of Ultrasound in Medicine
  • [ISO-abbreviation] J Ultrasound Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contrast Media; 0 / Phospholipids; 0 / contrast agent BR1; WS7LR3I1D6 / Sulfur Hexafluoride
  •  go-up   go-down


33. Raman JD, Stern JM, Zeltser I, Kabbani W, Cadeddu JA: Absence of viable renal carcinoma in biopsies performed more than 1 year following radio frequency ablation confirms reliability of axial imaging. J Urol; 2008 Jun;179(6):2142-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Absence of viable renal carcinoma in biopsies performed more than 1 year following radio frequency ablation confirms reliability of axial imaging.
  • PURPOSE: Radio frequency ablation is an emerging nephron sparing treatment option in select patients with small renal tumors.
  • Some have questioned the completeness of cell death and the reliability of axial imaging for radio frequency ablation followup.
  • MATERIALS AND METHODS: Patients who had no clinical evidence of disease, defined as absent lesion growth and contrast enhancement on computerized tomography, 1 year or more following radio frequency ablation underwent percutaneous renal biopsy to evaluate cell viability in the ablative zone.
  • RESULTS: Pre-ablation biopsies confirmed that 17 of 20 tumors were renal cell carcinoma, while the remaining 3 were oncocytoma.
  • At repeat biopsy all histology specimens showed unequivocal tumor eradication with no evidence of cellular viability.
  • Histological changes beyond 1 year demonstrated coagulative necrosis, hyalinization, inflammatory cell infiltration and residual ghost cells.
  • [MeSH-major] Carcinoma, Renal Cell / pathology. Carcinoma, Renal Cell / therapy. Catheter Ablation. Kidney Neoplasms / pathology. Kidney Neoplasms / therapy

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18423723.001).
  • [ISSN] 1527-3792
  • [Journal-full-title] The Journal of urology
  • [ISO-abbreviation] J. Urol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


34. Garcia E, Li M: Caveolin-1 immunohistochemical analysis in differentiating chromophobe renal cell carcinoma from renal oncocytoma. Am J Clin Pathol; 2006 Mar;125(3):392-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Caveolin-1 immunohistochemical analysis in differentiating chromophobe renal cell carcinoma from renal oncocytoma.
  • Chromophobe renal cell carcinoma (ChRCC) and oncocytoma might mimic each other histologically.
  • We studied the immunohistochemical staining pattern of caveolin-1 in 21 ChRCCs and 26 oncocytomas and compared it with cytokeratin (CK) 7 to evaluate its usefulness in differentiating these 2 neoplasms.
  • All 21 ChRCCs (100%) were positive for caveolin-1, 20 of which were stained in 20% or more of the tumor cells.
  • In contrast, only 3 (12%) of 26 oncocytomas showed positivity in fewer than 20% tumor cells and 23 (88%) of 26 were negative.
  • All 21 ChRCCs (100%) were positive for CK7, with 18 (86%) stained in 20% or more of the tumor cells and 3 (14%) in fewer than 20%.
  • Of 26 oncocytomas, 25 (96%) were positive for CK7, with 7 (27%) stained in 20% or more of the tumor cells and 18 (69%) in fewer than 20%.
  • These results strongly suggest that caveolin-1 immunohistochemical analysis is useful for differentiating ChRCC from oncocytoma and is superior to CK7.
  • [MeSH-major] Adenoma, Oxyphilic / pathology. Carcinoma, Renal Cell / pathology. Caveolin 1 / analysis. Kidney Neoplasms / pathology
  • [MeSH-minor] Biomarkers, Tumor / analysis. Cell Count. Diagnosis, Differential. Humans. Immunohistochemistry. Keratin-7. Keratins / analysis. Kidney / chemistry. Kidney / pathology


35. Fox JJ, Rohan S, Pandit-Taskar N: Breast carcinoma metastatic to renal oncocytoma detected on F-18-FDG PET/CT. Clin Nucl Med; 2009 May;34(5):294-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Breast carcinoma metastatic to renal oncocytoma detected on F-18-FDG PET/CT.
  • [MeSH-major] Adenoma, Oxyphilic / secondary. Breast Neoplasms / pathology. Fluorodeoxyglucose F18. Kidney Neoplasms / secondary. Radiopharmaceuticals
  • [MeSH-minor] Adult. Female. Humans. Lung Neoplasms / secondary. Lymphatic Metastasis. Positron-Emission Tomography. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Oncocytoma renal.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19387207.001).
  • [ISSN] 1536-0229
  • [Journal-full-title] Clinical nuclear medicine
  • [ISO-abbreviation] Clin Nucl Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


36. Arvanitis DL, Arvanitis LD, Panourias IG, Kitsoulis P, Kanavaros P: Mitochondria-rich normal, metaplastic, and neoplastic cells show overexpression of the epitope H recognized by the monoclonal antibody H. Pathol Res Pract; 2005;201(4):319-24
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The indirect immunoperoxidase method was applied using the mAbH to investigate the distribution of the epitope H in mitochondria-rich normal cells and in metaplastic and neoplastic oncocytic cells.
  • Immunohistochemical staining for the mAbH was observed in oxyphil cells of parathyroid glands, in striated duct cells of parotid glands, in urinary tubules of kidneys, in parietal cells of gastric body mucosa, in oxyphil cells of Hashimoto's thyroiditis, in epithelial cells of Warthin's tumors of the parotid gland, in neoplastic cells of oxyphil adenomas and carcinomas (Hürthle's tumors) of the thyroid gland, and in neoplastic cells of oncocytomas of the kidneys.
  • The present study shows that the epitope H is strongly expressed in mitochondria-rich normal cells, as well as in metaplastic and neoplastic oncocytic cells, which are known to have cytoplasms packed with mitochondria.
  • These findings may be of interest for gaining insight into the histophysiology of mitochondria-rich normal cells and into the pathogenesis of oncocytic lesions, since O-GlcNAc glycosylation may modify proteins involved in oncogenesis such as tumor suppressor proteins and oncoproteins, as well as proteins with important biological functions such as cytoskeletal proteins, transcription factors, heat-shock proteins, and chromatin proteins.
  • [MeSH-major] Acetylglucosamine / metabolism. Antibodies, Monoclonal. Mitochondria. Neoplasms / metabolism. Oxyphil Cells / metabolism
  • [MeSH-minor] Antigens, Neoplasm / immunology. Antigens, Neoplasm / metabolism. Biomarkers, Tumor / immunology. Biomarkers, Tumor / metabolism. Epitopes / immunology. Epitopes / metabolism. Fluorescent Antibody Technique, Indirect. Humans. Immunoenzyme Techniques. Metaplasia / immunology. Metaplasia / metabolism. Metaplasia / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15991839.001).
  • [ISSN] 0344-0338
  • [Journal-full-title] Pathology, research and practice
  • [ISO-abbreviation] Pathol. Res. Pract.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / Epitopes; V956696549 / Acetylglucosamine
  •  go-up   go-down


37. Haendl T, Strobel D, Legal W, Frieser M, Hahn EG, Bernatik T: [Renal cell cancer does not show a typical perfusion pattern in contrast-enhanced ultrasound]. Ultraschall Med; 2009 Feb;30(1):58-63
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Renal cell cancer does not show a typical perfusion pattern in contrast-enhanced ultrasound].
  • PURPOSE: Grayscale ultrasound has improved the outcome of renal cell cancer (RCC), since most significant RCCs are discovered coincidently during routine abdominal ultrasound examinations.
  • METHODS AND MATERIALS: We examined 30 patients with solid renal tumors before surgery with CEUS using the microbubble contrast agent SonoVue (Bracco, Italy).
  • RESULTS: 25 (83 %) had an RCC, and two (7 %) patients showed an urothelial carcinoma.
  • Benign tumors were diagnosed in three (10 %) patients.
  • All of them were oncocytomas.
  • In the early phase (< 30 s), 12 tumors showed hyperperfusion, three showed isoperfusion, and nine showed hypoperfusion.
  • During the late phase (60 - 120 s), five tumors showed hyperperfusion, nine showed isoperfusion, and ten showed hypoperfusion.
  • One small cystic tumor did not indicate contrast enhancement at any time.
  • [MeSH-major] Carcinoma, Renal Cell / blood supply. Carcinoma, Renal Cell / ultrasonography. Kidney Neoplasms / blood supply. Kidney Neoplasms / ultrasonography
  • [MeSH-minor] Abdomen / ultrasonography. Adenoma, Oxyphilic / ultrasonography. Contrast Media. Humans. Ultrasonography / methods

  • Genetic Alliance. consumer health - Kidney cancer.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19205086.001).
  • [ISSN] 1438-8782
  • [Journal-full-title] Ultraschall in der Medizin (Stuttgart, Germany : 1980)
  • [ISO-abbreviation] Ultraschall Med
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Contrast Media
  •  go-up   go-down


38. Hora M, Klecka J Jr, Hes O, Ferda J, Urge T: [Miniinvasive laparoscopic or retroperitoneoscopic radical nephrectomy for the parenchymal tumor]. Rozhl Chir; 2005 May;84(5):246-52
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Miniinvasive laparoscopic or retroperitoneoscopic radical nephrectomy for the parenchymal tumor].
  • [Transliterated title] Miniinvazivní laparoskopická ci retroperitoneoskopická radikální nefrektomie pro parenchymový tumor.
  • The tumor size according to the CT was 50 +/- 13 mm (30-82).
  • Histologically, 45x renal carcinomas, 4x oncocytomas, 1 x urothelial carcinomas were diagnosed.
  • Only a single major, however lethal, complication arised: In a 74-year old female, the left-sided LRNE due to the carcinoma pT3bG2 and at the same time vaginal hysterectomy, extraction of the renal preparation through the vagina and anterior and posterior vaginoplasty (for a prolaps) were conducted.
  • CONCLUSION: Miniinvasive RNE in TI tumors is a modem reproducible methodology suitable for application in clinical practice.
  • [MeSH-major] Kidney Neoplasms / surgery. Laparoscopy. Nephrectomy / methods

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16045121.001).
  • [ISSN] 0035-9351
  • [Journal-full-title] Rozhledy v chirurgii : měsíčník Československé chirurgické společnosti
  • [ISO-abbreviation] Rozhl Chir
  • [Language] cze
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Czech Republic
  •  go-up   go-down


39. Amin MB, Paner GP, Alvarado-Cabrero I, Young AN, Stricker HJ, Lyles RH, Moch H: Chromophobe renal cell carcinoma: histomorphologic characteristics and evaluation of conventional pathologic prognostic parameters in 145 cases. Am J Surg Pathol; 2008 Dec;32(12):1822-34
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chromophobe renal cell carcinoma: histomorphologic characteristics and evaluation of conventional pathologic prognostic parameters in 145 cases.
  • The aggregate literature suggests that chromophobe renal cell carcinoma (RCC) is biologically a tumor of low malignant potential with reported 5-year and 10-year survival rates of 78% to 100% and 80% to 90%, respectively.
  • The conventional prognostic parameters that determine the outcome of the tumors that progress remain to be fully characterized.
  • Most tumors were well circumscribed and averaged 8.0 cm (range, 1.0 to 30.0 cm); multifocality and bilaterality were present in 8% and 3% of patients.
  • A subset of eosinophilic chromophobe RCC contained or had areas similar to renal oncocytomas.
  • These tumors tended to be more commonly bilateral (11%) and multifocal (22%) and were not associated with necrosis or sarcomatoid change.
  • Sarcomatoid change was present in 12/145 (8%) tumors.
  • Nineteen percent, 21%, 28%, 13%, 4%, 1%, and 3% were pT (2002) stage pT1a, pT1b, pT2, pT3a, pT3b, pT3c, and pT4 tumors.
  • Two percent tumors were pN1 at presentation and 2.8% tumors were M1 at presentation.
  • In univariable analysis, tumor size (P=0.025), pT stage (P<0.001), broad alveolar architecture (P=0.012), Fuhrman nuclear grade (P<0.001), microscopic tumor necrosis (P=0.001), vascular invasion (P=0.020), and sarcomatoid change (P< or =0.001) were associated with progression.
  • The pT stage of tumor, tumor necrosis, and sarcomatoid change all predict aggressive phenotype of chromophobe RCC.
  • [MeSH-major] Carcinoma, Renal Cell / pathology. Kidney Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Neoplasm Staging. Phenotype. Prognosis


40. Walsh CA, Quinlan DM: Oncocytoma and synchronous urothelial carcinoma in same kidney: previously unreported association. Urology; 2005 Jul;66(1):194
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Oncocytoma and synchronous urothelial carcinoma in same kidney: previously unreported association.
  • Many cases of histologically distinct renal tumors occurring coincidentally in the same patient have been reported.
  • We report the first case of a benign oncocytoma and a urothelial carcinoma occurring synchronously in the same kidney in a man who underwent radical nephrectomy for a suspicious renal mass.
  • [MeSH-major] Adenoma, Oxyphilic / surgery. Carcinoma, Transitional Cell / surgery. Kidney Neoplasms / surgery. Neoplasms, Multiple Primary / surgery

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15921729.001).
  • [ISSN] 1527-9995
  • [Journal-full-title] Urology
  • [ISO-abbreviation] Urology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


41. Waalkes S, Atschekzei F, Kramer MW, Hennenlotter J, Vetter G, Becker JU, Stenzl A, Merseburger AS, Schrader AJ, Kuczyk MA, Serth J: Fibronectin 1 mRNA expression correlates with advanced disease in renal cancer. BMC Cancer; 2010;10:503
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The aim of this study was to elucidate the role of FN1 in development of renal cell cancer (RCC) and to determine a prognostic relevance for optimal clinical management.
  • METHODS: 212 renal tissue samples (109 RCC, 86 corresponding tissues from adjacent normal renal tissue and 17 oncocytomas) were collected from patients undergoing surgery for renal tumors and subjected to total RNA extraction.
  • 11 fold in clear cell compared to papillary RCC (p = 9×10-5; Wilcoxon rank sum test).
  • Applying subgroup analysis we found a significantly higher FN1 mRNA expression between organ-confined and advanced disease in the papillary and not in the clear cell RCC group (p = 0.02 vs. p = 0.2; Wilcoxon rank sum test).
  • There was an increased expression in RCC compared to oncocytoma (p = 0.016; ANOVA).
  • [MeSH-major] Adenoma, Oxyphilic / genetics. Biomarkers, Tumor / genetics. Carcinoma, Papillary / genetics. Carcinoma, Renal Cell / genetics. Fibronectins / genetics. Kidney Neoplasms / genetics
  • [MeSH-minor] Disease Progression. Female. Humans. Kidney / metabolism. Kidney / pathology. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Staging. Prognosis. RNA, Messenger / genetics. Reverse Transcriptase Polymerase Chain Reaction. Survival Rate

  • Genetic Alliance. consumer health - Kidney cancer.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Thromb Haemost. 2006 Jul;4(7):1461-9 [16839338.001]
  • [Cites] Arterioscler Thromb Vasc Biol. 2006 Jun;26(6):1193-5 [16709950.001]
  • [Cites] Nat Protoc. 2008;3(6):1101-8 [18546601.001]
  • [Cites] Urologe A. 2008 Sep;47(9):1182, 1184-6 [18679648.001]
  • [Cites] J Cancer Res Clin Oncol. 2009 Jun;135(6):799-805 [19023595.001]
  • [Cites] J Cancer Res Clin Oncol. 2009 Dec;135(12):1693-9 [19543914.001]
  • [Cites] Cancer Lett. 2000 Jul 31;155(2):199-205 [10822136.001]
  • [Cites] Cancer Res. 2000 Dec 1;60(23):6617-22 [11118044.001]
  • [Cites] Cancer Genet Cytogenet. 2000 Dec;123(2):128-32 [11156738.001]
  • [Cites] Clin Cancer Res. 2001 Apr;7(4):901-8 [11309340.001]
  • [Cites] Cancer Genet Cytogenet. 2001 Jul 1;128(1):1-6 [11454421.001]
  • [Cites] Methods. 2001 Dec;25(4):402-8 [11846609.001]
  • [Cites] Thromb Res. 2002 Jan 1;105(1):37-41 [11864705.001]
  • [Cites] Mod Pathol. 2002 Aug;15(8):826-30 [12181267.001]
  • [Cites] Am J Surg Pathol. 1982 Oct;6(7):655-63 [7180965.001]
  • [Cites] Semin Oncol. 1989 Feb;16(1 Suppl 1):3-11 [2645654.001]
  • [Cites] Jpn J Cancer Res. 1992 Dec;83(12):1327-33 [1483947.001]
  • [Cites] Br J Cancer. 1995 Mar;71(3):578-82 [7880741.001]
  • [Cites] Cancer Metastasis Rev. 1995 Sep;14(3):173-89 [8548867.001]
  • [Cites] World J Urol. 1996;14 Suppl 1:S30-7 [8738408.001]
  • [Cites] Int J Cancer. 1996 Nov 4;68(3):364-71 [8903479.001]
  • [Cites] Cancer. 1997 Sep 1;80(5):992-3 [9307205.001]
  • [Cites] Br J Cancer. 1997;76(6):777-83 [9310245.001]
  • [Cites] J Invest Dermatol. 1999 Feb;112(2):177-83 [9989793.001]
  • [Cites] Leukemia. 1999 Feb;13(2):266-74 [10025901.001]
  • [Cites] J Clin Oncol. 2005 Apr 20;23(12):2763-71 [15837991.001]
  • [Cites] Clin Chim Acta. 2006 Oct;372(1-2):83-93 [16730689.001]
  • (PMID = 20860816.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Fibronectins; 0 / RNA, Messenger
  • [Other-IDs] NLM/ PMC2949811
  •  go-up   go-down


42. Jeon HG, Lee SR, Kim KH, Oh YT, Cho NH, Rha KH, Yang SC, Han WK: Benign lesions after partial nephrectomy for presumed renal cell carcinoma in masses 4 cm or less: prevalence and predictors in Korean patients. Urology; 2010 Sep;76(3):574-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Benign lesions after partial nephrectomy for presumed renal cell carcinoma in masses 4 cm or less: prevalence and predictors in Korean patients.
  • OBJECTIVES: To investigate the prevalence and predictors associated with benign lesions in Korean patients after partial nephrectomy for presumed renal cell carcinoma (RCC) for lesions measuring ≤ 4 cm.
  • RESULTS: In the 376 patients, 81 tumors (21.5%) were benign, including 35 angiomyolipomas (9.3%), 26 complicated cysts (6.9%), 11 oncocytomas (2.9%), and 9 others (2.4%).
  • Tumor size, incidental diagnosis, and BMI were not significant predictors (P > .05).
  • However, the most common benign lesion was angiomyolipoma, compared with oncocytoma in Western countries.
  • [MeSH-major] Carcinoma, Renal Cell / epidemiology. Carcinoma, Renal Cell / pathology. Kidney Neoplasms / epidemiology. Kidney Neoplasms / pathology. Nephrectomy


43. Subramaniam RM, Durnick DK, Peller PJ: F-18 FDG PET/CT imaging of submandibular gland oncocytoma. Clin Nucl Med; 2008 Jul;33(7):472-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] F-18 FDG PET/CT imaging of submandibular gland oncocytoma.
  • F-18 FDG PET/CT is used to evaluate head and neck malignancies, including salivary gland tumors.
  • We describe the FDG PET/CT features of a submandibular gland oncocytoma.
  • An 85-year-old patient with small cell cancer of the lung and a history of squamous cell carcinoma of the lower lip was evaluated with FDG PET/CT.
  • There was an intensely hypermetabolic left submandibular gland lesion that was suspected for a metastasis.
  • Ultrasound-guided fine needle aspirate of the lesion proved to be a submandibular gland oncocytoma.
  • [MeSH-major] Adenoma, Oxyphilic / diagnosis. Adenoma, Oxyphilic / radionuclide imaging. Fluorodeoxyglucose F18. Positron-Emission Tomography / methods. Radiopharmaceuticals. Submandibular Gland Neoplasms / diagnosis. Submandibular Gland Neoplasms / radionuclide imaging. Tomography, X-Ray Computed / methods
  • [MeSH-minor] Aged, 80 and over. Biopsy, Fine-Needle. Carcinoma, Squamous Cell / complications. Carcinoma, Squamous Cell / pathology. Humans. Lip Neoplasms / complications. Lip Neoplasms / pathology. Lung Neoplasms / complications. Lung Neoplasms / pathology. Male. Neoplasm Metastasis. Neoplasm Staging / methods

  • MedlinePlus Health Information. consumer health - CT Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18580232.001).
  • [ISSN] 1536-0229
  • [Journal-full-title] Clinical nuclear medicine
  • [ISO-abbreviation] Clin Nucl Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


44. Zhang J, Lefkowitz RA, Ishill NM, Wang L, Moskowitz CS, Russo P, Eisenberg H, Hricak H: Solid renal cortical tumors: differentiation with CT. Radiology; 2007 Aug;244(2):494-504
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Solid renal cortical tumors: differentiation with CT.
  • PURPOSE: To retrospectively determine if solid renal cortical tumors can be differentiated on computed tomographic (CT) images on the basis of their morphologic features and enhancement patterns.
  • RESULTS: Of the 198 renal tumors (median size, 3.4 cm; range, 1.1-20.0 cm) included in this study, 108 (55%) were clear cell renal cell carcinomas (RCCs); 30 (15%), papillary lesions; 24 (12%), chromophobe adenomas; 14 (7%), oncocytomas; six (3%), lipid-poor angiomyolipomas; and 16 (8%), other or unclassified renal tumors.
  • Clear cell RCC most commonly manifested with a mixed enhancement pattern of both hypervascular soft-tissue components and low-attenuation areas that corresponded to necrotic or cystic changes (reader 1, 88% of clear cell tumors; reader 2, 79% of clear cell tumors).
  • This pattern was highly predictive of clear cell RCC (odds ratio of 22 and 54 for readers 1 and 2, respectively, for comparison with homogeneous pattern), whereas the homogeneous and peripheral enhancing patterns were more predictive of less aggressive papillary and chromophobe lesions.
  • Clear cell RCCs and oncocytomas tended to be hypervascular, chromophobe lesions and angiomyolipomas tended to enhance moderately, and papillary lesions were mostly hypovascular.
  • CONCLUSION: Certain imaging features and the degree of enhancement may be helpful in differentiating subtypes of renal cortical tumors.
  • [MeSH-major] Kidney Neoplasms / radiography. Tomography, X-Ray Computed / methods

  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17641370.001).
  • [ISSN] 0033-8419
  • [Journal-full-title] Radiology
  • [ISO-abbreviation] Radiology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contrast Media; 4419T9MX03 / Iohexol
  •  go-up   go-down


45. Blumenfeld AJ, Guru K, Fuchs GJ, Kim HL: Percutaneous biopsy of renal cell carcinoma underestimates nuclear grade. Urology; 2010 Sep;76(3):610-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Percutaneous biopsy of renal cell carcinoma underestimates nuclear grade.
  • RESULTS: The mean tumor size was 5.3 cm (range, 1-17).
  • The preoperative biopsy correctly identified 62 of 64 (97%) clear cell renal carcinomas, 9 of 10 (90%) papillary carcinomas, 0 of 3 (0%) chromophobe carcinomas, and 1 of 2 (50%) oncocytomas.
  • The final pathologies for 2 nondiagnostic biopsies were clear cell renal carcinoma and inflammatory pseudotumor.
  • For 67 tumors, the pathologists assigned a nuclear grade for both the biopsy and the final specimen.
  • CONCLUSIONS: Core biopsies for renal masses underestimate nuclear grade in most cases; however, histologic subtype is more reliably assessed, particularly for clear cell renal tumors.
  • [MeSH-major] Biopsy, Needle. Carcinoma, Renal Cell / pathology. Kidney Neoplasms / pathology

  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20163843.001).
  • [ISSN] 1527-9995
  • [Journal-full-title] Urology
  • [ISO-abbreviation] Urology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


46. Becker F: Editorial comment on: hybrid renal cell carcinomas containing histopathologic features of chromophobe renal cell carcinoma and oncocytoma have excellent oncologic outcomes. Eur Urol; 2010 Apr;57(4):666
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Editorial comment on: hybrid renal cell carcinomas containing histopathologic features of chromophobe renal cell carcinoma and oncocytoma have excellent oncologic outcomes.
  • [MeSH-major] Carcinoma, Renal Cell / pathology. Neoplasms, Complex and Mixed / pathology
  • [MeSH-minor] Adenoma, Oxyphilic / mortality. Adenoma, Oxyphilic / pathology. Adenoma, Oxyphilic / surgery. Biopsy. Disease-Free Survival. Humans. Kidney Neoplasms / mortality. Kidney Neoplasms / pathology. Kidney Neoplasms / surgery. Neoplasm Invasiveness. Neoplasm Staging. Nephrectomy. Survival Rate. Time Factors. Treatment Outcome


47. Nakazato Y: [Revised WHO classification of brain tumours]. Brain Nerve; 2008 Jan;60(1):59-77
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Revised WHO classification of brain tumours].
  • The WHO classification of brain tumours has been widely accepted and used in daily medical practice for more than 25 years since the first edition was published in 1979.
  • This revision updated the concept of grading, added several new entities and variants, modified and reclassified tumours, and changed the terminology.
  • Newly codified entities include atypical choroid plexus papilloma, angiocentric glioma, extraventricular neurocytoma, papillary glioneuronal tumour, rosette-forming glioneuronal tumour of the fourth ventricle, papillary tumour of the pineal region, anaplastic hemangiopericytoma, Ewing sarcoma - PNET, pituicytoma, and spindle cell oncocytoma of the adenohypophysis.
  • If a given tumour has an evidence of a different clinical features, genetic profile or prognostic behavior, it was considered to be histological variants; these included pilomyxoid astrocytoma, medulloblastoma with extensive nodularity, and anaplastic medulloblastoma.
  • [MeSH-major] Brain Neoplasms / classification. World Health Organization
  • [MeSH-minor] Humans. Neoplasm Staging

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18232334.001).
  • [ISSN] 1881-6096
  • [Journal-full-title] Brain and nerve = Shinkei kenkyū no shinpo
  • [ISO-abbreviation] Brain Nerve
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 106
  •  go-up   go-down


48. Al-Shraim MM, Hussein MR, Musalam AO, Al-Ghandi T, Al-Zahramit H, Mahrouz AA, Abu-Eshy SA: Hurthle cell neoplasms of thyroid in south-western region of Saudi Arabia. West Afr J Med; 2010 Nov-Dec;29(6):398-402
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hurthle cell neoplasms of thyroid in south-western region of Saudi Arabia.
  • BACKGROUND: Thyroid Hurthle cell neoplasm (THCN) is relatively rare.
  • METHODS: This was a retrospective chart review of all thyroid Hurthle cell neoplasms diagnosed at Aseer Central Hospital (ACH), Saudi Arabia during the period from October 1998 to April 2007.
  • Three cases were Hurthle cell carcinomas and six cases were Hurthle cell adenomas.
  • Adenomas presented as solitary nodules (two cases), as multinodular goiter (three cases) and as diffuse swelling (one case).
  • Fine needle aspiration cytology (FNAC) was diagnostic for THCN in two cases of carcinoma that presented as solitary nodules and hence total thyroidectomy was performed.
  • Total thyroidectomy was also done in one case of adenoma.
  • Hemithyroidectomy was performed in two cases of adenoma in which FNAC showed benign lesion and in one case of carcinoma based on clinical and ultrasonographic impression of benign MNG in the involved lobe and inconclusive FNAC result.
  • Subtotal thyroidectomy was performed in one case of adenoma.
  • Neither clinical nor FNAC findings can exclude carcinoma.
  • [MeSH-minor] Adult. Biopsy, Fine-Needle. Female. Humans. Male. Middle Aged. Retrospective Studies. Saudi Arabia. Thyroid Gland / pathology. Thyroid Neoplasms / pathology. Thyroid Neoplasms / surgery. Thyroidectomy. Treatment Outcome. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21465448.001).
  • [ISSN] 0189-160X
  • [Journal-full-title] West African journal of medicine
  • [ISO-abbreviation] West Afr J Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Nigeria
  • [Chemical-registry-number] Thyroid cancer, Hurthle cell
  •  go-up   go-down


49. Michael CW, Pang Y, Pu RT, Hasteh F, Griffith KA: Cellular adequacy for thyroid aspirates prepared by ThinPrep: how many cells are needed? Diagn Cytopathol; 2007 Dec;35(12):792-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cellular adequacy for thyroid aspirates prepared by ThinPrep: how many cells are needed?
  • Although it is well established that ThinPrep introduces artifacts to thyroid aspirates, no criteria have been established for adequacy of such specimens.
  • A total of 218 thyroid aspirates prepared by TP with surgical pathology follow-up were reviewed.
  • Cytologic diagnoses were classified as: Nondiagnostic (ND), cystic contents, thyroiditis, nodular hyperplasia (NH), follicular/Hurthle (F/H) cell lesion, F/H cell neoplasm, and carcinoma: qualify.
  • Histologic diagnoses were classified as: Cyst (colloid or otherwise), thyroiditis, NH, F/H adenoma, F/H carcinoma, carcinoma: qualify.
  • A 25-cell increase in average cells per cluster increases the odds of agreement between diagnoses by 65%.
  • [MeSH-major] Biopsy, Fine-Needle / standards. Cell Count / standards. Cytodiagnosis / standards. Pathology, Surgical / standards. Thyroid Diseases / diagnosis

  • MedlinePlus Health Information. consumer health - Thyroid Diseases.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2007 Wiley-Liss, Inc.
  • (PMID = 18008342.001).
  • [ISSN] 8755-1039
  • [Journal-full-title] Diagnostic cytopathology
  • [ISO-abbreviation] Diagn. Cytopathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


50. Shen SS, Krishna B, Chirala R, Amato RJ, Truong LD: Kidney-specific cadherin, a specific marker for the distal portion of the nephron and related renal neoplasms. Mod Pathol; 2005 Jul;18(7):933-40
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Kidney-specific cadherin, a specific marker for the distal portion of the nephron and related renal neoplasms.
  • Renal cell neoplasms are presumably derived from different cell types of the nephron.
  • Clear cell and papillary renal cell carcinoma (RCC) are thought to be of proximal tubular origin, whereas oncocytoma and chromophobe RCC are derived from intercalated cells of distal nephron.
  • A few molecules, such as RCC marker and CD10, have been shown to be markers for clear cell RCC and papillary RCC.
  • Such markers are not yet available for renal tumors presumably of the distal nephron.
  • The expression of kidney-specific (Ksp) cadherin, a recently cloned gene thought to be transcribed exclusively in the kidney, was studied in normal human kidney, as well as in 105 primary renal neoplasms, including 42 clear cell RCC, 30 papillary RCC, 13 chromophobe RCC, and 20 oncocytomas.
  • All 13 chromophobe RCC and 19 of 20 oncocytomas showed diffuse and strong immunoreactivity for Ksp-cadherin, while only 14% clear cell RCC and 13% papillary RCC showed focal positivity.
  • The RCC marker expression was detected in 85%, 98%, 15% and 0% of clear cell RCC, papillary RCC, chromophobe RCC, and oncocytoma, respectively.
  • A few clear cell RCC and papillary RCC showed dual expression of both RCC marker and Ksp-cadherin, which appear to have distinct histologic features.
  • [MeSH-major] Cadherins / analysis. Kidney / chemistry. Kidney Neoplasms / pathology. Nephrons / chemistry
  • [MeSH-minor] Adenocarcinoma, Clear Cell / metabolism. Adenocarcinoma, Clear Cell / pathology. Adenoma, Oxyphilic / metabolism. Adenoma, Oxyphilic / pathology. Biomarkers / analysis. Carcinoma, Papillary / metabolism. Carcinoma, Papillary / pathology. Carcinoma, Renal Cell / metabolism. Carcinoma, Renal Cell / pathology. Diagnosis, Differential. Humans. Immunohistochemistry. Kidney Tubules / chemistry

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15696118.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Cadherins; 0 / FAT1 protein, human
  •  go-up   go-down


51. Minamimoto R, Yamanaka S, Kawamoto M, Endoh M, Nishito R, Yoshida K, Nakaigawa N, Yao M, Kubota Y, Inoue T: High FDG uptake on oncocytoma located in the retroperitoneum mimicking malignancy. Clin Nucl Med; 2007 Jul;32(7):582-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High FDG uptake on oncocytoma located in the retroperitoneum mimicking malignancy.
  • [MeSH-major] Adenoma, Oxyphilic / radionuclide imaging. Adrenal Glands / abnormalities. Adrenal Glands / radionuclide imaging. Fluorodeoxyglucose F18. Retroperitoneal Neoplasms / radionuclide imaging

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17581356.001).
  • [ISSN] 0363-9762
  • [Journal-full-title] Clinical nuclear medicine
  • [ISO-abbreviation] Clin Nucl Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


52. Aiba M, Fujibayashi M: Histopathological diagnosis and prognostic factors in adrenocortical carcinoma. Endocr Pathol; 2005;16(1):13-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Histopathological diagnosis and prognostic factors in adrenocortical carcinoma.
  • A great majority of adrenocortical tumors are benign, and many adrenocortical carcinomas (ACC) are obviously malignant at presentation.
  • These special type tumors include pediatric adrenocortical tumors, oncocytomas, and aldosterone-producing tumors of pure zona glomerulosa type.
  • Then we present three cases with unusual small adrenocortical tumors.
  • The third was a pediatric patient with a tumor showing a nodule-in-nodule pattern with insulin-like growth factor II expression.
  • [MeSH-major] Adrenal Cortex Neoplasms / diagnosis. Adrenocortical Carcinoma / diagnosis
  • [MeSH-minor] Adenoma, Oxyphilic. Adult. Aged. Aged, 80 and over. Aldosterone / metabolism. Biomarkers, Tumor / metabolism. Cell Nucleus / pathology. Female. Humans. Immunohistochemistry. Infant. Insulin-Like Growth Factor II / metabolism. Male. Neoplasm Staging. Prognosis

  • Genetic Alliance. consumer health - Adrenocortical Carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Arch Surg. 2001 May;136(5):543-9 [11343545.001]
  • [Cites] J Biol Chem. 1991 Jun 15;266(17):10731-4 [2040591.001]
  • [Cites] Am J Surg Pathol. 2003 Jul;27(7):867-81 [12826878.001]
  • [Cites] Endocr Pathol. 2002 Summer;13(2):141-8 [12165663.001]
  • [Cites] Cancer. 2002 May 1;94(9):2333-43 [12015757.001]
  • [Cites] Surgery. 1992 Dec;112(6):981-6 [1360713.001]
  • [Cites] Med Pediatr Oncol. 1997 Mar;28(3):175-8 [9024511.001]
  • [Cites] Arch Surg. 1999 Feb;134(2):181-5 [10025460.001]
  • [Cites] Am J Surg Pathol. 1991 Oct;15(10 ):949-56 [1928551.001]
  • [Cites] Am J Clin Pathol. 1979 Sep;72(3):390-9 [474519.001]
  • [Cites] Endocr Pathol. 2003 Summer;14(2):107-16 [12858000.001]
  • [Cites] Pathol Int. 2004 Apr;54(4):273-8 [15028030.001]
  • [Cites] Mod Pathol. 2002 Sep;15(9):973-8 [12218215.001]
  • [Cites] Am J Pathol. 2003 Feb;162(2):521-31 [12547710.001]
  • [Cites] J Urol. 2003 Jan;169(1):5-11 [12478091.001]
  • [Cites] Acta Pathol Jpn. 1979 Mar;29(2):177-82 [552791.001]
  • [Cites] Am J Surg Pathol. 1989 Mar;13(3):202-6 [2919718.001]
  • [Cites] Am J Clin Pathol. 1991 Sep;96(3):334-40 [1652202.001]
  • [Cites] J Clin Endocrinol Metab. 2000 May;85(5):2048-56 [10843195.001]
  • [Cites] Mod Pathol. 2003 Aug;16(8):742-51 [12920217.001]
  • [Cites] Pathol Annu. 1992;27 Pt 1:1-53 [1736241.001]
  • [Cites] Am J Pathol. 1981 Jun;103(3):404-10 [7195152.001]
  • [Cites] Am J Pathol. 1986 Dec;125(3):431-5 [2432790.001]
  • [Cites] Cancer. 2001 Sep 15;92(6):1385-92 [11745214.001]
  • [Cites] Cancer. 1985 Feb 15;55(4):766-73 [3967172.001]
  • [Cites] Am J Surg Pathol. 1984 Mar;8(3):163-9 [6703192.001]
  • (PMID = 16000842.001).
  • [ISSN] 1046-3976
  • [Journal-full-title] Endocrine pathology
  • [ISO-abbreviation] Endocr. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 4964P6T9RB / Aldosterone; 67763-97-7 / Insulin-Like Growth Factor II
  •  go-up   go-down


53. Melck A, Bugis S, Baliski C, Irvine R, Anderson DW, Wilkins G, Zhang H, Wiseman SM: Hemithyroidectomy: the preferred initial surgical approach for management of Hurthle cell neoplasm. Am J Surg; 2006 May;191(5):593-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hemithyroidectomy: the preferred initial surgical approach for management of Hurthle cell neoplasm.
  • BACKGROUND: The objective of this study was to evaluate the cancer risk of patient clinicopathologic characteristics to determine the optimal approach for the surgical management of individuals with Hurthle cell neoplasm (HN) diagnosed by cytology.
  • METHODS: Patient clinicopathologic characteristics evaluated included age, sex, tumor size, and ipsilateral thyroid lobe nodularity.
  • Although none of the clinicopathologic characteristics evaluated were able to reliably differentiate benign from malignant tumors, large tumor size and male sex were significantly associated with a pathologic diagnosis of Hurthle cell carcinoma (P < .05).
  • CONCLUSIONS: Hemithyroidectomy represents the preferred initial surgical approach for the management of individuals presenting with nodular thyroid disease and a cytologic diagnosis of HN.
  • [MeSH-major] Adenoma, Oxyphilic / surgery. Thyroid Neoplasms / surgery. Thyroidectomy / methods

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16647343.001).
  • [ISSN] 0002-9610
  • [Journal-full-title] American journal of surgery
  • [ISO-abbreviation] Am. J. Surg.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


54. Shioi K, Komiya A, Hattori K, Huang Y, Sano F, Murakami T, Nakaigawa N, Kishida T, Kubota Y, Nagashima Y, Yao M: Vascular cell adhesion molecule 1 predicts cancer-free survival in clear cell renal carcinoma patients. Clin Cancer Res; 2006 Dec 15;12(24):7339-46
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Vascular cell adhesion molecule 1 predicts cancer-free survival in clear cell renal carcinoma patients.
  • PURPOSE: Vascular cell adhesion molecule 1 (VCAM1) is a cell surface glycoprotein implicated in various pathophysiologic conditions.
  • We measured VCAM1 expression levels in tumor tissues and evaluated its significance and prognostic use in renal cell carcinoma (RCC).
  • EXPERIMENTAL DESIGN: We used real-time quantitative PCR to examine the VCAM1 expression levels of a total of 485 sporadic renal tumors, including 429 clear cell, 21 papillary, 17 chromophobe, 11 oncocytomas, and 7 collecting duct carcinomas.
  • RESULTS: Compared with normal kidney samples (n = 43), VCAM1 was significantly up-regulated in clear cell RCC and papillary RCC, whereas it was down-regulated in chromophobe RCC and oncocytoma.
  • In clear cell RCC, VCAM1 expression levels were apparently high in patients asymptomatic at presentation and in patients with small tumor size, low-stage, low-grade, microvascular invasion-negative, and von Hippel-Lindau alteration-positive tumors.
  • Univariate analyses showed that VCAM1 high expression is strongly associated with better outcomes in clear cell and papillary RCCs.
  • Further, Cox multivariate analysis models combined with the split-sample method revealed that this association is significant only in cancer-free survival for patients with clear cell RCC after curative surgical resection.
  • CONCLUSIONS: VCAM1 expression levels were found to be histologically subtype specific in renal tumors.
  • Determination of the VCAM1 expression level as a biomarker can provide useful prognostic information for patients with clear cell RCC.
  • [MeSH-major] Carcinoma, Renal Cell / diagnosis. Kidney Neoplasms / diagnosis. Vascular Cell Adhesion Molecule-1 / metabolism. Vascular Cell Adhesion Molecule-1 / physiology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / metabolism. Biomarkers, Tumor / physiology. Carcinoma, Papillary / metabolism. Carcinoma, Papillary / mortality. Carcinoma, Papillary / pathology. Disease-Free Survival. Female. Gene Expression. Humans. Male. Middle Aged. Mutation. Neoplasm Metastasis / pathology. Neoplasm Staging. Prognosis. Survival Analysis. Treatment Outcome. Von Hippel-Lindau Tumor Suppressor Protein / genetics

  • Genetic Alliance. consumer health - Clear Cell Renal Cell Carcinoma.
  • Genetic Alliance. consumer health - Kidney cancer.
  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17189405.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Vascular Cell Adhesion Molecule-1; EC 6.3.2.19 / Von Hippel-Lindau Tumor Suppressor Protein
  •  go-up   go-down


55. Aslam MI, Spencer L, Garcea G, Pollard C, Metcalfe MS, Harrison RF, Dennison AR: A case of liver metastasis from an oncocytoma with a focal area of chromophobe renal cell carcinoma: a wolf in sheep's clothing. Int J Surg Pathol; 2009 Apr;17(2):158-62
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of liver metastasis from an oncocytoma with a focal area of chromophobe renal cell carcinoma: a wolf in sheep's clothing.
  • In 2004, the World Health Organization classified the renal oncocytomas as benign neoplasms of the kidney.
  • There are reports of subtypes of renal tumors, with similar histological morphology to oncocytoma, but with malignant potential, one of these tumors is the eosinophilic variant of chromophobe renal cell carcinoma.
  • It is important to characterize the histological features and the subtype of tumor, as this predicts biological behavior and cancer-specific survival rate.
  • A rare case of a liver metastasis from a focal area of eosinophilic variant of chromophobe renal cell carcinoma mixed in oncocytoma in a 69-year-old woman is reported.
  • Although some renal tumors may contain oncocytoma and eosinophilic variant of chromophobe renal cell carcinoma histology, caution should be exercised while diagnosing oncocytomas in needle biopsies as there may be unsampled area of chromophobe carcinoma which has a potential for metastatic spread representing a wolf in sheep's clothing.
  • [MeSH-major] Adenoma, Oxyphilic / secondary. Carcinoma, Renal Cell / secondary. Kidney Neoplasms / pathology. Liver Neoplasms / secondary


56. Prasad SR, Narra VR, Shah R, Humphrey PA, Jagirdar J, Catena JR, Dalrymple NC, Siegel CL: Segmental disorders of the nephron: histopathological and imaging perspective. Br J Radiol; 2007 Aug;80(956):593-602
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Recent advances in molecular genetics and immunocytochemistry have clarified the cell of origin in many renal disorders.
  • Renin-secreting tumours arise from juxtaglomerular cells.
  • Clear cell and papillary renal cell carcinoma (RCC) recapitulate the epithelium of the proximal tubules.
  • Oncocytoma and chromophobe RCC differentiate towards Type A and Type B intercalated cells of the cortical collecting duct, respectively.
  • Medullary collecting ducts are the target sites for the development of autosomal recessive polycystic kidney disease, collecting duct carcinoma and medullary carcinoma.
  • [MeSH-minor] Carcinoma, Renal Cell / pathology. Carcinoma, Renal Cell / radiography. Carcinoma, Renal Cell / ultrasonography. Humans. Kidney Glomerulus / pathology. Kidney Neoplasms / pathology. Kidney Neoplasms / radiography. Kidney Neoplasms / ultrasonography. Kidney Tubules / pathology. Magnetic Resonance Imaging. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Kidney Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17621606.001).
  • [ISSN] 1748-880X
  • [Journal-full-title] The British journal of radiology
  • [ISO-abbreviation] Br J Radiol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 55
  •  go-up   go-down


57. Faquin WC, Cibas ES, Renshaw AA: "Atypical" cells in fine-needle aspiration biopsy specimens of benign thyroid cysts. Cancer; 2005 Apr 25;105(2):71-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] "Atypical" cells in fine-needle aspiration biopsy specimens of benign thyroid cysts.
  • BACKGROUND: Cystic lesions of the thyroid are common.
  • However, occasionally, cells with atypical features are encountered, increasing the possibility of a cystic malignant neoplasm.
  • To refine the description of their morphologic features, with the belief that better recognition will avoid unnecessary surgery, the authors examined the cytologic and corresponding histologic features of thyroid cysts with "atypical" cells.
  • METHODS: A total of 149 FNAB specimens from thyroid cysts containing atypical cells were identified.
  • Seventy-five specimens with subsequent histologic correlation showing a benign cystic thyroid nodule were selected for study.
  • In addition, 12 FNAB specimens of histologically proven cystic papillary carcinoma diagnosed as atypical were reviewed for comparison.
  • RESULTS: The majority of specimens (94%) were diagnosed cytologically as atypical thyroid cysts.
  • However, in 29% of these specimens, a papillary or Hurthle cell neoplasm could not be excluded.
  • The most common features were cohesive flat sheets (84%), distinct cell borders (96%), nuclear enlargement (92%), nuclear grooves (79%), dense granular cytoplasm (79%), small distinct nucleoli (85%), fine chromatin (87%), and elongate to spindled cytomorphology (57%).
  • Immunohistochemical staining of a subset of the resected thyroid cysts showed that the cyst-lining cells were positive for keratin and thyroglobulin, consistent with thyroid follicular cells.
  • CONCLUSIONS: Atypical cyst-lining cells were found to have characteristic features (e.g., distinct cell borders, elongated shape, eosinophilic cytoplasm, and distinct nucleoli) and lacked nuclear crowding, intranuclear pseudoinclusions, and papillary architecture that, in many specimens, allowed them to be recognized as benign.
  • [MeSH-major] Biopsy, Fine-Needle. Cysts / pathology. Thyroid Diseases / pathology
  • [MeSH-minor] Carcinoma, Papillary / pathology. Diagnosis, Differential. Humans. Immunohistochemistry. Thyroid Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Thyroid Diseases.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2005 American Cancer Society.
  • [CommentIn] Cancer. 2006 Feb 25;108(1):72; author reply 73 [16400633.001]
  • (PMID = 15662703.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


58. Gumy-Pause F, Bongiovanni M, Wildhaber B, Jenkins JJ, Chardot C, Ozsahin H: Adrenocortical oncocytoma in a child. Pediatr Blood Cancer; 2008 Mar;50(3):718-21
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adrenocortical oncocytoma in a child.
  • Adrenocortical oncocytoma is a rare epithelial tumor only described in adults.
  • A diagnosis of adrenocortical oncocytoma was made after detailed histological, immunohistochemical, and ultrastructural studies.
  • [MeSH-major] Adenoma, Oxyphilic / pathology. Adrenal Cortex Neoplasms / pathology
  • [MeSH-minor] Acne Vulgaris / etiology. Adrenalectomy. Androstenedione / secretion. Child. Female. Humans. Neoplasm Proteins / analysis. Testosterone / secretion

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. TESTOSTERONE .
  • Hazardous Substances Data Bank. ANDROSTENEDIONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 Wiley-Liss, Inc.
  • (PMID = 17091483.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Neoplasm Proteins; 3XMK78S47O / Testosterone; 409J2J96VR / Androstenedione
  •  go-up   go-down


59. Junker K, Hindermann W, von Eggeling F, Diegmann J, Haessler K, Schubert J: CD70: a new tumor specific biomarker for renal cell carcinoma. J Urol; 2005 Jun;173(6):2150-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CD70: a new tumor specific biomarker for renal cell carcinoma.
  • PURPOSE: To date there have been no specific tumor markers available for the differential diagnosis of renal cell carcinoma (RCC).
  • In an earlier study we identified high RNA expression of CD70 in clear cell RCC.
  • CD70 is a type II transmembrane protein belonging to the tumor necrosis factor family.
  • It represents the ligand for CD27, a glycosylated transmembrane protein of the tumor necrosis factor receptor family.
  • To our knowledge the function of CD70 in solid tumors is not known.
  • MATERIALS AND METHODS: A total of 68 tumor samples of different histopathological subtypes were investigated by immunochemistry, including 41 clear cell, 19 papillary and 5 chromophobe RCCs, and 3 oncocytomas as well as their normal tissue counterparts.
  • In contrast, all clear cell RCCs expressed CD70 at a high level.
  • Five papillary tumor samples (26%) showed focal staining in less than 5% of cells.
  • CONCLUSIONS: Our study identified CD70 as a new specific tumor marker for clear cell RCC.
  • [MeSH-major] Antigens, CD / analysis. Biomarkers, Tumor / analysis. Carcinoma, Renal Cell / diagnosis. Kidney Neoplasms / diagnosis. Membrane Proteins / analysis
  • [MeSH-minor] Adenocarcinoma, Clear Cell / diagnosis. Adenocarcinoma, Clear Cell / pathology. Antigens, CD70. Carcinoma, Papillary / diagnosis. Carcinoma, Papillary / pathology. Diagnosis, Differential. Humans. Immunoenzyme Techniques. Kidney / pathology. Nephrectomy. Sensitivity and Specificity

  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Urol. 2005 Jun;173(6):1847 [15879760.001]
  • (PMID = 15879877.001).
  • [ISSN] 0022-5347
  • [Journal-full-title] The Journal of urology
  • [ISO-abbreviation] J. Urol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, CD70; 0 / Biomarkers, Tumor; 0 / CD70 protein, human; 0 / Membrane Proteins
  •  go-up   go-down


60. Jerónimo C: Quantitative methylation profiling of renal tumors and the discovery of a new generation of molecular markers. Future Oncol; 2005 Apr;1(2):197-200
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Quantitative methylation profiling of renal tumors and the discovery of a new generation of molecular markers.
  • Evaluation of: Gonzalgo ML, Yegnasubramanian S, Yan G et al.: Molecular profiling and classification of sporadic renal cell carcinoma by quantitative methylation analysis. Clin.
  • Overall, 16 gene promoters were surveyed for hypermethylation in a series of 38 renal cell tumors (comprising papillary and clear-cell renal cell carcinoma, and oncocytoma) and paired normal tissue samples.
  • Among the target genes analyzed, RASSF1A emerged as the most frequently methylated in renal tumors and also at higher levels.
  • Statistical analyses showed a significant association between RASSF1A promoter methylation and higher pathological stage, but not with tumor size or nuclear grade.
  • The discriminative power of a quantitative approach allowed for a segregation between renal carcinomas and oncocytomas, using a self-organizing hierarchical neural network.
  • These results hold the promise that epigenetic-based markers might prove clinically useful for the management of patients with renal tumors.
  • Nevertheless, further studies, including larger sets of patients and more diversified renal tumors, as well as benign lesions, are needed to validate these preliminary results.
  • [MeSH-major] Adenocarcinoma, Clear Cell / genetics. Biomarkers, Tumor / genetics. Carcinoma, Papillary / genetics. Carcinoma, Renal Cell / genetics. DNA Methylation. Kidney Neoplasms / genetics. Tumor Suppressor Proteins / genetics

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16555990.001).
  • [ISSN] 1479-6694
  • [Journal-full-title] Future oncology (London, England)
  • [ISO-abbreviation] Future Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / RASSF1 protein, human; 0 / Tumor Suppressor Proteins
  •  go-up   go-down


61. Johnson NB, Johnson MM, Selig MK, Nielsen GP: Use of electron microscopy in core biopsy diagnosis of oncocytic renal tumors. Ultrastruct Pathol; 2010 Aug;34(4):189-94
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Use of electron microscopy in core biopsy diagnosis of oncocytic renal tumors.
  • The distinction between oncocytoma and chromophobe renal cell carcinoma, important clinically, may be challenging, especially as the tissue sample size decreases.
  • The aim of this study was to examine the value of electron microscopy in differentiating between oncocytoma and chromophobe renal cell carcinoma on formalin fixed paraffin embedded needle core biopsies.
  • Despite formalin fixation and paraffin embedding, the classic ultrastructural features of these neoplasms were retained, revealing 80% sensitivity and 100% specificity by initial work-up.
  • [MeSH-major] Adenoma, Oxyphilic / ultrastructure. Kidney Neoplasms / ultrastructure
  • [MeSH-minor] Aged. Aged, 80 and over. Biopsy. Carcinoma, Renal Cell / ultrastructure. Cytoplasmic Vesicles / ultrastructure. Diagnosis, Differential. Female. Humans. Male. Microscopy, Electron, Transmission / methods. Middle Aged. Mitochondria / ultrastructure. Predictive Value of Tests

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20594037.001).
  • [ISSN] 1521-0758
  • [Journal-full-title] Ultrastructural pathology
  • [ISO-abbreviation] Ultrastruct Pathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


62. Jacques C, Baris O, Prunier-Mirebeau D, Savagner F, Rodien P, Rohmer V, Franc B, Guyetant S, Malthiery Y, Reynier P: Two-step differential expression analysis reveals a new set of genes involved in thyroid oncocytic tumors. J Clin Endocrinol Metab; 2005 Apr;90(4):2314-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Two-step differential expression analysis reveals a new set of genes involved in thyroid oncocytic tumors.
  • Thyroid oncocytic adenomas are a class of tumors characterized by the presence of abundant mitochondria.
  • We performed a differential display RT-PCR analysis on two oncocytic adenomas and their paired controls.
  • We then carried out a microarray analysis using the 460 selected, differentially expressed clones on four other oncocytomas and their paired controls.
  • Thirty genes, 12 encoded by mitochondrial DNA and 18 nuclear-encoded, were overexpressed by a factor of at least 2 in the tumors compared with the controls.
  • Seven of the 18 nuclear-encoded genes are involved in protein metabolism: DKFZP434I116, B3GTL, SNX19, RP42, SENP1, UBE2D3, and the CTSB gene, which is known to be particularly deregulated in most thyroid tumors.
  • We confirmed the overexpression of the AF1q oncogene in 56% of 18 oncocytic tumors by quantitative RT-PCR analysis, which attested to the heterogeneity of these tumors.
  • Our results show an increased expression of genes involved in protein metabolism in oncocytoma, the significance of which requires investigation.
  • [MeSH-major] Adenoma / genetics. Gene Expression Profiling. Thyroid Neoplasms / genetics
  • [MeSH-minor] Adenine Nucleotide Translocator 2 / genetics. DNA, Mitochondrial / genetics. Humans. Ion Channels. Membrane Transport Proteins / genetics. Mitochondrial Proteins / genetics. Neoplasm Proteins / metabolism. Oligonucleotide Array Sequence Analysis

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15623817.001).
  • [ISSN] 0021-972X
  • [Journal-full-title] The Journal of clinical endocrinology and metabolism
  • [ISO-abbreviation] J. Clin. Endocrinol. Metab.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adenine Nucleotide Translocator 2; 0 / DNA, Mitochondrial; 0 / Ion Channels; 0 / Membrane Transport Proteins; 0 / Mitochondrial Proteins; 0 / Neoplasm Proteins; 0 / mitochondrial uncoupling protein 2
  •  go-up   go-down


63. Alroy J, Ucci AA, Azabdoaftari G, Banner BF, Cheville JC: Expression of CD3 antigens in renal tubule epithelium and renal oncocytomas. Pathol Res Pract; 2005;201(12):803-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of CD3 antigens in renal tubule epithelium and renal oncocytomas.
  • The antibodies commonly used to recognize CD3 are directed against the epsilon-subunit of the T cell receptor.
  • We immunostained sections for CD3 from normal kidneys of several species, including humans, and from different primary human renal cortical neoplasms to determine if CD3 antigen is expressed in normal and in neoplastic tubular epithelium.
  • CD3 expression was strong in normal proximal and distal tubular epithelium in most species and in renal oncocytomas, weak in chromophobe carcinoma, and negative in clear cell carcinomas, in papillary renal cell carcinoma, and in a transitional cell carcinoma.
  • These findings suggest that this marker may be useful in the diagnostic workup and classification of renal cortical neoplasms.
  • [MeSH-major] Adenoma, Oxyphilic / metabolism. Antigens, CD3 / metabolism. Kidney Neoplasms / metabolism. Kidney Tubules / metabolism

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16308105.001).
  • [ISSN] 0344-0338
  • [Journal-full-title] Pathology, research and practice
  • [ISO-abbreviation] Pathol. Res. Pract.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antigens, CD3
  •  go-up   go-down


64. Couturier J: [Genomic classification of renal cell tumors in adults]. Ann Pathol; 2008 Oct;28(5):402-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Genomic classification of renal cell tumors in adults].
  • [Transliterated title] Classification génomique des tumeurs à cellules rénales de l'adulte.
  • Classification of adult renal-cell tumors, based for years on histological criteria only, has been recently updated by taking into account characteristic chromosome rearrangements and genome and transcriptome profiles identified by cytogenetic techniques, detection of fusion transcripts and by genomic analyses on DNA microarrays.
  • Type 2 is a heterogeneous group, including a low-grade subtype corresponding to genetically evolved type 1 tumors, and a high-grade subtype, identified by its expression profile which remains to be well characterized at the genomic level.
  • Mucinous tubular carcinoma exhibits a recurrent genomic profile with whole chromosome losses involving 1, 4, 6, 8, 9, 13, 14, 15, and 22, consequently without relationship with type 1 papillary tumors.
  • The profile of chromophobe-cell carcinoma corresponds to the same genomic mechanism, with losses of chromosomes 1, 2, 6, 10, 13, 17, and 21, without relationship with that of oncocytoma.
  • Juvenile carcinoma, that can occur also in adults, shows translocations involving genes of the MiTF/TFE family, TFE3, in Xp11.2, and TFEB, in 6p21.
  • So, molecular diagnosis, either by identification of specific translocations, or by genomic profiling, can be of valuable help for typing renal tumors when histological classification is difficult.
  • [MeSH-major] Carcinoma, Renal Cell / genetics. Kidney Neoplasms / genetics
  • [MeSH-minor] Adult. Carcinoma, Papillary / classification. Carcinoma, Papillary / genetics. Chromosome Mapping. Chromosomes, Human. Comparative Genomic Hybridization. Gene Expression Regulation, Neoplastic. Humans. Karyotyping. Oligonucleotide Array Sequence Analysis

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19068394.001).
  • [ISSN] 0242-6498
  • [Journal-full-title] Annales de pathologie
  • [ISO-abbreviation] Ann Pathol
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Number-of-references] 47
  •  go-up   go-down


65. Tong GX, Yu WM, Beaubier NT, Weeden EM, Hamele-Bena D, Mansukhani MM, O'Toole KM: Expression of PAX8 in normal and neoplastic renal tissues: an immunohistochemical study. Mod Pathol; 2009 Sep;22(9):1218-27
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Cell-lineage-specific transcription factors are a group of regulatory proteins expressed in embryonic, differentiated, or neoplastic cells of the same lineage and represent a valuable repertoire of tissue-specific markers for the diagnosis of human tumors.
  • In contrast to PAX2, little is known about the expression of PAX8 in adult kidney and renal tumors.
  • In this study, we used immunohistochemistry to investigate the expression of PAX8 in adult human kidney and renal epithelial tumors.
  • PAX8 was also present in 98% of clear cell renal cell carcinomas (RCCs), 90% of papillary RCCs, and 95% of oncocytomas, similar to PAX2.
  • Overall, PAX8 was detected in 85% of metastatic renal tumors.
  • PAX8 may be a useful additional marker for renal epithelial tumors; however, its specificity and sensitivity await further investigation.
  • [MeSH-major] Biomarkers, Tumor / analysis. Kidney / metabolism. Kidney Neoplasms / metabolism. Neoplasms, Glandular and Epithelial / metabolism. Paired Box Transcription Factors / biosynthesis

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19525927.001).
  • [ISSN] 1530-0285
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / PAX8 protein, human; 0 / Paired Box Transcription Factors
  •  go-up   go-down


66. Seethala RR, Dacic S, Cieply K, Kelly LM, Nikiforova MN: A reappraisal of the MECT1/MAML2 translocation in salivary mucoepidermoid carcinomas. Am J Surg Pathol; 2010 Aug;34(8):1106-21
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The MECT1/MAML2 translocation is identified in a large proportion of mucoepidermoid carcinomas (MEC) of the salivary gland and is an emerging favorable prognosticator.
  • We analyzed 55 salivary MEC and 36 potential MEC mimics (24 Warthin tumors, 5 oncocytomas, 3 squamous cell carcinomas, 2 squamoid salivary duct carcinomas, 1 lymphoepithelial cyst, 1 Schneiderian carcinoma ex papilloma) for presence of the MECT1/MAML2 translocation by fluorescent in-situ hybridization (FISH) and real-time RT-PCR.
  • Within high-grade MEC, MECT1/MAML2 positive tumors had lower rates of anaplasia (P=0.001), and mitotic counts (P=0.012).
  • There are 2 distinct subgroups within high-grade MEC, and the translocation negative tumors may actually be more appropriately categorized as another tumor type (such as adenosquamous carcinoma).
  • [MeSH-major] Carcinoma, Mucoepidermoid / genetics. Oncogene Proteins, Fusion / genetics. Salivary Gland Neoplasms / genetics. Translocation, Genetic
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Chi-Square Distribution. Child. Disease-Free Survival. Female. Gene Expression Regulation, Neoplastic. Humans. In Situ Hybridization, Fluorescence. Kaplan-Meier Estimate. Male. Middle Aged. Neoplasm Staging. Prognosis. Retrospective Studies. Reverse Transcriptase Polymerase Chain Reaction. Time Factors. Young Adult

  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20588178.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / 1P50 CA097190
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / MECT1-MAML2 fusion protein, human; 0 / Oncogene Proteins, Fusion
  •  go-up   go-down


67. Dasanu CA, Alexandrescu DT: Bilateral perinephric diffuse large B-cell lymphoma and synchronous renal oncocytoma. South Med J; 2008 Feb;101(2):196-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bilateral perinephric diffuse large B-cell lymphoma and synchronous renal oncocytoma.
  • An elderly patient who presented with bilateral perinephric diffuse large B-cell lymphoma and concomitant oncocytoma of the same location is reported.
  • To our knowledge, the anatomic proximity of the two tumors at the level of kidneys has not been previously described.
  • [MeSH-major] Adenoma, Oxyphilic / pathology. Kidney Neoplasms / pathology. Lymphoma, Large B-Cell, Diffuse / pathology. Neoplasms, Multiple Primary / pathology


68. Fellegara G, Rosai J: Signet ring cells in a poorly differentiated Hurthle cell carcinoma of the thyroid combined with two papillary microcarcinomas. Int J Surg Pathol; 2007 Oct;15(4):388-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Signet ring cells in a poorly differentiated Hurthle cell carcinoma of the thyroid combined with two papillary microcarcinomas.
  • [MeSH-major] Adenoma, Oxyphilic / pathology. Carcinoma, Papillary / pathology. Carcinoma, Signet Ring Cell / pathology. Oxyphil Cells / pathology. Thyroid Neoplasms / pathology
  • [MeSH-minor] Adult. Female. Humans. Neoplasms, Multiple Primary

  • Genetic Alliance. consumer health - Signet ring cell carcinoma.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17913947.001).
  • [ISSN] 1066-8969
  • [Journal-full-title] International journal of surgical pathology
  • [ISO-abbreviation] Int. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


69. Chao TC, Lin JD, Chen MF: Surgical treatment of Hurthle cell tumors of the thyroid. World J Surg; 2005 Feb;29(2):164-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgical treatment of Hurthle cell tumors of the thyroid.
  • Hurthle cell tumors are relatively rare thyroid tumors and their management and prognosis is controversial.
  • We retrospectively review 135 Hurthle cell adenomas and 28 Hurthle cell carcinomas of the thyroid surgically treated at our institute.
  • No significant difference was found between the adenoma and carcinoma groups in patient age, gender, and tumor size.
  • The sensitivity, specificity, accuracy, positive predictive value, and negative predictive value of frozen section in detecting malignancy of the thyroid gland were 40.0%, 100.0%, 92.9%, 100.0%, and 92.0%.
  • Most of the adenomas were treated with procedures no less invasive than lobectomy/isthmusectomy.
  • Meanwhile, most of the carcinoma patients underwent total thyroidectomy.
  • No recurrence of Hurthle cell adenomas was noted.
  • Five adenoma patients died of causes unrelated to their Hurthle cell tumors, but no carcinoma patients died during the follow-up period.
  • In conclusion, clinical factors and FNAC are not helpful in the differentiation between adenoma and carcinoma.
  • Unilateral Hurthle cell adenoma can be treated by lobectomy/isthmusectomy, and Hurthle cell carcinoma can be treated by total thyroidectomy with minimal operative morbidity.
  • [MeSH-major] Adenoma, Oxyphilic / surgery. Thyroid Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Surg Oncol. 2002 Mar;9(2):197-203 [11888879.001]
  • [Cites] Surgery. 1998 Dec;124(6):967-74 [9854570.001]
  • [Cites] Otolaryngol Clin North Am. 1990 Jun;23 (3):441-52 [2195433.001]
  • [Cites] Am J Otolaryngol. 1997 Jan-Feb;18(1):47-50 [9006677.001]
  • [Cites] Surgery. 2003 Dec;134(6):881-9; discussion 889 [14668719.001]
  • [Cites] Surg Oncol Clin N Am. 1998 Oct;7(4):893-910 [9735140.001]
  • [Cites] J Clin Endocrinol Metab. 1983 Jun;56(6):1131-8 [6841555.001]
  • [Cites] Cancer. 1986 Apr 15;57(8):1613-7 [3948132.001]
  • [Cites] Br J Radiol. 1998 Jan;71(841):87-9 [9534706.001]
  • [Cites] Surgery. 1986 Dec;100(6):1108-15 [3787466.001]
  • [Cites] World J Surg. 1988 Aug;12(4):488-95 [3048000.001]
  • [Cites] Am J Clin Pathol. 1988 Jun;89(6):764-9 [3369368.001]
  • [Cites] Surg Gynecol Obstet. 1974 Oct;139(4):555-60 [4479589.001]
  • [Cites] J Am Coll Surg. 1999 Sep;189(3):253-8 [10472925.001]
  • [Cites] Cancer. 1989 Mar 1;63(5):908-11 [2914297.001]
  • [Cites] Ann Surg. 1981 Dec;194(6):677-80 [7305479.001]
  • [Cites] Mayo Clin Proc. 1984 Dec;59(12):851-5 [6503367.001]
  • [Cites] Surgery. 1985 Dec;98(6):1162-5 [4071391.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2002 Mar;128(3):263-7 [11886341.001]
  • [Cites] Thyroid. 2003 Jun;13(6):577-84 [12930602.001]
  • [Cites] Cancer. 1991 Nov 1;68(9):1944-53 [1913544.001]
  • [Cites] Arch Surg. 1997 Jun;132(6):674-8; discussion 678-80 [9197862.001]
  • [Cites] Ann Surg. 1998 Apr;227(4):542-6 [9563543.001]
  • [Cites] Cancer. 2003 Mar 1;97(5):1186-94 [12599224.001]
  • [Cites] Am J Surg. 1992 Dec;164(6):603-5 [1463108.001]
  • [Cites] Otolaryngol Clin North Am. 1996 Aug;29(4):593-609 [8844732.001]
  • [Cites] Head Neck. 1999 Sep;21(6):506-11 [10449665.001]
  • [Cites] Am Surg. 1998 Aug;64(8):729-32; discussion 732-3 [9697901.001]
  • [Cites] Arch Surg. 1984 May;119(5):515-9 [6143549.001]
  • [Cites] Laryngoscope. 1983 Jul;93(7):884-8 [6865624.001]
  • [Cites] Head Neck. 1994 Jan-Feb;16(1):64-71 [8125790.001]
  • [Cites] World J Surg. 2001 Sep;25(9):1160-3 [11571953.001]
  • [Cites] Surgery. 1995 Oct;118(4):711-4; discussion 714-5 [7570326.001]
  • [Cites] J Clin Oncol. 2001 May 15;19(10):2616-25 [11352953.001]
  • [Cites] Thyroid. 1994 Fall;4(3):243-8 [7833658.001]
  • [Cites] Surgery. 1988 Dec;104(6):947-53 [3194846.001]
  • [Cites] Am J Surg. 1996 Dec;172(6):692-4 [8988680.001]
  • [Cites] Arch Surg. 1983 May;118(5):529-32 [6838358.001]
  • [Cites] JAMA. 1984 Jun 15;251(23):3114-7 [6726982.001]
  • [Cites] Head Neck. 1993 Jul-Aug;15(4):335-41 [8360056.001]
  • [Cites] Ann Surg. 1995 Jul;222(1):101-6 [7618962.001]
  • [Cites] J Surg Oncol. 1999 Feb;70(2):100-2 [10084652.001]
  • [Cites] Surgery. 1996 Dec;120(6):1000-4; discussion 1004-5 [8957486.001]
  • (PMID = 15650796.001).
  • [ISSN] 0364-2313
  • [Journal-full-title] World journal of surgery
  • [ISO-abbreviation] World J Surg
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


70. Economou MA, Seregard S, Sahlin S: Oncocytoma of the lacrimal gland. Acta Ophthalmol Scand; 2007 Aug;85(5):576-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Oncocytoma of the lacrimal gland.
  • [MeSH-major] Adenoma, Oxyphilic / pathology. Eye Neoplasms / pathology. Lacrimal Apparatus Diseases / pathology
  • [MeSH-minor] Aged. Biomarkers, Tumor / analysis. Humans. Magnetic Resonance Imaging. Male. Neoplasm Proteins / analysis

  • MedlinePlus Health Information. consumer health - Eye Cancer.
  • MedlinePlus Health Information. consumer health - Tears.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17590206.001).
  • [ISSN] 1395-3907
  • [Journal-full-title] Acta ophthalmologica Scandinavica
  • [ISO-abbreviation] Acta Ophthalmol Scand
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins
  •  go-up   go-down


71. Klieb HB, Perez-Ordoñez B: Oncocytic lipoadenoma of the parotid gland with sebaceous differentiation. Study of its keratin profile. Virchows Arch; 2006 Dec;449(6):722-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Oncocytic lipoadenoma of the parotid gland with sebaceous differentiation. Study of its keratin profile.
  • Oncocytic lipoadenomas of salivary gland are extremely rare tumors with only two previously reported cases.
  • In this paper, we describe an additional example of oncocytic lipoadenoma showing sebaceous differentiation, a hitherto unreported occurrence.
  • The tumor was encapsulated and measured 3 x 2.5 x 2 cm.
  • Microscopically, the tumor comprised a mixture of oncocytes with "light" and "dark" cells intimately associated with mature adipose tissue.
  • Calponin and actins were negative, indicating a lack of myoepithelial cells in the tumor.
  • The keratin profile and p63 expression of this oncocytic lipoadenoma suggest the presence of a dual cell population somewhat similar to the dual cell population described in some ultrastructural studies of pure salivary gland oncocytomas and may represent partial basal-cell differentiation.
  • The presence and nature of a dual cell population in oncocytic neoplasms of salivary glands merit further investigation to confirm these observations.
  • [MeSH-major] Adenoma / pathology. Keratins / analysis. Lipoma / pathology. Parotid Neoplasms / pathology

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg Pathol. 1991 Jun;15(6):514-28 [2031528.001]
  • [Cites] Hum Pathol. 1998 Apr;29(4):410-2 [9563794.001]
  • [Cites] Laryngoscope. 2005 Jun;115(6):1097-100 [15933529.001]
  • [Cites] Histopathology. 2000 Mar;36(3):285-6 [10809601.001]
  • [Cites] Cancer. 1996 Dec 1;78(11):2281-7 [8940996.001]
  • [Cites] Arch Otolaryngol. 1971 Jan;93(1):46-54 [5538740.001]
  • [Cites] Arch Otolaryngol. 1985 Feb;111(2):99-105 [2579635.001]
  • [Cites] Virchows Arch. 2003 Aug;443(2):122-32 [12884041.001]
  • (PMID = 17091251.001).
  • [ISSN] 0945-6317
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 68238-35-7 / Keratins
  •  go-up   go-down


72. Nordling S: Cytokeratin 14 is not a specific marker for renal oncocytomas. Am J Surg Pathol; 2006 Oct;30(10):1337
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytokeratin 14 is not a specific marker for renal oncocytomas.
  • [MeSH-major] Adenoma, Oxyphilic / chemistry. Biomarkers, Tumor / analysis. Immunohistochemistry / methods. Keratins / analysis. Kidney Neoplasms / chemistry

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Am J Surg Pathol. 2005 Jun;29(6):747-54 [15897741.001]
  • (PMID = 17001169.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Comment; Letter
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / KRT14 protein, human; 0 / Keratin-14; 68238-35-7 / Keratins
  •  go-up   go-down


73. Yen TH, Chen Y, Lin JL, Ng KF: Renal oncocytoma in Taiwan. Ren Fail; 2006;28(2):141-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Renal oncocytoma in Taiwan.
  • BACKGROUND: Renal oncocytoma has been repeatedly reported in Western countries, but only a few cases have been reported in Eastern countries.
  • This study aims to review the clinical course of renal oncocytoma in an Eastern country such as Taiwan.
  • MATERIALS AND METHODS: Sixteen cases of renal oncocytoma seen between 1987 and 2002 at Chang Gung Memorial Hospital, Taipei, Taiwan, were studied.
  • RESULTS: Preoperatively, all patients were diagnosed to have renal cell carcinoma, following various radiologic studies.
  • Perioperatively, frozen sections of three patients indicated renal oncocytoma in two and renal cell carcinoma in one.
  • Renal oncocytoma has marked similarities to renal cell carcinoma, according to various radiologic, cytologic, and pathological investigations, so an accurate diagnosis is difficult to achieve, either preoperatively or perioperatively.
  • Notably, all patients survived with no evidence of tumor recurrence.
  • CONCLUSIONS: The experience in Taiwan is generally that renal oncocytoma behaves benignly, as reported in other areas.
  • The excellent prognosis associated with this tumor appears to indicate that partial nephrectomy may suffice for removing the tumor, while sparing other unaffected renal parenchyma.
  • [MeSH-major] Adenoma, Oxyphilic. Kidney Neoplasms
  • [MeSH-minor] Aged. Carcinoma, Renal Cell / diagnosis. Diagnosis, Differential. Female. Humans. Male. Middle Aged. Nephrectomy. Taiwan

  • Genetic Alliance. consumer health - Oncocytoma renal.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16538972.001).
  • [ISSN] 0886-022X
  • [Journal-full-title] Renal failure
  • [ISO-abbreviation] Ren Fail
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


74. Roy C, Gengler L, Sauer B, Lang H: [Role of contrast enhanced US in the evaluation of renal tumors]. J Radiol; 2008 Nov;89(11 Pt 1):1735-44
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Role of contrast enhanced US in the evaluation of renal tumors].
  • [Transliterated title] Rôle de l'échographie de contraste dans l'évaluation des tumeurs rénales.
  • PURPOSE: To evaluate the role of contrast enhanced US in the characterization of renal tumors.
  • Eighty-six renal tumors (33 solid, 53 cystic) underwent contrast enhanced US after indeterminate CT/MRI (67 lesions) or US (19 lesions).
  • Lesions included: 19 renal cell carcinomas (4 conventional, 14 papillary, 1 tubulocystic), 5 oncocytomas, 3 metastases, 6 pseudomasses, and 53 cystic lesions including 6 malignant tumors.
  • RESULTS: Solid tumors were correctly identified in 100% of cases.
  • Characterization of solid tumors was possible with specificity of 92.9% for papillary carcinoma, 57.1% for clear cell carcinoma, and 100% for oncocytoma.
  • The specificity for distinguishing solid benign from solid malignant tumor was 100% based on the presence of hypoechogenicity relative to normal renal parenchyma on delayed imaging.
  • CONCLUSION: Contrast enhanced US is easily performed in clinical practice and allows improved characterization of some renal tumors compared to other cross sectional imaging techniques.
  • [MeSH-major] Contrast Media. Kidney Neoplasms / ultrasonography

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19106830.001).
  • [ISSN] 0221-0363
  • [Journal-full-title] Journal de radiologie
  • [ISO-abbreviation] J Radiol
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Multicenter Study
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Contrast Media
  •  go-up   go-down


75. Listewnik MH, Birkenfeld B, Chosia M, Elbl B, Niedziałkowska K, Sawrymowicz M: The occurrence of malignant thyroid lesions in patients after radioiodine treatment due to benign thyroid diseases. Endokrynol Pol; 2010 Sep-Oct;61(5):454-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The occurrence of malignant thyroid lesions in patients after radioiodine treatment due to benign thyroid diseases.
  • INTRODUCTION: Radioiodine treatment (RT) of benign thyroid diseases is a well-known, safe, and effective treatment.
  • In a group of patients after RT, who remained in long-term follow-up, sporadic cases of malignant thyroid lesions occurred.
  • Apart from thyroid function estimation, if needed, fine needle aspiration biopsy (FNAB) of the thyroid or neck focal lesions was performed based on ultrasonographic or clinical examination.
  • Suspicious thyroid lesion results were found in 9 patients (8 F, 1 M), aged 46-73 (average 56 years) followed up for 3-57 months after RT: papillary cancer in two patients, Hürthle cell tumour in one patient, and suspicious cells in two patients (with benign lesions on postoperative histopathology).
  • A follicular tumour in FNAB was suspected in two cases (no data about the first, and the second with lung cancer was not operable).
  • CONCLUSIONS: Malignant thyroid lesions in patients after RT due to benign thyroid diseases are seldom detected.
  • [MeSH-major] Iodine Radioisotopes / adverse effects. Thyroid Diseases / epidemiology. Thyroid Diseases / radiotherapy. Thyroid Neoplasms / epidemiology
  • [MeSH-minor] Adenocarcinoma, Follicular / diagnostic imaging. Adenocarcinoma, Follicular / epidemiology. Adenocarcinoma, Follicular / etiology. Adenocarcinoma, Follicular / pathology. Adenoma, Oxyphilic. Aged. Biopsy, Fine-Needle. Carcinoma. Causality. Female. Follow-Up Studies. Humans. Incidence. Lung Neoplasms / diagnosis. Lung Neoplasms / epidemiology. Lymphatic Metastasis / diagnosis. Male. Middle Aged. Ultrasonography

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • MedlinePlus Health Information. consumer health - Thyroid Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21049457.001).
  • [ISSN] 0423-104X
  • [Journal-full-title] Endokrynologia Polska
  • [ISO-abbreviation] Endokrynol Pol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Iodine Radioisotopes; Thyroid cancer, Hurthle cell; Thyroid cancer, papillary
  •  go-up   go-down


76. Shah VN, Branstetter BF 4th: Oncocytoma of the parotid gland: a potential false-positive finding on 18F-FDG PET. AJR Am J Roentgenol; 2007 Oct;189(4):W212-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Oncocytoma of the parotid gland: a potential false-positive finding on 18F-FDG PET.
  • [MeSH-major] Adenocarcinoma / radionuclide imaging. Adenoma, Oxyphilic / radionuclide imaging. Diagnostic Errors / prevention & control. Fluorodeoxyglucose F18. Neoplasms, Multiple Primary / radionuclide imaging. Parotid Neoplasms / radionuclide imaging. Positron-Emission Tomography / methods
  • [MeSH-minor] Aged. False Positive Reactions. Head and Neck Neoplasms / radionuclide imaging. Humans. Male. Radiopharmaceuticals

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17885033.001).
  • [ISSN] 1546-3141
  • [Journal-full-title] AJR. American journal of roentgenology
  • [ISO-abbreviation] AJR Am J Roentgenol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


77. Larrinaga G, Pérez I, Sanz B, Blanco L, López JI, Cándenas ML, Pinto FM, Gil J, Irazusta J, Varona A: Angiotensin-converting enzymes (ACE and ACE2) are downregulated in renal tumors. Regul Pept; 2010 Dec 10;165(2-3):218-23
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Angiotensin-converting enzymes (ACE and ACE2) are downregulated in renal tumors.
  • Dysregulation of these cell-surface peptidases has been associated with renal injury.
  • In the present study, ACE and ACE2 activity and protein and mRNA expression were analysed in a subset of clear-cell (CCRCC) and chromophobe (ChRCC) renal cell carcinomas, and in renal oncocytoma (RO).
  • The enzyme activities and immunohistochemistry showed that both enzymes are mainly downregulated in these neoplasms. qRT-PCR studies in CCRCC showed no positive correlation between ACE and ACE2 activity/protein expression and mRNA levels, whereas downregulation of ACE2 mRNA levels was observed in tumors from the distal nephron (ChRCC and RO).
  • [MeSH-major] Kidney Neoplasms / enzymology. Peptidyl-Dipeptidase A / metabolism

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier B.V. All rights reserved.
  • (PMID = 20692300.001).
  • [ISSN] 1873-1686
  • [Journal-full-title] Regulatory peptides
  • [ISO-abbreviation] Regul. Pept.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] EC 3.4.15.1 / ACE protein, human; EC 3.4.15.1 / Peptidyl-Dipeptidase A; EC 3.4.17.- / angiotensin converting enzyme 2
  •  go-up   go-down


78. Baccala A, Sercia L, Li J, Heston W, Zhou M: Expression of prostate-specific membrane antigen in tumor-associated neovasculature of renal neoplasms. Urology; 2007 Aug;70(2):385-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of prostate-specific membrane antigen in tumor-associated neovasculature of renal neoplasms.
  • Recently, PSMA has been found in the neovasculature in association with other solid malignant tumors, including clear cell renal carcinoma (RCC).
  • We studied the expression of PSMA in different primary renal tumors.
  • METHODS: A tissue microarray was constructed from 60 normal kidney, 21 clear cell RCC (CCRCC), 20 papillary RCC (PRCC), 16 chromophobe RCC, 19 oncocytoma, 14 transitional cell carcinoma, and 19 angiomyolipoma (AML) specimens.
  • PSMA expression in CD34-positive tumor-associated neovasculature was scored according to the staining intensity and the percentage of vessels.
  • RESULTS: PSMA was expressed in the proximal tubules of the normal kidney and in the tumor-associated vasculature in the renal tumors.
  • Positive PSMA staining was detected in 76.2% of CCRCC, 31.2% of chromophobe RCC, 52.6% of oncocytoma, 21.4% of transitional cell carcinoma, and 0% of PRCC and AML specimens.
  • Its expression was greater in CCRCC than PRCC, chromophobe RCC, transitional cell carcinoma, and AML (P <0.001), but was not significantly different from the expression in oncocytoma (P = 0.79).
  • CONCLUSIONS: PSMA is differentially expressed in the tumor-associated neovasculature in different renal tumors.
  • This finding suggests that antibodies against PSMA may potentially be used as a diagnostic marker and therapeutic target for renal neoplasms.
  • [MeSH-major] Antigens, Surface / biosynthesis. Carcinoma, Renal Cell / blood supply. Carcinoma, Renal Cell / immunology. Glutamate Carboxypeptidase II / biosynthesis. Kidney Neoplasms / blood supply. Kidney Neoplasms / immunology

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17826525.001).
  • [ISSN] 1527-9995
  • [Journal-full-title] Urology
  • [ISO-abbreviation] Urology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Surface; EC 3.4.17.21 / Glutamate Carboxypeptidase II; EC 3.4.17.21 / glutamate carboxypeptidase II, human
  •  go-up   go-down


79. Adley BP, Schafernak KT, Yeldandi AV, Yang XJ, Nayar R: Cytologic and histologic findings in multiple renal hybrid oncocytic tumors in a patient with Birt-Hogg-Dubé syndrome: a case report. Acta Cytol; 2006 Sep-Oct;50(5):584-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytologic and histologic findings in multiple renal hybrid oncocytic tumors in a patient with Birt-Hogg-Dubé syndrome: a case report.
  • BACKGROUND: Birt-Hogg-Dubé (BHD) syndrome is a rare autosomal dominant neoplastic syndrome characterized by multiple skin lesions, lung cysts and renal tumors.
  • A variety of histologic types of renal tumors have been reported, including clear cell renal cell carcinoma (RCC), papillary RCC, chromophobe RCC, oncocytoma and a recently described hybrid oncocytic tumor, which is thought to be highly associated with BHD.
  • CASE: We report a case of a 48-year-old woman with BHD who initially presented to our institution with spontaneous pneumothorax and was found to have multiple lung cysts and renal tumors on computed tomography.
  • We describe the fine needle aspiration findings of one of the renal tumors, which was suggestive of so-called hybrid oncocytic tumor.
  • We also describe the gross and histologic findings of the multiple kidney tumors that the patient subsequently had excised.
  • CONCLUSION: When multiple kidney tumors from a single patient appear oncycytic on fine needle aspiration, especially when focal clear cells are present, the possibility of oncocytomas and hybrid tumors associated with BHD must be entertained.
  • [MeSH-major] Adenoma, Oxyphilic / radiography. Cysts / radiography. Kidney / radiography. Kidney Neoplasms / radiography. Lung Neoplasms / radiography. Neoplasms, Multiple Primary / radiography


80. Németh I, Sükösd F, Béli L, Kiss A, Pajor L, Mikó T, Iványi B: [Adult renal neoplasms in the material of the Pathology Department of the Szeged University]. Orv Hetil; 2005 Apr 3;146(14):653-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Adult renal neoplasms in the material of the Pathology Department of the Szeged University].
  • AIMS: The authors investigated the frequencies of the various histological types of adult renal tumours.
  • RESULTS: 86.7% of all the tumours (n = 407) were malignant.
  • Among the malignant tumours, the frequency of renal cell carcinomas was 91.1% (n = 371).
  • 88.4% of the renal cell carcinomas (n = 328) were of conventional type, 5.6% (n = 21) were papillary and 4% (n = 15) were chromophobe.
  • 84.5% of the conventional carcinomas were clear cell (n = 277), 8.8% were eosinophilic granular (n = 29), 3.9% were multilocular cystic (n = 13) and 2.7% were sarcomatoid carcinomas (n = 9).
  • The median age of the patients with conventional carcinoma was 60 (median, range: 25-84), in the papillary group it was 62 (43-78), and in the chromophobe group was 59 (17-77).
  • The median age of patients affected by transitional cell carcinoma was 64 (range: 45-81).
  • As far as benign tumours are concerned (13.2%, n = 62), oncocytomas (n = 37, 7.8% of all the tumours) affected mainly females, whereas angiomyolipomas (n = 21, 4.4% of all the tumours) occurred in females only.
  • In 13 oncocytoma cases, the tumours were initially diagnosed as malignant.
  • CONCLUSIONS: Adult malignant renal tumours affect mainly patients around the age of 60.
  • The commonest diagnosis was clear cell carcinoma of conventional type.
  • The incidence of clear cell carcinoma was 5% higher than that reported in the literature (84.5% vs 70-80%) whereas that of papillary carcinoma was 5% lower (5% vs 10-15%).
  • In comparison with the literature data, oncocytomas were relatively common (8% instead of 3%), and not rarely, it was difficult to distinguish them from renal cell carcinomas.
  • [MeSH-major] Carcinoma / epidemiology. Carcinoma / pathology. Kidney Neoplasms / epidemiology. Kidney Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma, Clear Cell / epidemiology. Adenocarcinoma, Clear Cell / pathology. Adenoma, Chromophobe / epidemiology. Adenoma, Chromophobe / pathology. Adenoma, Oxyphilic / epidemiology. Adenoma, Oxyphilic / pathology. Adult. Aged. Angiomyolipoma / epidemiology. Angiomyolipoma / pathology. Carcinoma, Papillary / epidemiology. Carcinoma, Papillary / pathology. Carcinoma, Renal Cell / epidemiology. Carcinoma, Renal Cell / pathology. Carcinoma, Transitional Cell / epidemiology. Carcinoma, Transitional Cell / pathology. Female. Humans. Hungary / epidemiology. Male. Middle Aged. Nephrectomy

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15889540.001).
  • [ISSN] 0030-6002
  • [Journal-full-title] Orvosi hetilap
  • [ISO-abbreviation] Orv Hetil
  • [Language] hun
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Hungary
  •  go-up   go-down


81. Memeo L, Jhang J, Assaad AM, McKiernan JM, Murty VV, Hibshoosh H, Tong GX, Mansukhani MM: Immunohistochemical analysis for cytokeratin 7, KIT, and PAX2: value in the differential diagnosis of chromophobe cell carcinoma. Am J Clin Pathol; 2007 Feb;127(2):225-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunohistochemical analysis for cytokeratin 7, KIT, and PAX2: value in the differential diagnosis of chromophobe cell carcinoma.
  • Immunohistochemical staining for cytokeratin 7 (CK7), KIT, and PAX2 expression was performed on 91 renal neoplasms, 37 conventional (clear cell) renal cell carcinomas (CRCCs), 20 papillary RCCs (PRCCs), 11 chromophobe RCCs (ChCs), and 23 oncocytomas, with available karyotypes.
  • All ChCs, 19 PRCCs, 2 CRCCs, and 1 oncocytoma were CK7+; all ChCs, 22 oncocytomas, 2 CRCCs, and no PRCCs expressed KIT; PAX2 was positive in 31 CRCCs, 17 PRCCs, 20 oncocytomas, and 1 ChC.
  • The predominant expression profiles were as follows: CRCC, CK7-/KIT-/PAX2+ (26/37); PRCC, CK7+/KIT-/PAX2+ (17/20); ChC, CK7+/KIT+/PAX2- (10/11); and oncocytoma, CK7-/KIT+/PAX2+ (19/23).
  • These results identify specific staining patterns of the 4 major histologic subtypes of renal neoplasms and raise the question of a relationship between chromosome 10 loss and loss of PAX2 expression in ChC.
  • [MeSH-major] Carcinoma, Renal Cell / chemistry. Keratin-7 / analysis. Kidney Neoplasms / chemistry. PAX2 Transcription Factor / analysis. Proto-Oncogene Proteins c-kit / analysis
  • [MeSH-minor] Adenoma, Oxyphilic / chemistry. Cytogenetic Analysis. Diagnosis, Differential. Humans. Immunohistochemistry

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17210525.001).
  • [ISSN] 0002-9173
  • [Journal-full-title] American journal of clinical pathology
  • [ISO-abbreviation] Am. J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Keratin-7; 0 / PAX2 Transcription Factor; 0 / PAX2 protein, human; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit
  •  go-up   go-down


82. Deandrea M, Ragazzoni F, Motta M, Torchio B, Mormile A, Garino F, Magliona G, Gamarra E, Ramunni MJ, Garberoglio R, Limone PP: Diagnostic value of a cytomorphological subclassification of follicular patterned thyroid lesions: a study of 927 consecutive cases with histological correlation. Thyroid; 2010 Oct;20(10):1077-83
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnostic value of a cytomorphological subclassification of follicular patterned thyroid lesions: a study of 927 consecutive cases with histological correlation.
  • BACKGROUND: Fine-needle aspiration cytology (FNAC) has proved to be an effective diagnostic tool in patients with thyroid nodules.
  • METHODS: We report a cohort of 927 consecutive cases who underwent thyroid surgery in our hospital between 2000 and 2008.
  • Thy3 specimens were further divided into three subcategories (Thy 3a, or "follicular lesions of indeterminate significance": scant colloid, microfollicular pattern, or small clusters of thyrocytes with round nuclei usually without, but sometimes with, minimal cellular pleomorphism; Thy 3b, or "follicular neoplasm": absence of colloid, small clusters, or microfollicles of medium-large sized cell populations arranged in cohesive groups with nuclear overlapping, crowding, and pleomorphisms; and Thy 3c or "Hurthle-cell neoplasm": scant colloid, sheets or clusters of oxyphilic cells).
  • CONCLUSIONS: This study supports the National Cancer Institute consensus showing a different risk of malignancy for "follicular lesions of undetermined significance” compared with "follicular neoplasms" and "Hurthle cells neoplasms," which are more suspect for malignancy.
  • This subclassification could improve clinical management of thyroid nodules, helping to better select patients for surgery or follow up.
  • [MeSH-major] Adenocarcinoma, Follicular / diagnosis. Thyroid Gland / pathology. Thyroid Nodule / diagnosis
  • [MeSH-minor] Adenoma, Oxyphilic / diagnosis. Adenoma, Oxyphilic / pathology. Biopsy, Fine-Needle / methods. Humans. Thyroid Neoplasms / diagnosis. Thyroid Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20883171.001).
  • [ISSN] 1557-9077
  • [Journal-full-title] Thyroid : official journal of the American Thyroid Association
  • [ISO-abbreviation] Thyroid
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


83. Sarma DP, Santos EE: Oncocytoma of the parotid gland. Ear Nose Throat J; 2009 May;88(5):914
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Oncocytoma of the parotid gland.
  • [MeSH-major] Adenoma, Oxyphilic / pathology. Parotid Gland / pathology. Parotid Neoplasms / pathology

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19444786.001).
  • [ISSN] 1942-7522
  • [Journal-full-title] Ear, nose, & throat journal
  • [ISO-abbreviation] Ear Nose Throat J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


84. García CA, Melo-Uribe MA, Díaz JA: [Oncocytoma of the lacrimal caruncle]. Actas Dermosifiliogr; 2008 Sep;99(7):581-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Oncocytoma of the lacrimal caruncle].
  • [Transliterated title] Oncocitoma de carúncula ocular.
  • [MeSH-major] Adenoma, Oxyphilic / diagnosis. Eye Neoplasms / diagnosis. Lacrimal Apparatus

  • MedlinePlus Health Information. consumer health - Eye Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18682180.001).
  • [ISSN] 0001-7310
  • [Journal-full-title] Actas dermo-sifiliográficas
  • [ISO-abbreviation] Actas Dermosifiliogr
  • [Language] spa
  • [Publication-type] Case Reports; Letter
  • [Publication-country] Spain
  •  go-up   go-down


85. Hasumi H, Baba M, Hong SB, Hasumi Y, Huang Y, Yao M, Valera VA, Linehan WM, Schmidt LS: Identification and characterization of a novel folliculin-interacting protein FNIP2. Gene; 2008 May 31;415(1-2):60-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Birt-Hogg-Dube' syndrome characterized by increased risk for renal neoplasia is caused by germline mutations in the BHD/FLCN gene encoding a novel tumor suppressor protein, folliculin(FLCN), which interacts with FNIP1 and 5'-AMP-activated protein kinase(AMPK).
  • These data taken together with our previous results that demonstrated FNIP1 binding to the C-terminus of FLCN suggest that FLCN tumor suppressor function may be facilitated by interactions with both FNIP1 and FNIP2 through its C-terminus.
  • Interestingly FNIP1 and FNIP2 were oppositely expressed in human clear cell renal cell carcinoma (RCC), and coordinately expressed in chromophobe RCC and oncocytoma, suggesting their differential function in different histologic variants of RCC.

  • COS Scholar Universe. author profiles.
  • Gene Ontology. gene/protein/disease-specific - Gene Ontology annotations from this paper .
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • SciCrunch. HGNC: Data: Gene Annotation .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2002 Apr;11(4):393-400 [11927500.001]
  • [Cites] J Invest Dermatol. 2008 Jan;128(1):45-9 [17611575.001]
  • [Cites] Am J Surg Pathol. 2002 Dec;26(12):1542-52 [12459621.001]
  • [Cites] J Med Genet. 2002 Dec;39(12):906-12 [12471204.001]
  • [Cites] Arch Dermatol. 1977 Dec;113(12):1674-7 [596896.001]
  • [Cites] Mol Biol Evol. 1987 Jul;4(4):406-25 [3447015.001]
  • [Cites] J Mol Biol. 1990 Oct 5;215(3):403-10 [2231712.001]
  • [Cites] Comput Appl Biosci. 1996 Aug;12(4):357-8 [8902363.001]
  • [Cites] Arch Dermatol. 1999 Oct;135(10):1195-202 [10522666.001]
  • [Cites] Nat Genet. 2005 Jan;37(1):19-24 [15624019.001]
  • [Cites] J Pathol. 2005 Feb;205(3):377-87 [15682440.001]
  • [Cites] J Urol. 2005 May;173(5):1482-6 [15821464.001]
  • [Cites] Am J Hum Genet. 2005 Jun;76(6):1023-33 [15852235.001]
  • [Cites] J Natl Cancer Inst. 2005 Jun 15;97(12):931-5 [15956655.001]
  • [Cites] Oncogene. 2006 May 11;25(20):2885-9 [16369488.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Oct 17;103(42):15552-7 [17028174.001]
  • [Cites] Clin Cancer Res. 2007 Jan 1;13(1):152-60 [17200350.001]
  • [Cites] J Pathol. 2007 Apr;211(5):524-31 [17323425.001]
  • [Cites] Cancer Cell. 2002 Aug;2(2):157-64 [12204536.001]
  • (PMID = 18403135.001).
  • [ISSN] 0378-1119
  • [Journal-full-title] Gene
  • [ISO-abbreviation] Gene
  • [Language] ENG
  • [Grant] United States / Intramural NIH HHS / / Z01 SC006659-25; United States / Intramural NIH HHS / / Z99 CA999999; United States / NCI NIH HHS / CO / N01 CO012400; United States / NCI NIH HHS / CA / N01CO12400; United States / NCI NIH HHS / CO / N01-CO-12400
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Carrier Proteins; 0 / FLCN protein, human; 0 / FNIP1 protein, human; 0 / FNIP2 protein, human; 0 / Multiprotein Complexes; 0 / Proto-Oncogene Proteins; 0 / RNA, Messenger; 0 / Tumor Suppressor Proteins; EC 2.7.4.3 / Adenylate Kinase
  • [Other-IDs] NLM/ NIHMS66289; NLM/ PMC2727720
  •  go-up   go-down


86. Tan TJ, Tan TY: CT features of parotid gland oncocytomas: a study of 10 cases and literature review. AJNR Am J Neuroradiol; 2010 Sep;31(8):1413-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CT features of parotid gland oncocytomas: a study of 10 cases and literature review.
  • Oncocytomas of the salivary glands are rare benign epithelial tumors which occur most commonly in the parotid gland.
  • The aim of our study was to characterize the clinical-radiologic-pathologic spectrum of parotid oncocytomas in a series of 10 cases seen in our institution between January 2003 and November 2008.
  • The CT features of parotid oncocytomas in the largest imaging series of this rare but important benign lesion include a well-defined enhancing tumor with a "deformable" appearance when large, and a non-enhancing curvilinear cleft or cystic component.
  • These CT findings are potentially helpful in distinguishing these benign lesions from other parotid tumors in clinical scenarios that preclude surgical resection or when biopsy results are non-diagnostic.
  • [MeSH-major] Adenoma, Oxyphilic / radiography. Parotid Neoplasms / radiography. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - CT Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20395389.001).
  • [ISSN] 1936-959X
  • [Journal-full-title] AJNR. American journal of neuroradiology
  • [ISO-abbreviation] AJNR Am J Neuroradiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  •  go-up   go-down


87. Sakthikumar KR, Mohanty S, Dineshkumar K: Solitary oncocytoma of the submandibular salivary gland in an adolescent female: A case report. Indian J Otolaryngol Head Neck Surg; 2007 Jun;59(2):171-3
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Solitary oncocytoma of the submandibular salivary gland in an adolescent female: A case report.
  • We report a rare presentation of Oncocytoma of the submandibular salivary gland in an young adolescent female who presented with progressive swelling in the left submandibular region since childhood with pain for the past one month.
  • Fine needle aspiration revealed Oncocytoma for which a conventional submandibular excision was done.
  • There are few articles about the rare presentation of submandibular Oncocytoma and literature favors older population for this rarity.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Otolaryngol Clin North Am. 1999 Oct;32(5):861-73 [10477792.001]
  • [Cites] Otolaryngol Clin North Am. 1999 Oct;32(5):875-86 [10477793.001]
  • (PMID = 23120423.001).
  • [ISSN] 2231-3796
  • [Journal-full-title] Indian journal of otolaryngology and head and neck surgery : official publication of the Association of Otolaryngologists of India
  • [ISO-abbreviation] Indian J Otolaryngol Head Neck Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC3451789
  • [Keywords] NOTNLM ; Oncocytoma / Oxyphil adenoma / Salivary gland tumors / Submandibular gland neoplasm
  •  go-up   go-down


88. Elliott DD, Pitman MB, Bloom L, Faquin WC: Fine-needle aspiration biopsy of Hurthle cell lesions of the thyroid gland: A cytomorphologic study of 139 cases with statistical analysis. Cancer; 2006 Apr 25;108(2):102-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fine-needle aspiration biopsy of Hurthle cell lesions of the thyroid gland: A cytomorphologic study of 139 cases with statistical analysis.
  • BACKGROUND: Lesions of the thyroid gland composed of Hurthle cells encompass pathologic entities ranging from hyperplastic nodules with Hurthle cell metaplasia to Hurthle cell carcinomas.
  • Many cytologic features of Hurthle cell lesions that distinguish neoplastic Hurthle cell lesions requiring surgery from those that are benign and nonneoplastic have been described, but with variable usefulness.
  • A morphologic study was made of 139 Hurthle cell lesions of the thyroid gland and statistical analysis applied to identify a set of cytomorphologic features that distinguish benign Hurthle cell lesions (BHCL) from Hurthle cell neoplasms (HCN).
  • METHODS: Fine-needle aspiration biopsies (FNABs) of thyroid nodules with a predominant Hurthle cell component and corresponding histologic followup were included in the study.
  • All cases were reviewed to assess the following 14 cytologic features: overall cellularity, cytoarchitecture, percentage of Hurthle cells, percentage of single cells, percentage of follicular cells observed as naked Hurthle cell nuclei, background colloid, chronic inflammation, cystic change, transgressing blood vessels (TBV), intracytoplasmic lumina, presence of multinucleated Hurthle cells, nuclear to cytoplasmic ratio, nuclear pleomorphism/atypia, and nucleolar prominence.
  • Six of the 14 cytologic features evaluated were shown by univariate analysis to be statistically significant in predicting HCN: nonmacrofollicular architecture (P < 0.001), absence of background colloid (P < 0.001), absence of chronic inflammation (P < 0.001), presence of TBV (P < 0.001), > 90% Hurthle cells (P < 0.001), and >10% single Hurthle cells (P = 0.014).
  • CONCLUSIONS: In the current study of 139 FNAB specimens of thyroid Hurthle cell nodules, 14 cytologic features were examined and 6 were found to be statistically significant in identifying HCN.
  • [MeSH-major] Adenoma / pathology. Adenoma, Oxyphilic / pathology. Oxyphil Cells / pathology. Thyroid Gland / pathology. Thyroid Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biopsy, Fine-Needle. Cell Nucleus / pathology. Colloids / analysis. Cytoplasm / pathology. Data Interpretation, Statistical. Diagnosis, Differential. Female. Humans. Logistic Models. Male. Metaplasia / pathology. Middle Aged

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2006 American Cancer Society.
  • (PMID = 16453320.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Colloids
  •  go-up   go-down


89. Dancer JY, Truong LD, Zhai Q, Shen SS: Expression of Galectin-3 in renal neoplasms: a diagnostic, possible prognostic marker. Arch Pathol Lab Med; 2010 Jan;134(1):90-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of Galectin-3 in renal neoplasms: a diagnostic, possible prognostic marker.
  • CONTEXT: Galectin-3, a member of the lectin family, was shown to be expressed in normal distal tubular cells and in renal cell carcinomas (RCC).
  • OBJECTIVES: To describe the expression of Galectin-3 among different histologic subtypes of renal neoplasms and to determine their diagnostic and prognostic significances.
  • DESIGN: The expression of Galectin-3 was evaluated in 217 renal neoplasms by tissue microarray and immunohistochemistry with semiquantitative analysis.
  • RESULTS: Strong expression of Galectin-3 was observed in 92 of 217 of renal neoplasms (42.4%).
  • Although 22 of 23 oncocytomas (95.7%) and 19 of 21 chromophobe RCCs (90.5%) express Galectin-3, only 4 of 32 papillary RCCs (12.5%) and 47 of 137 clear cell RCCs (34.3%) express Galectin-3, suggesting that it may be used as a potential diagnostic marker.
  • Galectin-3 expression was seen in 55% of high-grade (Fuhrman nuclear grades 3 and 4) versus 21% low-grade (grades 1 and 2) clear cell RCCs (P < .001).
  • CONCLUSIONS: This study confirms that Galactin-3 is strongly overexpressed in renal cell neoplasms of distal tubular differentiation, that is, oncocytoma and chromophobe RCCs, suggesting it might be used as a possible differential diagnostic tool for renal cell neoplasm with oncocytic or granular cells.
  • Furthermore, we observed a strong association of overexpression of Galectin-3 and high nuclear grade in clear cell RCC.
  • These results also suggest a possible pivotal role for Galectin-3 in the differentiation and prognosis of clear cell RCC.
  • [MeSH-major] Carcinoma, Renal Cell / diagnosis. Carcinoma, Renal Cell / metabolism. Galectin 3 / metabolism. Kidney Neoplasms / diagnosis. Kidney Neoplasms / metabolism
  • [MeSH-minor] Biomarkers, Tumor / metabolism. Humans. Kidney / metabolism. Kidney / pathology. Prognosis. Retrospective Studies. Survival Rate

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20073610.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Galectin 3
  •  go-up   go-down


90. Huo L, Sugimura J, Tretiakova MS, Patton KT, Gupta R, Popov B, Laskin WB, Yeldandi A, Teh BT, Yang XJ: C-kit expression in renal oncocytomas and chromophobe renal cell carcinomas. Hum Pathol; 2005 Mar;36(3):262-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] C-kit expression in renal oncocytomas and chromophobe renal cell carcinomas.
  • C- kit encodes the membrane-bound tyrosine kinase KIT, whose expression has been identified in several types of human neoplasms.
  • Recently, KIT has been reported to be a marker for chromophobe renal cell carcinoma (RCC) and renal angiomyolipoma.
  • However, expression of this molecule has not been adequately studied in other renal tumors, particularly oncocytoma, which may morphologically resemble chromophobe RCC.
  • In this study, we analyzed c- kit messenger RNA (mRNA) levels in 17 chromophobe RCCs and 20 renal oncocytomas obtained from complementary DNA (cDNA) microarrays.
  • Furthermore, comprehensive immunohistochemical analysis of KIT protein using a monoclonal antibody was performed in 226 renal tumors including chromophobe RCC (n=40), oncocytoma (n=41), clear-cell RCC (n=40), renal angiomyolipoma (n=29), and papillary RCC (n=21) on tissue microarrays (TMAs) and was compared with immunostaining results from 25 chromophobe RCCs and 30 oncocytomas using standard sections.
  • All chromophobe RCCs and oncocytomas showed significant overexpression of c- kit mRNA.
  • The average increase of mRNA compared with normal kidney tissue was 7.4-fold for chromophobe RCCs and 7.4-fold for oncocytomas.
  • Immunohistochemical expression of KIT was found in most chromophobe RCCs (95% in TMAs and 96% in conventional sections) and oncocytomas (88% in TMAs and 100% in conventional sections) but was infrequently observed in renal angiomyolipomas (17%), papillary RCCs (5%), and clear-cell RCCs (3%).
  • Furthermore, the average KIT immunoreactivity in TMAs was stronger in chromophobe RCC (1.93) and oncocytoma (2.07) than in other subtypes of renal tumors tested, including angiomyolipomas (0.17), papillary RCCs (0.05), and clear-cell RCCs (0.03).
  • In conclusion, we found a significant elevation of c- kit mRNA by cDNA expression microarrays and overexpression of KIT protein by immunohistochemistry not only in chromophobe RCCs but also in oncocytomas.
  • In contrast, immunohistochemical expression of KIT was not detected in most other types of renal cell tumors evaluated.
  • The differential expression of c- kit in these renal tumors may have diagnostic and therapeutic implications.
  • [MeSH-major] Adenoma, Oxyphilic / genetics. Carcinoma, Renal Cell / genetics. Gene Expression. Kidney Neoplasms / genetics. Proto-Oncogene Proteins c-kit / genetics. RNA, Messenger / analysis

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15791570.001).
  • [ISSN] 0046-8177
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / RNA, Messenger; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit
  •  go-up   go-down


91. Okada A, Sasaki S, Fujiyoshi Y, Niimi K, Kurokawa S, Umemoto Y, Kohri K: A case of oncocytic papillary renal cell carcinoma. Int J Urol; 2009 Sep;16(9):765-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of oncocytic papillary renal cell carcinoma.
  • Papillary renal cell carcinomas (RCC) are the second most frequently identified pathological subtypes of RCC.
  • Occasionally, papillary RCC demonstrate pathological characteristics of renal oncocytomas (RO), benign renal tumors.
  • We report the case of an 81-year-old woman with an oncocytic papillary RCC, which was difficult to differentiate from a hybrid of RO and papillary RCC, who underwent left radical nephrectomy.
  • Morphological examination showed oncocytic tumor region and partially scattered regions with papillary structure.
  • Comprehensively, this case could be diagnosed as oncocytic papillary RCC.
  • [MeSH-major] Adenoma, Oxyphilic / pathology. Carcinoma, Papillary / pathology. Carcinoma, Renal Cell / pathology. Kidney Neoplasms / pathology
  • [MeSH-minor] Aged, 80 and over. Biomarkers, Tumor / analysis. Chromosomes, Human, Pair 7. Diagnosis, Differential. Female. Humans. Immunohistochemistry. In Situ Hybridization, Fluorescence. Karyotyping. Racemases and Epimerases. Treatment Outcome


92. Verine J, Lehmann-Che J, Soliman H, Feugeas JP, Vidal JS, Mongiat-Artus P, Belhadj S, Philippe J, Lesage M, Wittmer E, Chanel S, Couvelard A, Ferlicot S, Rioux-Leclercq N, Vignaud JM, Janin A, Germain S: Determination of angptl4 mRNA as a diagnostic marker of primary and metastatic clear cell renal-cell carcinoma. PLoS One; 2010;5(4):e10421
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Determination of angptl4 mRNA as a diagnostic marker of primary and metastatic clear cell renal-cell carcinoma.
  • BACKGROUND: We have previously shown that angiopoietin-like 4 (angptl4) mRNA, a hypoxia-inducible gene, is highly expressed in clear cell renal-cell carcinoma (ccRCC), the most common subtype of RCC for which no specific marker is available.
  • We here investigated whether angptl4 mRNA 1) could be a useful diagnostic and/or prognostic marker of ccRCC in a large and comprehensive retrospective series, 2) induction is dependent on the VHL status of tumors.
  • METHODOLOGY/PRINCIPAL FINDINGS: Using in situ hybridization, we report that angptl4 mRNA is expressed in 100% of both sporadic (n = 102) and inherited (n = 6) primary ccRCCs, without any statistical association with nuclear grade (p = 0.39), tumor size (p = 0.09), stage grouping (p = 0.17), progression-free survival (p = 0.94), and overall survival (p = 0.80).
  • In contrast, angptl4 mRNA was neither expressed in 94% non-ccRCC renal tumors (papillary RCCs (n = 46), chromophobe RCCs (n = 28), and oncocytomas (n = 9)), nor in non-renal clear cell carcinomas (n = 39).
  • Angptl4 expression was also examined in tumors associated (n = 23) or not associated (n = 66) with VHL disease.
  • 40 (98%) hemangioblastomas expressed angptl4 whereas all pheochromocytomas (n = 23) and pancreatic tumors (n = 25) were angptl4-negative, whatever their VHL status.
  • Moreover, angptl4 mRNA allows to discriminate the renal origin of metastases of clear-cell carcinomas arising from various organs.
  • [MeSH-major] Angiopoietins / genetics. Carcinoma, Renal Cell / diagnosis. Molecular Diagnostic Techniques. RNA, Messenger / analysis
  • [MeSH-minor] Biomarkers. Diagnosis, Differential. Humans. In Situ Hybridization. Neoplasm Metastasis. RNA, Neoplasm / analysis. Retrospective Studies

  • Genetic Alliance. consumer health - Clear Cell Renal Cell Carcinoma.
  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proc Natl Acad Sci U S A. 2001 Aug 14;98(17):9754-9 [11493696.001]
  • [Cites] Hum Pathol. 2009 Dec;40(12):1671-8 [19695674.001]
  • [Cites] Am J Pathol. 2003 May;162(5):1521-8 [12707035.001]
  • [Cites] Histopathology. 2004 Nov;45(5):452-9 [15500648.001]
  • [Cites] Am J Surg Pathol. 1982 Oct;6(7):655-63 [7180965.001]
  • [Cites] Nat Genet. 1994 May;7(1):85-90 [7915601.001]
  • [Cites] N Engl J Med. 2005 Dec 8;353(23):2477-90 [16339096.001]
  • [Cites] PLoS Med. 2006 Jan;3(1):e13 [16318415.001]
  • [Cites] Semin Diagn Pathol. 2005 Feb;22(1):51-68 [16512599.001]
  • [Cites] Actas Urol Esp. 2006 Mar;30(3):281-6 [16749584.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Dec 5;103(49):18721-6 [17130448.001]
  • [Cites] Ann Oncol. 2007 Mar;18(3):581-92 [17287242.001]
  • [Cites] Lancet Oncol. 2007 Jun;8(6):554-8 [17540307.001]
  • [Cites] Annu Rev Pathol. 2007;2:145-73 [18039096.001]
  • [Cites] Histopathology. 2008 Jan;52(2):158-66 [18036175.001]
  • [Cites] Cell. 2008 Apr 4;133(1):66-77 [18394990.001]
  • [Cites] Biochem Soc Trans. 2008 Jun;36(Pt 3):472-8 [18481984.001]
  • [Cites] Am J Surg Pathol. 2008 Jul;32(7):1051-9 [18496143.001]
  • [Cites] Clin Cancer Res. 2008 Aug 1;14(15):4726-34 [18676741.001]
  • [Cites] Am J Surg Pathol. 2008 Oct;32(10):1462-7 [18685487.001]
  • [Cites] Nat Rev Cancer. 2008 Nov;8(11):865-73 [18923434.001]
  • [Cites] J Urol. 2009 Feb;181(2):849-60 [19095258.001]
  • [Cites] Am J Surg Pathol. 2009 Feb;33(2):241-7 [18941400.001]
  • [Cites] FASEB J. 2009 Mar;23(3):940-9 [19019854.001]
  • [Cites] Lancet. 2009 Mar 28;373(9669):1119-32 [19269025.001]
  • [Cites] BMC Med. 2009;7:9 [19291283.001]
  • [Cites] Am J Surg Pathol. 2009 May;33(5):739-48 [19238077.001]
  • [Cites] J Biol Chem. 2009 May 1;284(18):11942-52 [19246456.001]
  • [Cites] Int J Urol. 2009 May;16(5):432-43 [19453547.001]
  • [Cites] Int J Cancer. 2009 Jul 15;125(2):474-82 [19391132.001]
  • [Cites] Lancet Oncol. 2009 Aug;10(8):764-71 [19576851.001]
  • [Cites] J Pathol. 2002 Feb;196(2):186-93 [11793370.001]
  • (PMID = 20454689.001).
  • [ISSN] 1932-6203
  • [Journal-full-title] PloS one
  • [ISO-abbreviation] PLoS ONE
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / ANGPTL4 protein, human; 0 / Angiopoietins; 0 / Biomarkers; 0 / RNA, Messenger; 0 / RNA, Neoplasm
  • [Other-IDs] NLM/ PMC2861680
  •  go-up   go-down


93. Alvarez Ardura M, Hernández Cañas V, de la Morena Gallego JM, Rengifo Abbad D, González-Chamorro Ladrón de Guevara F, Llorente Abarca C: [Giant renal oncocytoma]. Actas Urol Esp; 2005 Sep;29(8):791-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Giant renal oncocytoma].
  • Renal oncocytoma is a benign neoplasms arising from cells of the distal renal tubule.
  • They acount for 3-7% of all renal tumors. most are incidental findings.
  • Differential diagnosis with renal cells carcinoma is often difficult.
  • Here we report a case of big renal oncocytoma as an incidental finding while performing an abdominal ultrasound in a patient with low abdominal pain.
  • [MeSH-major] Adenoma, Oxyphilic / diagnostic imaging. Kidney Neoplasms / diagnostic imaging

  • Genetic Alliance. consumer health - Oncocytoma renal.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16304913.001).
  • [ISSN] 0210-4806
  • [Journal-full-title] Actas urologicas espanolas
  • [ISO-abbreviation] Actas Urol Esp
  • [Language] spa
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


94. Badmus TA, Adesunkanmi AR, Agbakwuru CA, Salako AA, Uhunmwagho O, Eziyi AK: Giant renal oncocytoma masquerading as infiltrating renal cell carcinoma: case report and literature review. Cent Afr J Med; 2006 Jan-Feb;52(1-2):16-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Giant renal oncocytoma masquerading as infiltrating renal cell carcinoma: case report and literature review.
  • Renal oncocytomas (RO) are tumours containing a population of cells with highly differentiated eosinophilic granular cytoplasm, extremely rich in mitochondria.
  • It is estimated they account for about 3 to 7% of all solid renocortical tumours that were previously regarded as renal cell carcinoma.
  • Based on their clinical behaviour and distinct pathologic features they are now regarded as benign renal tumours, often less than 5cm in diameter.
  • We present a case of giant renal oncocytoma in a patient with synchronous bladder tumour, with pre-operative clinical, urographic and ultrasound features of locally advanced renal cell carcinoma (RCC).
  • Findings at surgery included huge right renal tumour with infiltration to the duodenum; hepatic colic flexure; gall bladder; liver capsule and the greater omentum with small indurations at the base of the bladder.
  • There was no tumour extension to the renal vein, no peritoneal seedling, no nodal metastasis and no ascites.
  • In view of the difficulties at establishing pre-operative diagnosis in this disease and because nephron-sparing surgery is curative, especially for the well-circumscribed tumours, RO should be considered in the management of patients with features of infiltrating RCC.
  • [MeSH-major] Adenoma, Oxyphilic / diagnosis. Kidney Neoplasms / diagnosis
  • [MeSH-minor] Carcinoma, Renal Cell / diagnosis. Diagnosis, Differential. Female. Humans. Middle Aged


95. Han XN, Peng LR, Liu GH, Wang J: [Multiphasic spiral CT scanning features in 100 patients with small renal cell carcinoma]. Zhonghua Zhong Liu Za Zhi; 2007 May;29(5):382-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Multiphasic spiral CT scanning features in 100 patients with small renal cell carcinoma].
  • OBJECTIVE: To investigate the role of multiphasic spiral computed tomography (SCT) in the differential diagnosis of small renal cell carcinoma.
  • METHODS: The data of 100 patients with small renal cell carcinoma (< or = 3.0 cm) proved by pathology were retrospectively reviewed in order to analyze the features of SCT during plain, corticomedullary and excretory phases.
  • RESULTS: There were 38 tumor masses in the left kidney and 62 in the right one.
  • According to the 2004 WHO histological classification criteria for the tumors of the kidney.
  • Seventy-six patients had clear cell renal cell carcinoma, 4 multilocular clear cell renal cell carcinomas, 9 papillary renal cell carcinoma, 4 chromophobe renal cell carcinomas and 7 unclassified renal cell carcinomas.
  • Clear cell renal cell carcinoma exhibited rich blood supply and inhomogeneous density due to hemorrhage, necrosis or cystic degeneration.
  • Multilocular clear cell renal cell carcinoma presented as a multilocular cystic mass with thin wall and septa, instead of an expansile nodule.
  • Papillary renal cell carcinoma showed inhomogeneous density and hypovascular distribution.
  • Chromophobe renal cell carcinoma was relatively homogeneous and hypovascular.
  • Compared with clear cell renal cell carcinoma, unclassified renal cell carcinoma showed inhomogeneous density and hypervascular distribution with more invading growth features than the other subtypes.
  • CONCLUSION: Commonly encountered subtypes of the small renal cell carcinoma exhibit their own specific features in multiphasic spiral CT, which may be helpful in differential diagnosis, but each subtype should be differentiated from the renal oncocytoma, cystic nephroma, complex renal cyst, renal angiomyolipoma with minimal fat and renal infiltrating urothelial carcinoma.
  • [MeSH-major] Carcinoma, Renal Cell / radiography. Kidney Neoplasms / radiography. Tomography, Spiral Computed / methods
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Carcinoma, Papillary / radiography. Child. Diagnosis, Differential. Female. Humans. Male. Middle Aged. Prognosis. Retrospective Studies

  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17892138.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


96. Gerashchenko GV, Bogatyrova OO, Rudenko EE, Kondratov AG, Gordiyuk VV, Zgonnyk YM, Vozianov OF, Pavlova TV, Zabarovsky ER, Rynditch AV, Kashuba VI: Genetic and epigenetic changes of NKIRAS1 gene in human renal cell carcinomas. Exp Oncol; 2010 Jul;32(2):71-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genetic and epigenetic changes of NKIRAS1 gene in human renal cell carcinomas.
  • Renal cell carcinoma (RCC) is the most common malignant tumor of kidney associated with the worst clinical outcome.
  • Large-scale screening of 3p human chromosome genes/loci in RCC and histologically normal tissues surrounding the tumors using NotI-microarray approach demonstrated that NKIRAS1 gene contained the largest percent of genetic/epigenetic changes in RCC tumor cells.
  • METHODS: DNA and RNA were isolated from freshly-frozen renal tumors' samples (n = 12) and from normal tissues surrounding the tumors.
  • High grade tumors (3 and 4) showed lower expression of NKIRAS1 at the mRNA level than tumors of low grade (1 and 2).
  • Analysis of NKIRAS1 gene copy number was performed in 19 tumor samples.
  • Changes in NKIRAS1 gene copy number were detected in all 3 benign oncocytomas, 1 papillary cancer and 1 sarcoma, where hemizygous deletion was observed.
  • It was shown the decreased expression level of NKIRAS1 in this type of tumor.
  • [MeSH-major] Carcinoma, Renal Cell / genetics. Epigenesis, Genetic. Kidney Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20693965.001).
  • [ISSN] 1812-9269
  • [Journal-full-title] Experimental oncology
  • [ISO-abbreviation] Exp. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ukraine
  •  go-up   go-down


97. Gudbjartsson T, Hardarson S, Petursdottir V, Thoroddsen A, Magnusson J, Einarsson GV: Renal oncocytoma: a clinicopathological analysis of 45 consecutive cases. BJU Int; 2005 Dec;96(9):1275-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Renal oncocytoma: a clinicopathological analysis of 45 consecutive cases.
  • OBJECTIVE: To evaluate the clinical behaviour and pathology of renal oncocytoma in a well-defined population over a 30-year period.
  • PATIENTS AND METHODS: In a retrospective population-based study we assessed relevant clinical and pathological factors in 45 patients (31 men and 14 women) diagnosed with renal oncocytoma in Iceland between 1971 and 2000.
  • RESULTS: The age-standardized incidence was 0.3 per 100,000 per year for both men and women, the incidence of oncocytomas being 5.5% of renal cell carcinomas (RCCs) diagnosed during the same period in Iceland.
  • All the patients had a radical nephrectomy, except for one with bilateral oncocytoma who had a partial nephrectomy.
  • The mean (range) tumour size was 5.7 (0.9-12) cm.
  • Eighteen patients (58%) were diagnosed at Tumour-Node-Metastasis stage I, 10 at stage II (32%) and three at stage III (10%), all of those at stage III having renal capsular penetration or tumour invasion into perirenal fat tissue (T3aN0M0).
  • After a median follow-up of 8.3 years there were no recurrences or deaths from oncocytoma (100% disease-specific survival).
  • CONCLUSIONS: In most cases renal oncocytoma behaves like a benign tumour; the long-term prognosis is excellent.
  • Thus, in the present patients, radical nephrectomy could be regarded as an over-treatment and nephron-sparing surgery as more appropriate, especially in patients with small tumours.
  • [MeSH-major] Adenoma, Oxyphilic / pathology. Kidney Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Staging / methods. Retrospective Studies. Statistics, Nonparametric. Survival Analysis

  • Genetic Alliance. consumer health - Oncocytoma renal.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16287444.001).
  • [ISSN] 1464-4096
  • [Journal-full-title] BJU international
  • [ISO-abbreviation] BJU Int.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


98. de la Cruz Burgos R, Martel Villagrán J: [Renal oncocytoma. Fundamental radiologic manifestations and enhancement patterns in tri-phase helical CT]. Radiologia; 2007 Mar-Apr;49(2):109-14
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Renal oncocytoma. Fundamental radiologic manifestations and enhancement patterns in tri-phase helical CT].
  • [Transliterated title] Oncocitoma renal. Manifestaciones radiológicas fundamentales y patrones de captación en tomografía computarizada helicoidal trifásica.
  • OBJECTIVE: Oncocytoma is a relatively uncommon benign kidney tumor.
  • To date, it has been impossible to differentiate this tumor from renal cell carcinoma radiologically, although few articles report on the use of tri-phase CT in this tumor.
  • We describe the triphasic CT findings in these tumors and evaluate whether some characteristics, although not sufficient to ensure the diagnosis, can suggest the possibility of oncocytoma.
  • MATERIAL AND METHODS: We describe the tri-phase CT findings in 10 cases of oncocytoma in eight patients (one case was bilateral and multifocal).
  • RESULTS: All the tumors were found incidentally at ultrasound examination prior to CT study.
  • Tumors all had well-defined borders, and their size ranged from 3 to 15 cm, with a mean diameter of 5.2 cm.
  • One patient had bilateral tumors (2 right and 1 left).
  • All but one of the tumors had a star-shaped scar inside, with a marked lobular pattern in one case.
  • All tumors showed avid uptake, with mean enhancement of 120 HU in the arterial phase and 116 HU in the venous phase.
  • CONCLUSIONS: Although oncocytoma cannot be differentiated from renal cell carcinoma with certainty, the possibility of oncocytoma should be suggested in the case of small tumors with a central scar, without necrosis or infiltration, and an enhancement pattern as described here.
  • Regardless of the size of the tumor, lobular morphology should also suggest this possibility.
  • [MeSH-major] Adenoma, Oxyphilic / radiography. Kidney Neoplasms / radiography. Tomography, Spiral Computed

  • Genetic Alliance. consumer health - Oncocytoma renal.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17403340.001).
  • [ISSN] 0033-8338
  • [Journal-full-title] Radiología
  • [ISO-abbreviation] Radiologia
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


99. Rogers CG, Ditlev JA, Tan MH, Sugimura J, Qian CN, Cooper J, Lane B, Jewett MA, Kahnoski RJ, Kort EJ, Teh BT: Microarray gene expression profiling using core biopsies of renal neoplasia. Am J Transl Res; 2009;1(1):55-61
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Microarray gene expression profiling using core biopsies of renal neoplasia.
  • We investigate the feasibility of using microarray gene expression profiling technology to analyze core biopsies of renal tumors for classification of tumor histology.
  • Core biopsies were obtained ex-vivo from 7 renal tumors-comprised of four histological subtypes-following radical nephrectomy using 18-gauge biopsy needles.
  • Genes with significant variation across all non-biopsy tumor samples were identified, and the relationship between tumor and biopsy samples in terms of expression levels of these genes was then quantified in terms of Euclidean distance, and visualized by complete linkage clustering.
  • Final pathologic assessment of kidney tumors demonstrated clear cell renal cell carcinoma (4), oncocytoma (1), angiomyolipoma (1) and adrenalcortical carcinoma (1).
  • Five of the seven biopsy samples were most similar in terms of gene expression to the resected tumors from which they were derived in terms of Euclidean distance.
  • We demonstrate the feasibility of gene expression profiling of core biopsies of renal tumors to classify tumor histology.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Urol. 2008 Oct;180(4):1257-61; discussion 1261 [18707712.001]
  • [Cites] Urology. 2000 Mar;55(3):348-52 [10699608.001]
  • [Cites] J Urol. 2007 Oct;178(4 Pt 1):1184-8; discussion 1188 [17698122.001]
  • [Cites] J Urol. 2007 Aug;178(2):379-86 [17561170.001]
  • [Cites] Eur Urol. 2007 May;51(5):1289-95; discussion 1296-7 [17081679.001]
  • [Cites] BJU Int. 2007 Feb;99(2):290-5 [17092279.001]
  • [Cites] AJR Am J Roentgenol. 2007 Feb;188(2):563-70 [17242269.001]
  • [Cites] J Urol. 2006 Nov;176(5):1957-62 [17070218.001]
  • [Cites] J Natl Cancer Inst. 2006 Sep 20;98(18):1331-4 [16985252.001]
  • [Cites] BJU Int. 2006 May;97(5):946-9 [16643475.001]
  • [Cites] Hum Pathol. 2005 Dec;36(12):1309-15 [16311125.001]
  • [Cites] J Natl Cancer Inst. 2005 Oct 5;97(19):1407-27 [16204691.001]
  • [Cites] J Urol. 2005 Jul;174(1):44-6 [15947574.001]
  • [Cites] J Urol. 1999 May;161(5):1470-4 [10210375.001]
  • [Cites] JAMA. 1999 May 5;281(17):1628-31 [10235157.001]
  • [Cites] J Urol. 2004 May;171(5):1802-5 [15076280.001]
  • [Cites] J Urol. 2003 Dec;170(6 Pt 1):2163-72 [14634372.001]
  • [Cites] Oncogene. 2003 Oct 2;22(43):6810-8 [14555994.001]
  • [Cites] Cancer. 2003 Jun 15;97(12):2960-71 [12784330.001]
  • [Cites] Am J Pathol. 2003 Mar;162(3):925-32 [12598325.001]
  • [Cites] J Urol. 2003 Jan;169(1):71-4 [12478106.001]
  • [Cites] Cancer Res. 2002 Nov 15;62(22):6598-605 [12438255.001]
  • [Cites] AJR Am J Roentgenol. 2002 Aug;179(2):373-8 [12130435.001]
  • [Cites] Clin Cancer Res. 2002 May;8(5):1155-66 [12006532.001]
  • [Cites] Clin Cancer Res. 2002 Mar;8(3):794-801 [11895911.001]
  • [Cites] Am J Surg Pathol. 2002 Mar;26(3):281-91 [11859199.001]
  • [Cites] J Mol Diagn. 2002 Feb;4(1):30-6 [11826185.001]
  • [Cites] Transplantation. 2001 Sep 15;72(5):948-53 [11571464.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Aug 14;98(17):9754-9 [11493696.001]
  • [Cites] Am J Pathol. 2001 May;158(5):1639-51 [11337362.001]
  • [Cites] Radiology. 2000 Aug;216(2):506-10 [10924578.001]
  • [Cites] Nature. 2000 Jun 15;405(6788):827-36 [10866209.001]
  • [Cites] Nat Biotechnol. 2000 Apr;18(4):457-9 [10748532.001]
  • [Cites] Eur Urol. 2008 May;53(5):1003-11 [18061339.001]
  • (PMID = 19966938.001).
  • [ISSN] 1943-8141
  • [Journal-full-title] American journal of translational research
  • [ISO-abbreviation] Am J Transl Res
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2776289
  • [Keywords] NOTNLM ; amplification / biopsy / cDNA microarray / gene expression profiling / kidney tumor
  •  go-up   go-down


100. Van Genechten M, Schelfout K, Germonpré PR, Deschepper K, Van Schil PE: Benign oncocytoma of the trachea. Ann Thorac Surg; 2005 Jul;80(1):e3-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Benign oncocytoma of the trachea.
  • A 16-year-old girl was referred with a presumed muco-epidermoid carcinoma of the distal trachea, which was diagnosed by bronchoscopic biopsy.
  • Final pathologic examination of the resected specimen revealed a benign oncocytic adenoma.
  • This neoplasm is composed predominantly of oncocytes and is extremely rare in this location.
  • [MeSH-major] Adenoma, Oxyphilic / pathology. Tracheal Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15975328.001).
  • [ISSN] 1552-6259
  • [Journal-full-title] The Annals of thoracic surgery
  • [ISO-abbreviation] Ann. Thorac. Surg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down






Advertisement